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DNA editing is a vital tool in the development of biological systems for both 
research and commercial applications. Novel enabling tools accelerate strain 
engineering for the study of cellular mechanisms or production of small molecules 
and proteins. CRISPR (Clustered Regularly Interspersed Short Palindromic 
Repeats) technologies, where small RNA molecules (gRNA) direct Cas (CRISPR-
associated) proteins to DNA in a highly accurate, sequence-dependent manner 
have increased the rate at which DNA modifications can be made.  
We developed and expanded the CRISPR toolbox for recombination and 
deaminase-guided genome editing, protein engineering and transcriptional 
regulation within the industrial workhorse Bacillus subtilis.  
A co-transformational system, consisting of a single plasmid for nuclease 
and gRNA expression and a linear donor DNA (dDNA) was established for use with 
both Streptococcus pyogenes Cas9, the most commonly utilised CRISPR nuclease, 
as well as the potentially highly commercially relevant nuclease, MAD7, also known 
as Eubacterium rectale Cas12a. Editing efficiencies of ≥83% were observed for both 
nucleases.  
Using our CRISPR-Cas9 genome editing tool, a novel variant of the 
commercially relevant protein, subtilisin E, was engineered exhibiting an increase in 
both thermostability and proteolytic efficiency. Two systems for transcriptional down-
regulation (CRISPRi) were demonstrated, including the first reported catalytically 
inactive variant of MAD7. Finally, Cas9 was further modified to incorporate fusions 
with DNA deaminases allowing the first reported example of CRISPR targeted 





Over the years, bacteria have got quite a bad reputation within the general 
public for the spread of illness in people and animals. Not all bacteria are bad 
though. For example, Bacillus subtilis has been designated as safe for decades and 
is found widely in the soil, as well as in some foods.  
Another great use for B. subtilis is that it has an incredible ability to release 
enzymes into the environment around it. This ability has been used for a very long 
time to make enzymes that we use every day in our society. Uses include enzymes 
that help clean clothes in biological washing powder, and to help break down corn to 
make bioethanol which is used in fuel for cars. We can make these enzymes faster 
and develop new enzymes with better properties, for example to work well in a more 
diverse and potentially harsh environment. To make these changes though we need 
the ability to change the genetic code, DNA, within the bacteria.  
In 2012, a type of immune system used by some bacteria known as 
CRISPR-Cas9 was modified to quickly and highly accurately change DNA. 
CRISPR-Cas9 causes a cut in DNA which has to be repaired or prevented for the 
cell to survive. It is in the repair of this cut that we can introduce changes. We can 
remove DNA, add new DNA and make precise changes without changing the total 
amount of DNA.  
The work in this thesis adapts some of the tools to change DNA in other 
bacteria, and more complex organisms, for use in B. subtilis. We successfully show 
the basic CRISPR-Cas9 system to be just as effective in B. subtilis, as well as 
further developing a tool which is free to use within industry to maximise the impact 
of this technology. We used these tools to develop a new form of an enzyme, which 
is used within washing powder, and works 46% faster than the unchanged enzyme.  
We hope the tools developed here are used broadly within the scientific 
community to increase the speed and accuracy by which new, better products can 
be created. This will hopefully broaden the uses for enzymes and further reduce our 
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IPTG – isopropyl β-D-1-
thiogalactopyranoside 
Kan – kanamycin 
KI – knock-in  
KO – knock-out 
L – litre (can be combined with metric 
SI prefixes) 
LB – lysogeny broth 
LIC- ligation independent cloning 
m – meter (can be combined with 
metric SI prefixes) 
MCS – multiple cloning site 
min – minute 
mol – mole (can be combined with 
metric SI prefixes) 
MTP – microtitre plate 
NHEJ – non-homologous end joining 
nt – nucleotide 
NUC – nuclease domain 
OAPS – oligonucleotide annealing 
based promoter shuffling 
OD600 – optical density at 600 nm 
OE-PCR – overlap extension PCR 
PAGE – polyacrylamide gel 
electrophoresis 
PAM – protospacer adjacent motif 
PCR – polymerase chain reaction 
PEG – polyethylene glycol 
QPS – qualified presumption of safety  
R&D – research and development 
RBS – ribosome binding site 
rcf – relative centrifugal force 
REC – recognition domain 
RNA – ribonucleic acid 
RNAP – RNA polymerase 
rpm – revolutions per minute 
RT qRT-PCR – real time quantitative 
reverse transcription PCR 
SD – standard deviation 
SDS – sodium dodecyl sulphate 
SEC – size exclusion chromatography 
s - second 
sgRNA – single guide RNA 
SM – starvation medium 
Spec – spectinomycin 
SRP – signal recognition particle 
SSB – single strand binding protein 
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ssDNA – single-stranded DNA 
TAE – tris-acetate-EDTA 
tracrRNA - trans-activating CRISPR 
RNA 
TALENs – transcription activator-like 
effector nucleases 
Tat – twin arginine translocation 
Tm – melting temperature 
UV – ultra violet 
V – volts (can be combined with metric 
SI prefixes) 
v/v – volume per volume 
WT – wild-type 
w/v – weight per volume 
ZFNs – zinc finger nucleases 
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Chapter 1 – Introduction 
 
1.1 Context and motivation 
Historically, production of chemicals and energy has relied on fossil 
fuel-based approaches. In the current context, there is an urgent need to move 
away from this model and towards a set of processes with a lower environmental 
impact. One promising approach is to replace energy-intensive chemistry with 
natural processes. Biotechnological applications, such as industrial enzyme 
production or riboflavin (vitamin B2) secretion by Bacillus subtilis, have the capacity 
to reduce significantly environmental impact in comparison to their industrial 
chemistry equivalents3. However, to reach a point of commercial viability, 
bioprocesses within a host must be optimised to increase productivity rates. 
Therefore, it is important to increase the speed and accuracy with which genetic 
modifications can be made. 
Since the advent of simple, targeted genome editing in 2012 with the 
exploitation of the Clustered Regularly Interspersed Short Palindromic Repeats 
(CRISPR) and CRISPR-Associated (Cas) proteins, many areas of the biological 
sciences involving genomic modifications have been revolutionised. Experiments 
that would previously have taken considerable time and resources with transcription 
activator-like effector nucleases (TALENs) or zinc finger nucleases (ZFNs) can be 
reduced to a fraction of the time and cost4. Where previously expensive, complex 
and laborious methods were required to make relatively small changes, now the 
scientific community has a tool for rapid, relatively cheap and simple changes from 
the single base pair alteration, to the modification of an entire genome through 
multiplexed (multiple targets) genome deletions5.  
The bacterial industrial workhorse B. subtilis is used globally for the 
large-scale manufacturing of enzymes used in diverse applications such as the food, 
textile, paper, detergent, pharmaceuticals and bioethanol production industries, as 
well as bulk chemical production3,6. It is found naturally in the soil, and is also a 
model organism for Gram-positive bacteria. The development of CRISPR tools for 
use within B. subtilis, building on the well-established protocols for genetically 
modifying this host, has the potential to increase the rate by which new 




1.2 Bacillus subtilis: industrial workhorse and model 
organism 
B. subtilis is one of the most intensively studied microorganisms. Its lack of 
endotoxin production has enabled its qualification as “generally regarded as safe” 
(GRAS) from the United States Food and Drug Administration (FDA), and the similar 
QPS (qualified presumption of safety) by the European Food Safety Authority 
(EFSA). It has been used for centuries within the Japanese food, including in “nattō” 
a breakfast food produced from soybeans fermented with B. subtilis derived from 
rice straw7. This, coupled with its well understood, inducible genetic competence 
pathway has made it one of the primary industrially utilised bacterial species3,8.  
Since Bacilli are capable of 20-25 g/L secretion of proteins3,9,10, their use as 
enzyme production hosts has been extensive, with production of ~60% of 
commercially available enzymes10 within a global enzyme market with a value of 
$5.5 billion in 2018, and predicted to reach $7 billion by 202311. The enzymes 
produced vary in function with some examples being amylases, amylomaltase, 
cellulases, proteases and xylanases3. While B. subtilis is the model for other Bacilli, 
notable alternative production hosts have preferential characteristics, depending on 
the target enzyme being produced. Bacillus licheniformis is widely used for alkaline 
serine protease production, can grow anaerobically8 and its optimal growth 
temperature is ~46 °C12. Bacillus amyloliquefaciens secretes its native amylase at 
high levels, is used for starch degradation in the beverage industry9, and has also 
been shown to improve plant tolerance to abiotic stress such as elevated salt 
concentrations13. 
Bacilli are not only used for the production of proteins. They are also used to 
produce fine chemicals such as nucleotides, which are used in the food industry as 
the umami flavour enhancer and had a global demand of 23,000 tonnes in 20093. 
B. subtilis has been modified to achieve >14 g/L production of adenosine14, while 
B. amyloliquefaciens has been shown to achieve secretion of 10 g/L inosine3. 
Vitamin B2, also known as riboflavin, has an annual global demand of 4000 tonnes 




1.2.1 Natural competence and genetic manipulation of B. subtilis 
The increased knowledge of the genetic competency mechanisms, and 
development of natural competence induction by Anagnostopoulous and Spizizen16, 
has made B. subtilis the model organism for Gram-positive bacteria. The 
development of online tools, such as SubtiWiki, has facilitated greater understanding 
through improved communication of data17.  
B. subtilis has the capacity to differentiate into several physiological states, 
depending on the environmental conditions. When the vegetative cell enters 
stationary growth phase, subpopulations become motile, form biofilms, secrete 
degradative enzymes and antibiotics, become naturally competent and lastly 
sporulate for long-term survival18. The main factor in B. subtilis differentiation is the 
level of phosphorylated Spo0A. This acts as a global regulator which, along with 
AbrB, CodY, Rok and the DegS-DegU two-component system, act to regulate tightly 
the transcription levels of the competency master regulator, ComK18. Such tight 
regulation leads to natural competence only being achieved by ~10% of cells of 
B. subtilis within a growth culture19 and even fewer B. licheniformis cells20. Once at 
sufficient levels within the cell, ComK causes the cell to enter a state of competency 
through the activation of expression for ~100 genes involved in DNA uptake, repair, 
binding and recombination21. Double-stranded DNA (dsDNA) binds to a receptor 
(ComG) via a pseudopilus, then is cleaved by a membrane-bound nuclease and 
internalised as a linear single-stranded DNA (ssDNA) molecule by ComEA22. Strains 
of B. subtilis18 and B. licheniformis20 have been modified to incorporate an inducible 
expression cassette for ComK to allow the induction of natural competence, as an 
alternative to the starvation-based approaches used in the absence of such 
expression16,23,24.  
The ssDNA is protected from exonucleases within the cell following the 
binding of RecN to the 3´-OH25. DprA, SsbA and SsbB also bind to the internalised 
ssDNA. DprA has been found to be more important during the transformation of 
replicative plasmids due to the increased stabilisation required to allow ssDNA 
strand annealing and subsequent DNA synthesis26. Furthermore, DprA facilitates the 
replacement of SsbA and SsbB with RecA, which goes on to be the major 
component enabling homologous recombination (HR) - discussed in detail in the 
context of double-strand break (DSB) repair within section 1.4.218. 
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This efficient competency and HR capacity has led to several tools being 
developed for the genetic manipulation of B. subtilis to construct production strains 
without antibiotic resistance genes. Counterselection mechanisms are such an 
example. Here, an inducible expression cassette for a toxic gene such as the 
Escherichia coli toxin gene, mazF, can be incorporated alongside an antibiotic gene. 
The antibiotic gene enables selection of colonies which have undergone successful 
integration events. Induction of mazF expression produces a toxic endoribonuclease 
which cleaves free mRNA at ACA sequences. Thus, for the B. subtilis host to 
survive, mazF must be removed. This occurs between homology sites generally 
flanking mazF, as well as the antibiotic resistance gene. Thereby, mazF and the 
antibiotic resistance gene are removed and an engineered host constructed3,27. 
Other counterselectable markers include the upp gene in the presence of 
5-fluorouracil (requiring inactivation of the native upp gene)28, the blaI cassette in a 
lysine auxotroph29, and the heat-inducible hen egg white lysozyme gene30.  
Following transformation by HR, removal of the toxin and antibiotic 
resistance genetic elements can be further boosted through the use of a 
recombinase enzyme31. The bacteriophage P1 Cre/loxP site-specific recombination 
system utilises the Cre recombinase to catalyse the reciprocal, site-specific 
recombination between two loxP sites, excising the DNA between the sites (such as 
an antibiotic resistance gene) and leaving a single loxP site as a scar31. However, 
this system was not readily compatible with multiple rounds of editing due the 
presence of the loxP scar interfering with the subsequent round of editing by 
removing the incorrect section of DNA between the initial loxP scar and the 
subsequent loxP sites. The development of the lox66 and lox71 mutant sites 
addressed this concern as they recombine to leave the 34 bp lox72 scar which has 
a greatly reduced binding affinity for Cre and thus does not interfere with 
subsequent rounds of genomic modifications32. While counterselectable systems 
may require a specific background, or result in spontaneous resistance to the 
counterselection mechanism, Cre/loxP editing does not require any specific 
background in the cell. That being said, Cre/loxP results in strains containing scars 




1.2.2 Bacilli as protein production hosts 
B. subtilis, as well as other Bacilli, are capable of secreting proteins to a high 
titre within industrial fermentation processes (20-25 g/L)3,9. As such, protein 
secretion pathways have been highly analysed and their function is now well 
understood3,33. The primary secretory pathway utilised, Sec, is discussed below. 
The other known secretory pathways, the twin arginine translocation (Tat) pathways, 
ATP-binding cassette (ABC) transporters and the pseudopilin export pathway are 
characterised33.  
 
1.2.2.1 Protein secretion via the Sec pathway 
The Sec pathway is the primary protein secretory pathway used within 
B. subtilis33. Unfolded protein polypeptides are targeted to the cytoplasmic 
membrane by signal peptides found at the N-terminus of the eventual final protein. 
These consist of a positively charged N-terminal region, a hydrophobic region and a 
polar C-terminal region10. Following ribosomal translation, the peptides are kept in 
their unfolded, translocation-competent state by the signal recognition particle (SRP) 
and FtsY chaperones34. The Sec apparatus, which consists of the SecA ATPase 
motor (activated by interactions with the signal peptide33), and the membrane 
channel proteins SecY, SecE, SecG (SecYEG) and SecDF, can then be utilised to 
pass the peptide through the cytoplasmic membrane. The exact function of SecDF 
is still unknown, however it is required for efficient protein secretion, particularly in 
high-scale protein production hosts (≈1.3 g/L) and under cold conditions (15 °C)35. 
Once the peptide has passed though the SecYEG channel, the signal peptide is 
cleaved at the C-terminal region and degraded by signal peptidases, such as SppA, 
which is important as undegraded signal peptides can inhibit translocation of other 
proteins33.  
Once translocated, the protein is correctly folded in the extracytoplasmic 
space. The extracellular chaperone, PrsA facilitates protein folding in the majority of 
cases36, but this process can also be assisted by thiol-disulphide oxidoreductases 
BdbB, BdbC and BdbD37. Some B. subtilis proteins, such as the serine protease 
subtilisin E (encoded by aprE) have a further propeptide which assists in processing 
the enzyme into its final form, before autoprocessing the removal of the 
propeptide38. Furthermore, metal ions such as Fe3+, Mg2+ and, in the case of 
Subtilisin E, Ca2+, aid folding and stabilise the final active enzyme. Lastly, the 
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membrane-bound proteases HtrA and HtrB, as well as the cell wall associated 
protease WprA act as “quality control” proteases, ensuring there are no blockages in 
the secretion system, before the final secreted protein is released into the 
extracellular environment. 
 
1.2.2.2 Other protein secretion pathways in B. subtilis 
The alternative secretory pathways within B. subtilis are the Tat pathway, 
ABC transporters and very rarely the pseudopilin export pathway. Secreted proteins 
utilising the Tat pathway have a highly conserved twin-arginine motif within their 
signal peptides and are transported across the cell membrane in their folded state 
and can include tightly folded proteins and multimeric proteins, such as the 
phosphodiesterase, PhoD, involved in degradation of teichoic acid within the cell 
wall during phosphate starvation3,33. ABC transporters function as multidomain 
permeases to import or export various ions, amino acids peptides antibiotics or 
proteins across the cell membrane in prokaryotes and eukaryotes. In B. subtilis, the 
signal peptide structure for proteins destined for ABC transporters, such as 
lantibiotics, is significantly different to that utilised by the Sec or Tat pathways in that 
it lacks the hydrophobic region33. Lastly, the pseudopilin export pathway is involved 
in the transport of proteins required for the development of natural genetic 
competency33. These proteins remain in the extracytoplasmic space between the 
membrane and the cell wall to fulfil their function33. 
 
1.2.2.3 Alteration of the extracellular proteome of B. subtilis to maximise 
protein yields 
Within industrial fermentation processes, to maximise extracellular levels of 
the target protein, the extracellular proteome of B. subtilis can be altered. Deletion of 
extracellular proteases can substantially increase the level of heterologous protein 
production. B. subtilis secretes at least eight extracellular proteases through the Sec 
pathway. These are, the previously mentioned and model for protein engineering39, 
alkaline serine protease, subtilisin E (AprE), as well as neutral protease (NprE), 
minor protease (Epr), bacillopeptidase F (Bpr), metalloproteases (Mpr), cell wall 
associated WprA, Vpr and NprB proteases. Of these, 95% of the extracellular 
proteolytic activity is attributed to AprE and NprE3. Knock-outs of these proteases 
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have been constructed, producing strains without antibiotic resistance markers or 
extracellular proteases as a platform for heterologous protein production40,41.  
Further deletions of major extracellular proteins, such as the 
starch-degrading α-Amylase (encoded by amyE), can also aid in downstream 
processing by limiting the level of contaminants required for removal during target 
protein purification. Lastly, deletion of the surfactin synthase protein SrfAC has been 
found to reduce the level of foaming during large-scale fermentation, thus reducing 
product loss41. 
 
1.3 CRISPR-Cas mechanisms and their utilisation for genome 
engineering 
1.3.1 An immune system for bacteria and archaea 
CRISPR-Cas systems are natively found in 50% of analysed bacterial 
genomes and 87% of analysed archaea genomes42. These act in a similar manner 
to an immune response when the host is targeted by, bacteriophages, or plasmid 
DNA invades the cell42,43. CRISRP-Cas systems have been split into six distinct 
types (I-VI), with each type having its own Cas proteins associating to CRISPR RNA 
(crRNA) to induce DNA interference42,44. The most widely studied type of CRISPR 
system is type II, in which a single Cas9 protein performs a wide variety of roles in 
contrast to type I and III systems where a complex of Cas proteins perform the same 
role. The type V system, comprising Cpf1 nucleases (also referred to as Cas12a), is 
also a multipurpose enzyme, however it differs significantly from Cas9 in that it is 
guided by a single RNA molecule, as opposed to two, and cleaves DNA in a 
staggered manner, as opposed to a blunt DSB44,45. 
In the type II CRISPR-Cas9 system, the natural process occurs in three 
stages. Firstly, the cell acknowledges the invading viral or plasmid DNA and 
incorporates short sections (protospacers) into the CRISPR loci. These are then 
transcribed into precursor CRISPR RNA (pre-crRNA) consisting of a 20-25 bp 
targeting region, and a stretch of 12 bp which is constant in all pre-crRNA43,46. 
Pre-crRNA are matured to crRNA by association with a trans-activating CRISPR 
RNA (tracrRNA)42,43. These mature crRNA-tracrRNA complexes allow binding of the 
foreign DNA by the Cas9 protein. The invading DNA is then cleaved 3 bp upstream 
of the protospacer adjacent motif (PAM) which is required for Cas9 activity42,43. The 
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newly acquired protospacer is maintained in the CRISPR loci, and upon invasion of 
the same stretch of DNA, transcription of the pre-crRNA and expression of Cas9 
removes the invading DNA42,47,48.  
 
1.3.2 Characterisation of CRISPR-Cas9 for its use within genomic 
engineering  
Due to its simplicity the type II system, utilising Cas9 as described here, has 
become the most widely utilised42. The potential of CRISPR-Cas9 for highly targeted 
genomic modifications through DSB repair mechanisms was identified by Jinek et 
al.43. The relatively common PAM motif (5´-NGG-3´) required by Streptococcus 
pyogenes Cas9 (henceforth, Cas9 refers to that from S. pyogenes unless otherwise 
stated) in all organisms led to this becoming the system of choice for genome 
editing, with only one heterologous gene required for highly efficient genome editing 
(cas9). Type II systems contain tracrRNA which associates to, and aids in the 
maturation of, the guiding crRNA42,46. Development of the crRNA-tracrRNA into a 
single guide RNA (sgRNA), joined by a linker loop, simplified the system further, and 
was found to be just as or more efficient than when separated43,47. sgRNAs have 
since been further developed, for example to include a secondary structure 
preventing hybridisation at an incorrect target, in an attempt to limit the off-target 
effects observed with CRISPR systems in eukaryotes49. 
 
1.3.2.1 Target interrogation and cleavage by Cas9 
Cas9 is a bilobe endonuclease composed of the alpha-helical recognition 
(REC) lobe and the nuclease (NUC) lobe which contains both the HNH 
(Histidine-Asparagine-Histidine, targeting the DNA strand complementary to the 
gRNA) and RuvC (named after an endonuclease domain found in E. coli RuvC) 
nuclease domains42,47. Crystal structure of the isolated, apo-Cas950, shows the apo 
form to be substantially altered at the PAM recognition site following binding to the 
crRNA-tracrRNA/sgRNA complex, yielding holo-Cas9 (Figure 1.1)46. This inactive 
state of the PAM recognition region supported the findings of Jinek et al. in which 
Cas9 was found to be inactive as a nuclease without the presence of a gRNA43.  
Once bound to the targeting RNA, Cas9 interrogates the DNA for the 
presence of a PAM site. Following identification of such a site, the length of time the 
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nuclease interrogates that site is determined by the homology to the targeting RNA. 
The 10-12 nt region directly upstream of the PAM site, within the targeting region, is 
known as the seed region (Figure 1.1). Any mutations within this seed region have a 
highly deleterious effect on Cas9 activity43,51, while mismatches within the 
PAM-distal end of the gRNA is tolerated to a greater degree52.  
Once the Cas9-RNA complex has found the target site, the Cas9 relaxes the 
DNA at the target site, known as the R-loop. This enables gRNA strand invasion and 
the formation of a DNA-RNA duplex, through Watson-Crick base pairing, and a 
single DNA strand (Figure 1.1)53. Once the R-loop has fully unwound to allow 
interrogation of the full protospacer, provided there are no mismatches within the 
seed region and no more than 3 mismatches, the DNA is cut by the HNH and RuvC 
nuclease domains.  
Holo-Cas9 is only fully active when the full gRNA hybridises to the DNA 
enabling a conformational change in the HNH domain, which in turn promotes a 
change in the RuvC domain, in each case bringing the target DNA into the catalytic 
site of the domain53. The HNH domain cleaves the DNA strand to which the gRNA 
has hybridised, while the RuvC domain cleaves the complementary strand43,54. The 
cut induced by Cas9 is blunt and takes place 3 bp upstream of the PAM site, within 
the seed region (Figure 1.1). Following DNA cleavage, Cas9 remains bound to the 
cleaved DNA until displaced by other cellular factors55. 
The Cas9 derived DSB must be repaired or inhibited for the host to survive. It 
is this requirement that provides the CRISPR-Cas systems with their unparalleled 
genome editing efficiency when compared to established editing techniques in 
B. subtilis (section 1.2.1), and when compared to the complexity of changing the 
target location for other targeted nuclease editing techniques, such as TALENs or 
ZFNs, where complex protein modifications are required for accurate DNA 
cleavage4. The DSB can be prevented by HR of a donor DNA (dDNA), or repaired 
by cellular DNA repair mechanism, of which the most common are the error-prone 
non-homologous end joining (NHEJ) or the more controlled homology directed 
repair (HDR) when a dDNA template is present – generally a polymerase chain 
reaction (PCR) product, or a plasmid borne template containing the intended 
modification as well as an alteration of the PAM site to prevent further cutting (DNA 





Figure 1.1 – Schematic of the mechanism by which CRISPR-Cas9 associates to, and cleaves its DNA target.  
Cas9 undergoes a conformational change, aligning the PAM interacting region correctly, following the binding of guide RNA (shown here as a combined 
single guide RNA (sgRNA), but this can also be individual crRNA-tracrRNA components). Abbreviations: NUC, nuclease lobe; PAM, protospacer 




Cas9 has been shown to have two crucial amino acids for its catalytic activity 
(Asp10 and His840)43. It was established that replacing one or both of these with an 
alanine residue would lead to a partially or fully inactive variant respectively, while 
maintaining its capacity for binding DNA43,47. Catalytically altered versions of Cas9 
are known as nickase Cas9 (nCas9 – the DNA strand specific D10A or H840A 
mutations preventing cleavage of a single DNA strand though inactivation of the 
RuvC or HNH nuclease domains respectively) and deactivated/dead Cas9 (dCas9 – 
both D10A and H840A mutations are present). These have become widely used 
since their development with just some examples being nCas9 used to increase 
genome editing accuracy in mammalian hosts through the limitation of off-target 
DSBs (off-target single strand nicks are efficiently repaired while editing only takes 
place when two nicks, from different gRNA, are in close proximity to create a 
DSB)56, and enabling selection of strains which have undergone successful 
deaminase base editing (section 1.3.5) by cleavage of the non-edited strand54,57. 
dCas9 has also been utilised for deaminase base editing54,57, but is perhaps most 
broadly utilised for transcriptional regulation where, in bacteria, it sterically hinders 
the binding or progression or RNA polymerase (RNAP). Alternatively, when fused to 
an effector protein, RNAP can be recruited to a specific site at a greater rate, 
resulting in an increase in transcription of the targeted gene58–61.  
 
1.3.3 CRISPR nucleases with alternative PAM site, cleavage and 
guide RNA characteristics 
Cas9 has been engineered to accept alternative PAM sites62. Although the 
NGG PAM sequence occurs relatively often in organisms with a medium to high GC 
content, less options for editing targets are available in AT-rich genomic regions. As 
a result, an NGG PAM site could be prohibitively distant from the point at which 
editing is desired. Having several Cas9 variants accepting alternative PAM sites 
allows closer, targeted editing to occur62. As well as variants of S. pyogenes Cas9, 
Cas9 nucleases from other microorganisms allow targeting of different PAM sites 
(Table 1.1). Furthermore, the utilisation of the type V CRISPR-Cpf1 nucleases, 
including the recently released commercially relevant MAD7 nuclease, offer 




Table 1.1 - Cas9/Cpf1 proteins and corresponding PAM sites. These have been shown 








Cas9 NGG Streptococcus pyogenes Yes43,63 
VRQR-Cas9 NGA Engineered from Cas9. No64 
VRER-Cas9 NGCG Engineered from Cas9. No64 
Nm_Cas9 
N4GMTT  
(M = A or C) 
Neisseria meningitides No64 
Sa_Cas9 
N2GRRT  
(R = A or G) 




(R = A or G) 
Engineered from Sa_Cas9. No64 
Bl_Cas9 
N4CND  
(D = A, G or T) 
Brevibacillus laterosporus No64 
CasX TTCN Deltaproteobacteria Yes65 
CasY NTA Katanobacteria Yes65 
As_Cpf1 TTTV Acidaminococcus sp. BV3L6 Yes66 
Lb_Cpf1 TTTV Lachnospiraceae bacterium ND206 Yes66 
MAD7 YTTN Eubacterium rectale Yes67 
C2c1 TTN Alicyclobacillus acidoterrestris Yes44 
 
Cpf1 CRISPR nucleases, also known as Cas12a nucleases, are members of 
the type V group of CRISPR systems. These are similar to Cas9 in that they are a 
single protein, as opposed to a large complex to perform DNA interference. Cpf1 
nucleases however differ in that they naturally utilise a single gRNA molecule to 
associate to the nuclease, and target the complex to the DNA (Figure 1.2)45,68. Once 
the target has been identified, Cpf1 nuclease induces a staggered cut, rather than a 
blunt cut as with Cas9 (Figure 1.2). Furthermore, this 5-8 nt cut is introduced at the 
PAM distal end of the protospacer region69. Cpf1 nucleases cleave at T-rich PAM 
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sites (Table 1.1) and have the capacity to cleave both DNA and RNA. This RNA 
cleavage capacity allows native Cpf1 systems to mature their own pre-crRNA array 
transcripts following the formation of an RNA pseudoknot45. Similar to Cas9, Cpf1 
nucleases relax and interrogate DNA following binding of gRNA, initially identifying 
PAM sites, and thereafter analysing the protospacer region. The critical seed region 
of the protospacer within Cpf1s is 5-6 nt proximal to the PAM.  
 
 
Figure 1.2 – Comparison of the basic characteristic found with native Cas9 and Cpf1 
nucleases. 
Cas9 requires a G-rich protospacer adjacent motif (PAM) while Cpf1 requires a T-rich PAM. 
Native Cas9 systems use two RNA molecules to guide the nuclease to the target location 
(crRNA (green) and tracrRNA (blue)), while Cpf1 uses a single guiding crRNA molecule with 
a shorter total length. Cas9 causes a blunt double-strand break (DSB), proximal to the PAM, 
while Cpf1 causes a 5 nt staggered cut, distal to the PAM (yellow triangles indicate cleavage 
sites). The seed region required for Cas9 binding and cleavage is indicated for both sets of 
nucleases. 
 
Recently, Inscripta Inc. (USA) released an alternative CRISPR nuclease 
isolated from Eubacterium rectale with the trade name, MAD7. This nuclease 
exhibits many of the same characteristics as Cpf1 nucleases, with Acidaminococcus 
sp. BV3L6 (AsCpf1) being the closest known relative at the time of its release (31% 
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identity)67,70. Indeed, MAD7 has since been identified as having a closer homology 
to other Cpf1 nucleases, and has been designated by some as ErCas12a71. 
MAD7 has the potential to be of significant commercial interest with Inscripta 
claiming it is free to use in commercial R&D as well as there being no read-through 
royalties on any strains developed using MAD7, so long as the final strain no longer 
contains a copy of the nuclease or any derivatives67. This is in stark contrast to Cas9 
and other Cpf1 nucleases which are surrounded by relative confusion in terms of 
their use within commercial enterprises and who provides a licence for their use. 
This, alongside potentially costly read-through royalties on strains developed with 
Cas9 or Cpf1 nucleases could have limited the level of commercial exploitation of 
CRISPR genome engineering within small-medium sized commercial enterprises, 
and in large-scale fermentations where profit margins can be slim depending on the 
product.  
 
1.3.4 Transcriptional regulation with catalytically inactive variants of 
Cas9 
The engineering of dCas9 has led to the development of two new branches 
of research: CRISPR interference (CRISPRi), and CRISPR activation 
(CRISPRa)61,72. CRISPRi refers to inhibition of gene transcription by associating the 
dCas9 to the promoter or 5´ end of a gene, which, in bacteria, sterically hinders the 
RNA polymerase, preventing transcription. This can be a powerful tool as studies 
have shown the effect of CRISPRi can be comparable to having a full knock out 
(KO) of the gene in question in both eukaryotes and prokaryotes61,72. CRISPRi has 
also been used as a knockdown tool to lower the transcription of essential genes 
which are otherwise impossible to KO without supplementing the host with either the 
product the deleted protein creates or adding either an exact copy or heterologous 
homolog of the deleted gene72,73.  
CRISPRi has been further exemplified within Cpf1 based systems following 
inactivation of the DNA cleaving function within the DNase dead variants (ddCpf1 
E993A)68. Within E. coli it was found that targeting the template strand within a 
target gene yielded greater transcriptional repression efficiencies (~330-fold 
repression for three gRNA) than when the non-template strand was targeted 
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(~6-fold for two gRNA and no repression for a third) when compared to a control 
strain without a targeting gRNA74.  
CRISPRa on the other hand stimulates stronger transcription of a gene59,75,76. 
Here, dCas9 is fused to a transcription effector molecule and targeted to a region 
upstream of the promoter elements. This stimulates the recruitment of the RNAP 
through interactions with the fused effector, for example VPR in Saccharomyces 
cerevisiae77, the ω RNAP subunit in Escherichia coli mutants in which this subunit is 
not expressed59, and the ω or α RNAP subunits within B. subtilis60. When using 
dCas9 for CRISPRi or dCas9 fused to an effector protein for CRISPRa, and multiple 
simultaneously transcribed sgRNAs, the knockdown or up regulation of several 
genes (multiplexing) can be achieved in parallel59–61,72,75,78.  
In B. subtilis these have recently been combined to repress transcription of 
genes encoding extracellular proteases (for a similar outcome to strains described in 
section 1.2.2.3), while increasing the transcription of the primary extracellular 
chaperon encoding gene, prsA. dCas9-ω was targeted upstream of prsA 
(upregulation) and within the coding sequence for bpr, vpr and nprB 
(downregulation). This system, combined with an oligonucleotide annealing based 
promoter shuffling (OAPS) technique, was used to increase the heterologous 
extracellular production level of B. licheniformis α-Amylase (BLA) by 260-fold 
(100-fold by OAPS and a further 2.6-fold by CRISPRi/CRISPRa)60. 
 
1.3.5 CRISPR-enabled deaminase base editing for genomic editing 
without a double-strand break or donor DNA 
The fusion of effector proteins to dCas9 is not limited to CRISPRi or 
CRISPRa. Deaminase subunits, such as the activation-induced cytidine deaminase 
(AID) enzyme from humans (encoded by AICDA)79 or the evolved E. coli  adenine 
deaminase, TadA80, have also been fused to dCas9 or nCas9 to enable editing 
without the need for DSB repair. CRISPR-enabled base editing facilitates 
nucleobase deamination by hydrolysing the amino group from deoxycytosine (C) or 
deoxyadenosine (A), resulting in the formation of deoxyuridine (U) or inosine (I) 
respectively. These are subsequently altered to thymidine (T) and deoxyguanosine 
(G) respectively during DNA replication, provided the deaminated base is not 
removed before DNA replication can utilise it as a template81,82. To date, CRISPR 
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enabled deaminase base editing in prokaryotes has been exemplified in E. coli80,83, 
Brucella melitensis83,  Corynebacterium glutamicum54,84, and in this study (Chapter 
6) within B. subtilis.  
 
1.4 Mechanisms enabling CRISPR-Cas editing 
Cas nucleases cleave DNA causing a DSB. This must be repaired by NHEJ 
or by HDR, when dDNA is present, for the host to survive47. Alternatively, HR of the 
dDNA can occur prior to the DSB. Since dDNA encodes a programmed target site 
edit, together with a mutation disrupting the PAM, Cas nucleases are no longer able 
to cut the hosts DNA at the target location, allowing the host to survive so long as 
there are no additional, off-target, DSB events. Thus, in the later scenario, Cas 
nucleases act as a counterselection mechanism against cells without the 
recombined genotype, as opposed to the initiating cause requiring HDR or NHEJ to 
proceed.  
While eukaryotes have efficient NHEJ and HDR repair mechanisms, in most 
bacteria and yeast HDR is the only viable repair pathway. In E. coli, this is due to the 
lack of the proteins responsible for NHEJ, the DNA-binding protein Ku and the 
ligase/polymerase LigD75,81. In Saccharomyces cerevisiae and some prokaryotes, 
such as B. subtilis, NHEJ is only active at certain points in the cell cycle81,85,86. In 
B. subtilis, cell-cycle dependent NHEJ is active when the cells carry one single copy 
of the chromosome (1C) for long periods of time – late in stationary phase, or when 
sporulating. In exponential growth phase, due to constant DNA replication and the 
desire to produce a viable spore with 1C, the cell ensures it has >1C, mediated by 
the proteins Sda (preventing sporulation while DNA replication is active) and SirA 
(prevents new rounds of DNA replication when the cell enters sporulation)81. 
However, efficient HR systems, such as that present in B. subtilis could also lead to 
the prevention of DSB formation due to dDNA recombining and disrupting the DNA 
cleavage site, prior to CRISPR-Cas interrogation. This, along with the potential 
benefit to HR efficiency from the CRISPR-Cas system, is investigated within this 




1.4.1 Prevention is better than cure: homologous recombination can 
prevent lethal double-strand breaks following CRISPR-Cas 
interrogation 
In most bacteria, including B. subtilis, a DSB is lethal and thus the repair 
process, or the avoidance of the cut being introduced is vital81. The ability of the 
CRISPR-Cas system to continually reintroduce the DSB following accurate repair of 
the DNA acts as a counterselection mechanism. Thus, HR of dDNA carrying the 
mutation of interest as well as a synonymous PAM site mutation is vital for the cell to 
survive. 
As described in section 1.2.1, double-stranded dDNA used within B. subtilis 
transformation experiments is incorporated to the cell in a ssDNA manner following 
nuclease degradation (Figure 1.3)22. ssDNA is protected within the cell by DprA, 
SsbA, SsbB and RecN22. The ATPase recombinase, RecA, is added to the 5´ of the 
ssDNA by RecN, forming a nucleoprotein filament. RecA scans the chromosome for 
homologous DNA and causes strand invasion. This is followed by branch migration, 
enabled by RecG or RuvAB, and subsequent formation of Holliday junctions (Figure 
1.3)87. Holliday junctions are resolved following cleavage by RecU. The replaced 
recipient ssDNA strand is degraded within the cell and the resulting strain contains a 
heteroduplex with different alleles on each strand (Figure 1.3)87. Following DNA 
replication and daughter cell formation, one cell will contain the recombined 
genotype, while the other will contain the original parental genotype. If the 
introduced change provides a dominant phenotype, the subsequent population will 
be enriched for the modified genotype.  
Following such an event, CRISPR-Cas systems confer a counterselection 
against the daughter cells with the parental genotype, thus ensuring only modified 
cells survive to form colonies. However, in B. subtilis there has yet to be 
experimental evidence presented to show if HR or HDR is the primary mechanism 





Figure 1.3 – Homologous recombination pathway following natural competency 
mediated transformation of B. subtilis. 
A) dsDNA is bound by ComG pseudopilus and the ComEC channel internalises a single 
strand while the other is degraded. Single strand binding (SSB) proteins SsbA and SsbB 
bind and protect the ssDNA before DprA facilitates the addition of RecA to the 5´ of the 
ssDNA, replacing SSB. B) RecA-ssDNA proteofilament identifies target with homology to 
ssDNA upon the chromosome. C) RecA mediates strand invasion and RecG or RuvAB 
mediates branch migration. D) RecU mediates resolution of Holliday junctions. E) The 
replaced recipient strand is degraded within the cell and a DNA heteroduplex is formed. 
Subsequent DNA replication and cell division results in one daughter cell with the inserted 





1.4.2 Homology directed repair 
In the absence of the CRISPR-Cas mechanism, B. subtilis efficiently repairs 
DNA DSBs, in the vegetative state, by HR. DNA damage can happen regularly by 
stalled DNA replication and by environmental factors, such as ionising radiation. 
Thus, an efficient and accurate method of DNA repair is essential to maintain 
genetic stability. Due to this efficiency, it is possible that DSB formation could 
increase the level by which dDNA recombination can take place.  
DSB repair is initiated by RecN which responds early (<3 seconds88), and 
PNPase (encoded by pnpA) following DNA DSB (Figure 1.4)89. Recent single 
molecule imaging by Rösch et al. showed RecN diffusion within the cell changes 
dramatically, following DSB induction by the DNA damaging agent mitomycin C, 
from being very diffuse to rapidly scanning the DNA for DSBs88. RecN forms repair 
complexes at DNA DSB sites and is thought to bind the 3´-OH site of the DSB, 
preventing DNA degradation by non-specific exonucleases88.  
The RecN complex causes the association of the AddAB complex which in 
turn disassociates RecN from the DSB (Figure 1.4). AddA is a helicase and 
endonuclease which cleaves the 3´-5´ strand. AddB on the other hand does not 
have a helicase function, only acting as a nuclease for the 5´-3´ strand. AddAB 
degrades both strands until a Chi site is reached, which in B. subtilis consists of the 
sequence 5´-AGCGG-3´. Following the Chi site, to which AddB binds, the DNA 
continues to be unwound by AddAB, while only the 3´-5´ strand continues to be 
degraded by AddA, releasing an eventual ssDNA as a substrate for the 
recombinase RecA to bind. SsbA, however, initially protects this ssDNA from 
nucleases and prevents the formation of secondary structures90. This is then 
displaced by RecO and RecR which additionally facilitates, alongside RecF (forming 
the RecFOR complex), the binding of the RecA recombinase, to the ssDNA forming 







Figure 1.4 – Model for DNA double-strand break repair in B. subtilis (previous page).  
A) Double strand break (DSB) created in the genome. B) DSB is identified and ‘repair 
centres’ are established by RecN and PNPase. C) The DSB can be repaired using the 
error-prone non-homologous end joining (NHEJ) system, consisting of a dsDNA binding 
protein (Ku) to bridge the gap and recruit a ligase (LigD) to complete the DSB repair. D) the 
ends are processed by the AddAB helicase/nuclease complex, or perhaps alternatively by 
RecQ or RecS helicases and RecJ nuclease. Both strands are degraded until a Chi site is 
reached, after which only the 5´-3´ strand is further degraded. The exposed ssDNA is bound 
by SSB (Single strand binding protein). E) RecFOR mediates the disassociation of SSB and 
loading of RecA, forming the ssDNA-RecA nucleoprotein filament. F) The nucleoprotein 
filament undergoes a homology search and forms a displacement loop (D-loop) upon pairing 
with a template, displacing one strand from the template. G) Using the homologous strand as 
a template, the 3´ ends of each strand are extended by DNA polymerase. H) RecG or 
RuvAB can cause strand migration, increasing the degree of strand exchange. I) Double 
Holliday Junctions are resolved by RecU. J) If RecU cleaves the daughter strand (dashed 
line in I), DNA conversion results where the flanking sequences are the same. K) If RecU 
cleaves the parental strand (dotted line in I), DNA conversion and exchange results where 
the sequence downstream of the DSB are exchanged between the two strands. 
 
In B. subtilis DNA replication initiation occurs rapidly during growth in nutrient 
rich media, termed nutrient-mediated growth rate regulation92, ensuring ample dDNA 
for HR following DSB events. RecA catalyses the hydrolysis of ATP which, in the 
presence of SsbA and SsbB stimulates strand exchange in regions of 
complementarity. Branch migration is then performed by RecG or RuvAB while DNA 
polymerase extends the 3´ end to fill the gaps in the DNA strands93, using the 
homologous strand as a template (Figure 1.4). Once polymerisation is complete, the 
strands are sealed by a ligase, forming a double Holliday junction. In the resolution 
of these Holliday junctions by RecU, equal numbers of conversion or conversion and 
exchange products are expected, depending on the strand which is cleaved by 
RecU (Figure 1.4)94,95. 
 
1.4.3 Non-homologous end joining 
The expression of the Ku and LigD proteins, responsible for NHEJ, is 
regulated, in B. subtilis, by the forespore-specific sigma factor G (σG)96. σG initiates 
expression of 81 genes, including the DNA binding protein SpoVT. SpoVT initiates 
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the expression of 20 genes, including Ku and LigD96,97. Under sporulation 
conditions, such as extreme temperatures or lack of nutrients, σG is expressed and 
is responsible for late forespore gene expression98. σG acts as an auto regulator, in 
combination with σF (early forespore gene expression) enabling further expression 
during the spore life-span and allowing efficient genome maintenance96,98.  
Crucial to NHEJ is the binding of the Ku homodimer prior to basal DSB 
end-processing, by the proteins RecN and PNPase – the first steps in HDR99. NHEJ 
can still be utilised after DNA tethering by RecN, but once DSB ends have been 
processed to expose a 3´ tail and RecA binds, the cell is committed to HDR99,100. Ku 
binds and bridges the dsDNA ends while recruiting the DNA ligase LigD which joins 
the two DNA strands (Figure 1.4)99,100. B. subtilis Ku was confirmed to be functional 
in DSB repair in vivo, by KO mutants for Ku and RecA shown to be very susceptible 
to DSB forming agents101. Additionally, Wang et al. showed that Ku is 
compartmentalised to the forespore during its expression. It was confirmed in vitro 
that Ku enables an increase in the polymerisation and ligation efficiency of LigD of 
gaps ≥ 2 nt101.   
NHEJ has, however, been reported to not play a role within CRISRP-Cas9 
editing within B. subtilis102. Furthermore, Zheng et al. investigated the ability of 
B. subtilis Ku and LigD for DNA repair in E. coli, and found them not to enable repair 
of the Cas9 induced DSB. This was in contrast to Mycobacterium smegmatis Ku and 
LigD which were found to be highly efficient for DSB repair, enabling large genomic 
deletions (67 kbp and 123 kbp)103.  
 
1.4.4 Base excision repair 
In bacteria, the base excision repair (BER) pathway fixes non-bulky lesions 
in DNA. BER is thought to be the most commonly used DNA repair mechanism due 
to many sources having the capacity to introduce these lesions – alkylation, 
oxidation, depurination/depyrimidation, deamination and dUTP incorporation during 
DNA replication81. Lesions are detected and the damaged base removed by 
glycosylases hydrolysing the N-glycosidic bond. This results in the formation of an 
abasic (AP) site which is in turn recognised by AP endonucleases and AP lyases, 
breaking the phosphodiester bond at the 5´ and 3´ sides of the AP site respectively. 
The AP site is subsequently processed by an exonuclease or a 
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deoxyribophosphodiesterase. The small gap is closed by DNA polymerase and 
ligated to restore the damaged base to its undamaged form81. 
 
1.5 Utilisation of CRISPR systems within Bacilli 
The well understood and efficient mechanisms and tools for natural 
competence and HR in B. subtilis may account for the relatively slow uptake of the 
CRISPR-Cas9 genome editing toolkit, in comparison to other hosts with less 
efficient HR, such as Escherichia coli43 or Lactobacillus reteri104. However, the first 
example of the use of CRISPR-Cas9 in B. subtilis came in 2016 by Jakutyte-
Giraitiene and Gasiunas. Here Streptococcus thermophilus cas9, and one of two 
sgRNA expression cassette targeting the bacteriophage SPP1 were genomically 
integrated into the amyE locus of B. subtilis YB886. A third nonsense sgRNA strain 
was included as a control. These guides allowed a reduction in sensitivity to SPP1 
bacteriophage by 5-6 orders of magnitude, proving the ability for Cas9 to target non-
native DNA in B. subtilis105. This is commercially significant due to the susceptibility 
of industrial scale fermentations to bacteriophage contamination105.  
Westbrook et al. demonstrated CRISPR-Cas9 use in B. subtilis 168 using 
genomic integration of Cas9 in the lacA locus. The sgRNA expression cassette was 
integrated at the ‘recombination hotspot’ thrC with the glucose repressed mazF 
counter-selectable marker. In both cases, an antibiotic selection marker was used to 
select for genomic integration. Utilising the toxic nature of mazF, the sgRNA was 
flanked by short direct repeats which allowed a single crossover event to occur in 
the absence of glucose, thus removing the sgRNA expression cassette and mazF 
gene. A new sgRNA expression cassette could then be introduced at the same 
locus106. The same study found that a chromosomally maintained and expressed 
Cas9 does not affect hyaluronic acid production106. Multiplexing was analysed and a 
high efficiency of single KO for two genes, ugtP and amyE (85% and 86% 
respectively), and double KO for both was achieved (85%) using optimised HDR 
conditions: a plasmid based homology template for amyE, PCR based homology 
template for ugtP; 1000 bp homology arms; and PAM site close to gene start 
codon106.  Lastly, the authors developed a CRISPRi method targeting repression of 
lacZ expression. Using RT qRT-PCR they found 8 fold less lacZ mRNA and a 
corresponding 8 fold loss of β-galactosidase activity106. While this was a 
comprehensive toolbox for CRISPR-Cas9 activity in B. subtilis, representing the first 
44 
 
such example for gene KO or KI (knock-in), the need for genomic integration limits 
the speed with which experiments can be carried out. Westbrook et al. went on to 
utilise this genome editing approach to enhance heterologous production of 
hyaluronic acid by the streptococcal hyaluronan synthase in B. subtilis. CRISPRi 
was utilised to downregulate the expression of both pfkA and zwf to improve the titre 
of hyaluronic acid by 108%107. They subsequently went on to engineering the cell 
membrane, utilising dCas9 to downregulate the level of ftsZ, known to initiate cell 
division, which caused a dispersion in the cardiolipin within the membrane since its 
synthase, ClsA, localises to FtsZ108.  
Similarly, Peters et al. developed a specific and titratable CRISPRi protocol 
for gene knock down in B. subtilis. dcas9 was integrated into the lacA locus, while 
gRNAs were integrated at amyE or thrC. All 289 known (258) and proposed (31) 
essential genes within B. subtilis were analysed. It was established that dCas9 
inhibition acts upon genes downstream of the target gene within an operon, 
upstream genes were also affected. Growth curves and cell morphology microscopy 
allowed the determination of gene knock-down effect in vivo, providing a framework 
for essential gene functional analysis in Gram-positive organisms73. CRISPRa has 
also been exemplified within B. subtilis recently by Lu et al., as discussed in section 
1.3.460. 
Altenbuchner, developed a plasmid based system used for gene KO and KI 
with Cas963. Using a single plasmid system containing S. pyogenes Cas9, sgRNA 
expression cassette and dDNA for HDR with 700 bp homology arms, 4.1 kbp and 
25.1 kbp deletions were introduced to B. subtilis 168. Additionally, introduction of an 
isoleucine codon in the trpC2 gene cured the tryptophan auxotrophic nature of the 
strain. Once all editing was completed, the plasmid was removed with a heat 
sensitive origin of replication, pE19463. This tool was then utilised by Watzlawick and 
Altenbuchner to stably incorporate up to five copies of the β-galactosidase encoding 
gene, ganA, to the chromosome of B. subtilis and showing this to be more stable 
than a strain containing a multicopy plasmid expressing ganA109. Toymentseva and 
Altenbuchner also developed a set of CRISPR plasmids for use in other Bacilli, 
based on the heat sensitive pE194 origin. These enabled the use of CRISPR-Cas 
systems by conjugation, which is generally utilised in strains of B. subtilis or other 
Bacilli where natural competency is inefficient or totally absent102. Subsequently, the 
CRISPR-Cas9 plasmid initially developed by Altenbuchner was utilised to alter 
bacteriophage DNA in vivo to enable viral phenotypic investigations110. Recently, 
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Yi et al. utilised the Altenbuchner method for investigation of B. subtilis HS3, and 
adapted the plasmid for use with Bacillus mycoides EC18 to investigated the 
interactions of these rhizosphere-associated bacteria with plant roots111. 
Zhang at al. developed an alternative plasmid based Cas9/sgRNA with 
dDNA to improve the industrial applicability of an industrial relevant, poorly 
transformable strain, B. subtilis ATCC 6051a by lowering the level of foam (srfC), 
removing extracellular proteases (nprE and aprE) and α-amylase (amyE), as well as 
the ability to form spores (spoIIAC), by deleting the genes responsible for each112. 
The final strain produced 2.5-fold more of the industrially relevant enzyme 
β-cyclodextrin glycosyltransferase. 
Other CRISPR-Cas9 systems have been developed for large genomic 
deletions. Burby and Simmons developed a single plasmid system for cas9 and 
sgRNA expression, as well as containing the dDNA (similar to the method 
developed by Altenbuchner) to delete the 30.5 kbp PBSX prophage which is 
induced following DNA damage and has the ability to cause cell lysis113. So et al., 
developed a two-plasmid system in which B. subtilis was transformed with the cas9 
expressing plasmid, before making this strain competent and transforming with a 
second plasmid expressing a sgRNA and carrying dDNA. Using this approach, a 
38 kbp plipastatin-synthesising pps operon was deleted (80% efficient), as well as 
spo0A deletion (100% efficient), point mutations (68% efficient) and GFP insertion in 
sigE (97% efficient)114. 
Recently, Li et al. developed a method for genome editing in B. licheniformis. 
Their system incorporated nCas9 within the chromosome, before electroporating the 
subsequent strain with replicative plasmids containing dDNA and a sgRNA 
expression cassette. A 42.7 kbp region was deleted (79% efficiency), two genes 
were simultaneously deleted (11.6% efficiency), the aprN gene from B. subtilis was 
inserted (76.5% efficient) and lastly extracellular protease genes (wprA, mpr, aprE, 
vpr, epr) were sequentially deleted115. Liu et al. created a similar system for use 
within B. subtilis recently. A two plasmid system, one expressing nCas9 while the 
second expressed sgRNA(s) and harboured dDNA, enabled efficiencies of 80% for 
DNA deletion (1-8 kbp), 90% for 1-2 kbp insertions, and up to 65% for three 
simultaneous point mutations when ligD was deleted from the cell116. 
Lastly, Mougiakos et al. developed a CRISPR-Cas9 method for use within 
the facultative thermophile, Bacillus smithii. This host is industrially attractive since 
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its ability to grow in elevated temperatures reduces cooling costs, increases 
substrate and product solubility, reduces contamination risk, and is the optimal 
temperature for enzymatic lignocellulosic degradation enabling simultaneous 
saccharification and fermentation117. This study utilised a single plasmid to express 
cas9 and sgRNA, while also containing dDNA. The high natural recombination 
efficiency was used to incorporate the dDNA while Cas9 was heat-inactivated at 
45-55 °C. The temperature was subsequently lowered to 37 °C and Cas9 was used 
to counterselect cells which had not undergone HR of the dDNA117.  
 
1.6 Aims 
The study presented here aims to improve upon the tools currently available 
by combining the flexibility of plasmid based CRISPR systems and the use of rapidly 
constructed dDNA in the form of a PCR product. This increases the rate at which 
experiments can be implemented as it removes the requirement for cloning of the 
dDNA within the plasmid expressing the Cas nuclease and gRNA. This 
co-transformational approach is made possible by the high rate of natural 
competence inducible within B. subtilis. This can, for example, allow the rapid in situ 
engineering of industrially relevant proteins, such as subtilisin E, with a single 
targeting plasmid and a library of dDNA. As it had not been established in B. subtilis 
if HDR increased the editing efficiency in B. subtilis, or if HR, prior to the DSB, alone 
prevented DNA cleavage, this was also investigated. 
The exploitation of the industrially significant CRISPR nuclease, MAD7, 
within B. subtilis was investigated and engineered to enable licence and royalty free 
methods of CRISPR enabled genome editing and CRISPRi. This has the capacity to 
overcome current licencing restrictions associated to Cas9 and Cpf1 nucleases 
which can be a significant disincentive to its use for industrial fermentation strain 
construction. These tools were utilised to initiate the construction a heterologous 
protein expression library through sequential knock-out of extracellular proteases.   
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Chapter 2 – Materials and methods 
 
In this chapter, the experimental techniques and materials used throughout 
this study are described. 
 
2.1 Bacterial strains and plasmids 
All bacterial strains and plasmids used in this study are described at the start 
of the relating chapter. Schematic representations of the major plasmids used in this 
study can be found in Appendix A. All cloning of plasmids was carried out in 
Escherichia coli Top10 (Invitrogen (F- mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 
ΔlacX74 recA1 araD139 Δ(araleu) 7697 galU galK rpsL (StrR) endA1 nupG)). 
 
2.2 Growth and maintenance of bacterial cultures 
2.2.1 General growth and storage of cultures 
Lysogeny broth (LB) medium was used for all general-purpose E. coli and 
Bacillus subtilis growth cultures. No salt LB medium was used for E. coli 
electrocompetent cell preparation (Section 2.4.1). B. subtilis was transformed by the 
induction of natural competence following the method described by Bennallack et al. 
(Section 2.4.2). Growth media components are described fully in Appendix B. 
Growth was monitored by measuring optical density at 600 nm (OD600) in a 
spectrophotometer. When growth was desired on a solid agar plate, select agar was 
added to 1.5% (w/v) during medium preparation. 
Unless otherwise stated, growth cultures were performed in non-baffled 125 
mL Erlenmeyer flasks at 37 °C with orbital shaking at 250 rpm. When appropriate, 
isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to a final concentration of 
1 mmol L-1 to induce protein expression. When appropriate, antibiotics were added 
to the relevant concentration as described in Table 2.1.  
Unless otherwise stated, to ensure comparability between strains and 
replicates, growth was synchronised through the use of a pre-culture to grow diluted 
overnight cultures to exponential growth phase, in the same conditions as the assay 
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culture. Generally, overnight cultures were diluted to OD 600nm 0.05 for subsequent 
pre-culture growth. 
For long term storage of bacterial cultures, overnight LB cultures were 
supplemented to 10% (v/v) glycerol. These were stored at -80 °C in cryovials. 
 








Ampicillin (Amp) H2O 200 200 
Chloramphenicol 
(Cm) 
100% (v/v) ethanol 34 10 
Spectinomycin 
(Spec) 
H2O 100 200 
Kanamycin (Kan) H2O 100 10 
 
2.2.2 Platereader growth curves and GFP detection 
Due to the autofluorescence associated with LB medium an alternative 
medium with lower autofluorescence was used for CRISPRa experiments where 
small changes in GFP expression could be encountered. CHG medium was used 
when small changes in GFP expression levels were being detected118. Growth 
media components are described fully in Appendix B.  
2 mL LB medium overnight cultures, supplemented with the appropriate 
antibiotics, in 24-well plates, grown at 37 °C, 250 rpm, were used to inoculate 
200 µL CHG medium pre-cultures to OD600 0.05. These were subsequently grown 
to mid-exponential phase (OD600 0.6-0.8) at 37 °C, 300 rpm. At this point, when the 
cell states have been normalised to increase the reproducibility of experiments, the 
pre-cultures were used to inoculate the pre-warmed assay cultures. Growth curves 
and GFP detection was carried out in 96-well U-bottom plates (Greiner Bio-One, 
Austria) using the FLUOstar Omega Microplate Reader (BMG LABTECH, 
Germany). 200 µL cultures were incubated at 37 °C, 300 rpm. OD600 was measured 
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every 10 minutes. GFP was detected every 10 minutes at 485/520 nm 
(excitation/emission) and gain was set at 1264. 
 
2.2.3 RoboLector analysis 
To perform growth curves and detect small changes in GFP expression 
levels, the RoboLector XL microfermentation system (m2p-labs, Germany) was 
used. Biomass and GFP were monitored.  
Prior to RoboLector XL analysis, single colonies were used to inoculate 2 mL 
CHG medium cultures, supplemented with the appropriate antibiotics, and grown 
overnight in 24-well plates. These were used to inoculate 2 mL pre-warmed CHG 
medium in 24-well plates to OD600 0.1 and subsequently were grown to 
mid-exponential phase (OD600 0.6-0.8) at 37 °C, 200 rpm in a Multitron Standard 
Infors HT (Switzerland) incubator. The pre-cultures were diluted to OD600 0.1 in 1 mL 
pre-warmed CHG medium in 48-well FlowerPlate®. These plates were incubated in 
the RoboLector XL at 37 °C, 800 rpm, 85% humidity. Biomass (excitation: 620 nm, 
gain: 4) and GFP (excitation: 488 nm, emission: 520 nm, gain: 10) were monitored 
with measurements taken every 15 minutes. 
 
2.2.4 Minimal media for tryptophan auxotroph curing selection 
To select colonies for prototrophic phenotype, M9 agar plates were prepared 
with the appropriate antibiotics and glucose as the carbon source. 20 mg/L 
Tryptophan was also included where appropriate as a control to ensure all other 
components of the medium were included. Growth media components are described 
fully in Appendix B. Prior to spreading transformation colonies (Section 2.4.2), the 
cells were washed three times with phosphate buffered saline (10 mmol L-1 
phosphate buffer, 2.7 mmol L-1 potassium chloride, 137 mmol L-1 sodium chloride, 
pH 7.4). 
 
2.2.5 Cell Growth Quantifier system for growth analysis 
The effect of TadA-nCas9 on growth rate, when compared to TadA-dCas9, 
was analysed using the Cell Growth Quantifier (CGQ) system (Aquila Biolabs 
GmBH, Germany). The CGQ system measures light backscatter of growth cultures 
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to determine culture density. As the LEDs and photodiodes for measurements are 
situated in situ underneath the shake flask, there is no need to remove the cultures 
from incubation. Measurements were taken every 60 seconds.  
Growth rate (µ) was determined by the CGQ software (A.U./min) using 
Equation 2-1 in which two time points (t1 and t2) are compared and X is the cell 
density (determined by light backscatter) at each time point (Xt1 and Xt2). 
 




(𝒕𝟐  −  𝒕𝟏)
 
 
Since the small differences between shake-flasks can affect the backscatter 
reading, growth was zero’d to allow comparison between replicates by the 
subtraction of the first measurement from each subsequent reading. 
 
2.3 Chemicals 
All chemicals and reagents were obtained from Merck (USA) unless 
otherwise stated. 
 
2.4 Bacterial transformations 
2.4.1 Preparation and transformation of electrocompetent 
Escherichia coli 
E. coli, as well as other species, can be transformed with DNA by the 
addition of an electrical charge to promote migration of DNA across the cell 
membrane. To prepare electrocompetent E. coli cells, a 400 mL No Salt LB media 
culture, in a 2 L baffled Erlenmeyer flask was inoculated to OD600 0.1 from an 
overnight LB culture and grown at 37 °C, 250 rpm to mid exponential phase (OD600 
0.5 – 0.7). The cells were then chilled on ice before harvesting by centrifugation and 
undergoing two washes with ice cold sterile H2O. The cells were washed once more 
with ice cold, sterile 20% (v/v) glycerol. The cells underwent a final resuspension in 
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4 mL ice cold, sterile 20% (v/v) glycerol before being aliquoted in ice cold 1.5 mL 
tubes and storing at -80 °C until required for use.  
To transform the electrocompetent E. coli, 50 µL of competent cells were 
defrosted on ice and mixed with up to 5 µL of the ice-cold DNA containing solution. 
This mixture was added to a 1 mm electroporation cuvette. A 1.7 kV, 200 Ω and 
25 µF electric current was applied to the cuvette using a Bio-Rad (USA) GenePulser 
electroporator. 945 µL S.O.C. medium was added to the cuvette and the cell 
suspension was transferred to a 1.5 mL tube. This was incubated at 37 °C, 250 rpm 
for 1 hour before the cells were spread on an LB agar plate with the appropriate 
antibiotics and incubated overnight at 37 °C.  
 
2.4.2 Preparation and transformation of competent Bacillus subtilis  
The natural competence pathway well described in B. subtilis based on the 
expression of the master competency regulator protein, ComK, was utilised to 
prepare competent B. subtilis. The method described by Bennallack et al. was 
followed, with some modifications24. Information on growth medium components can 
be found in Appendix B. 
A single colony was used to inoculate 10 mL LB medium in a 125 mL 
non-baffled flask, with the appropriate antibiotics where required, and incubated 
overnight at 37 °C, 250 rpm. In a 125 mL flask, 14 mL starvation medium 1 (SM1) 
was inoculated with 1 mL of the overnight culture and grown until the culture enters 
stationary phase. 15 mL pre-warmed starvation medium 2 (SM2) was added and 
grown for a further 90 minutes under the same conditions. At this point, and for the 
next 2 hours, the cells are highly competent. In a 15 mL tube, 500 µL of cells were 
mixed with the DNA to transform the cell and incubated at 37 °C, 250 rpm for 
30 minutes. 300 µL of LB medium was added and incubated further at 37 °C, 
250 rpm for 30 minutes. The transformation mixture was then spread on an LB agar 




2.5 DNA manipulation 
General molecular biology techniques for DNA manipulation were performed 
as per Sambrook and Russell (2001)119. More detail is provided in the following 
sections.  
 
2.5.1 Purification of plasmid DNA 
Plasmid DNA was purified from E. coli overnight cultures using the Monarch® 
Plasmid Miniprep Kit (New England BioLabs® Inc. (NEB), USA) following the 
manufacturer’s instructions. This kit uses a column-based system that contains a 
silica membrane to which plasmid DNA can be bound, washed and eluted. All 
plasmid DNA was eluted with molecular biology grade H2O. 5 mL of bacterial culture 
was spun down and resuspended in 200 µL Plasmid Resuspension Buffer. 200 µL 
Plasmid Lysis Buffer was added and mixed well by inversion before incubating for 1 
minute. 400 µL Plasmid Neutralisation Buffer was added and mixed well by 
inversion before incubation at room temperature for 2 minutes. This lysate was 
clarified by centrifugation at 16,000 rcf for 5 minutes and the supernatant was added 
to a spin column. The plasmid DNA was bound to the silica by centrifugation at 
16,000 rcf for 1 minute. The column was washed with 200 µL Plasmid Wash Buffer 
1 by centrifugation at 16,000 rcf for 1 minute, before being washed again with 
400 µL of Plasmid Wash Buffer 2 by centrifugation at 16,000 rcf for 1 minute. The 
DNA was eluted with 50 µL of DNA Elution Buffer. 
When a large volume of plasmid DNA was required, the QIAGEN® 
(Germany) Plasmid Midi Kit was utilised as per the manufacturer’s instructions. 
100 mL of bacterial culture was spun down and resuspended in 6 mL Buffer P1. 
6 mL Buffer P2 was added to this, mixed by inversion and incubated at room 
temperature for 5 minutes. 6 mL chilled Buffer P3 was added to this, mixed by 
inversion and poured into QIAfilter Cartridge, with a cap screwed into the tip, before 
10 minutes incubation at room temperature. A HiSpeed Midi Tip was equilibrated by 
adding 4 mL Buffer QBT, which was allowed to pass through the column under 
gravity. The tip was removed from the QIAfilter Cartridge the cell lysate was filtered 
into the equilibrated HiSpeed Tip by gently pushing a plunger into the QIAfilter 
Cartridge. The lysate was allowed to enter the resin of the HiSpeed Tip under 
gravity. The HiSpeed Tip was then washed with 20 mL Buffer QC, before eluting the 
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DNA with 5 mL Buffer QF. The DNA was precipitated by adding 3.5 mL isopropanol 
to the eluted DNA, mixed and incubated at room temperature for 5 minutes. This mix 
was then gently passed through a QIAprecipitator using a syringe using a constant 
pressure. Using the same syringe, the DNA bound to the QIAprecipitator was 
washed with 2 mL 70% v/v ethanol. Air was then passed through the QIAprecipitator 
several times to ensure the ethanol was fully removed. Using a fresh syringe, the 
DNA was eluted in 1 mL TE Buffer and passed though the QIAprecipitator several 
times to ensure maximum DNA recovery. 
 
2.5.2 DNA quantification 
DNA concentration was quantified using the Qubit® 2.0 Fluorometer (Thermo 
Fisher Scientific, USA) in conjunction with the Qubit® dsDNA HS Assay Kit (Thermo 
Fisher Scientific, USA). The manufacturer’s instructions were followed with the 
exception of a fraction of the DNA sample being diluted 10x prior to addition to the 
assay buffer to maximise the accuracy of quantification. The Qubit® dsDNA HS 
working solution was prepared by mixing 1 µL of the Qubit® dsDNA HS Reagent 
with 199 µL Qubit® dsDNA HS Buffer, per sample to be analysed as well as for two 
additional standards. 199 µL of this was added to each tube for analysis of samples, 
while 190 µL was added to each tube for standard analysis. 1 µL of the diluted 
sample was added to each sample tube, while 10 µL of each standard (0 ng/µL and 
10 ng/µL) were added to each standard tube. Following 2 minutes incubation at 
room temperature and ensuring no bubbles were present in the base of the tube, 
these were analysed using the Qubit® 2.0 Fluorometer on the dsDNA HS setting. 
 
2.5.3 Isolation of genomic DNA from Bacillus subtilis 
To purify genomic DNA from B. subtilis, 1 mL of an LB medium overnight 
culture, containing the appropriate antibiotics where applicable, was harvested at 
16,000 xg for 1 minute at room temperature. The supernatant was discarded and 
the pellet was resuspended in 100 µL 0.85% (w/v) sodium chloride, supplemented 
with 5 µL 10 mg/mL RNAse ONE (Promega, USA) and 0.8 µL 125 mg/mL Lysozyme 
from chicken egg white. This was incubated at 37 °C for 5 minutes. 300 µL Cell 
Lysate Solution (25 mmol L-1 ethylenediaminetetraacetic acid (EDTA), 2% (w/v) 
sodium dodecyl sulphate (SDS)) was added and mixed well before addition of 
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168 µL Protein Precipitation Solution (10 mol L-1 ammonium acetate). The mix 
underwent 20 seconds of vortexing before 5 minutes incubation on ice. The cellular 
debris was removed by centrifugation at 16,000 xg for 10 minutes before 
transferring the supernatant to a new tube. 600 µL 100% (v/v) isopropanol was 
added and mixed well. DNA was isolated by centrifugation at 16,000 xg. The 
supernatant was removed and the DNA was washed with 200 µL 70% (v/v) ethanol. 
Following centrifugation at 16,000 xg for 2 minutes, the supernatant was discarded. 
Any remaining ethanol was removed by incubation at 55 °C for 10 minutes. The 
isolated genomic DNA (gDNA) was resuspended in 100 µL molecular biology grade 
H2O and stored at 4 °C. 
 
2.5.4 Oligonucleotides 
Unless otherwise stated, all single strand DNA (ssDNA) oligonucleotides 
used in this study were obtained from Merck. All oligonucleotides are described in 
Appendix C. If used for PCR, oligonucleotides were designed using the Clone 
Manager software (SciEd, USA). Oligonucleotides used for sgRNA protospacer 
cloning were designed as described in section 2.7.1. Upon delivery, oligonucleotides 
were resuspended in molecular biology grade H2O. 100 µmol L-1 stocks were stored 
at -40 °C, and 10 µmol L-1 working solutions were stored -20 °C.  
 
2.5.4.1 Oligonucleotide phosphorylation and annealing 
ssDNA oligonucleotide pairs designed for ligation with an additional piece of 
prepared DNA were 5´ phosphorylated, using T4 Polynucleotide Kinase (NEB, 
USA), and annealed in a one-pot reaction. The reaction mixture and thermo-cycler 









Table 2.2 – Reaction mixture and conditions for ssDNA oligonucleotide 
phosphorylation and annealing.  






 Lid Temperature: 105 °C 
100 µmol L-1 
Oligonucleotide 1 





100 µmol L-1 
Oligonucleotide 2 
5 10 µmol L-1  37 30 
10x T4 polynucleotide 
kinase buffer 
5 1x  65 20 
10 mmol L-1 ATP 5 1 mmol L-1  90 5 
100 mmol L-1 DTT 2.5 5 mmol L-1  85 1 
50% (w/v) PEG8000 5 5% (w/v)  80 1 
10 units/µL T4 
Polynucleotide Kinase 
1 10 units  75 1 
H2O 21.5   70 1 
    65 1 
    60 0.5 
    55 0.5 
    50 0.5 
    45 0.5 
    40 0.5 
    35 0.5 
    30 0.5 
    25 0.5 
    20 3 
  
2.5.5 Polymerase chain reaction (PCR) 




2.5.5.1 High fidelity DNA amplification 
DNA to be used in plasmid cloning or genomic intergradation was prepared 
using Phusion® High-Fidelity DNA polymerase (NEB) as per the manufacturer’s 
instructions (Table 2.3). The thermo-cycling conditions for a routine PCR reaction 
using Phusion® High-Fidelity DNA polymerase is described in Table 2.4. Primer 
annealing temperatures were determined using the NEB Tm calculator online tool. 
 
Table 2.3 – Standard PCR reaction using Phusion® High-Fidelity DNA polymerase. 
Component Volume (µL) Final concentration 
5x Phusion HF buffer 10 1x 
10 mmol L-1 dNTPs 1 200 µmol L-1 
10 µmol L-1 forward primer 2.5 0.5 µmol L-1 
10 µmol L-1 reverse primer 2.5 0.5 µmol L-1 
Template DNA Variable < 250 ng 
2 units/µL Phusion® High-
Fidelity DNA polymerase 
0.5 1 unit 
H2O Up to 50 µL  
 
Table 2.4 – Standard thermo-cycling reaction conditions for use with Phusion® High-
Fidelity DNA polymerase. 
Step Temperature (°C) Time Cycles 
Initial denaturation 98 30 seconds 1 
Denaturation 98 10 seconds 
35 cycles 
Primer annealing 45 – 72 20 seconds 
Extension 72 
15 seconds per 
kbp 




2.5.5.2 Colony PCR (cPCR) 
PCR was also used to identify colonies were cloning of a DNA fragment into 
a vector had been successful, or to identify where colonies had successfully had a 
region of DNA deleted or inserted. Here, a picked colony is suspended in 10 µL LB 
medium with the relevant antibiotic and used as the PCR template. This colony PCR 
(cPCR) procedure was performed using OneTaq® Quick-Load® 2x Master Mix with 
Standard Buffer (NEB, USA). See Table 2.5 for a routine reaction mix composition, 
and Table 2.6 for routine thermo-cycling reaction conditions when using OneTaq® 
Quick-Load® 2x Master Mix with Standard Buffer. The remaining colony suspension 
from any successful constructs was used to streak the strain out on LB agar with the 
appropriate antibiotic. 
 
Table 2.5 – Standard cPCR reaction using OneTaq® Quick-Load® 2x Master Mix with 
Standard Buffer. 
Component Volume (µL) Final concentration 
OneTaq® Quick-Load® 2x Master 
Mix with Standard Buffer 
10 1x 
10 µmol L-1 forward primer 1.5 0.75 µmol L-1 
10 µmol L-1 reverse primer 1.5 0.75 µmol L-1 
Colony suspension template DNA Variable  
H2O Up to 20 µL  
 
Table 2.6 – Standard cPCR thermo-cycling reaction conditions for use with OneTaq® 
Quick-Load® 2x Master Mix with Standard Buffer.  
Step Temperature (°C) Time Cycles 
Initial denaturation 94 5 minutes 1 
Denaturation 94 30 seconds 
30 cycles Primer annealing 45 – 68 30 seconds 
Extension 68 1 minute per kbp 




2.5.5.3 Overlap extension PCR 
Two DNA fragments, prepared using PCR, are fused in a two-step process, 
known as overlap extension PCR (OE-PCR). These two DNA fragments share 20 
bp with 100% homology at the extreme end where the two fragments are to be 
fused120. The two DNA fragments are added at the same molar ratio. This region of 
homology (~20 nt) acts as priming regions during the first PCR phase (Table 2.7 
and Table 2.8). During a pause in the thermo-cycling program, oligonucleotide 
primers are added hybridising to the 5´ end of the first fragment, and the 3´ end of 
the second fragment. During the second PCR phase, these primers amplify the final 
full construct. This product is isolated for subsequent purification by agarose gel 
electrophoresis (Section 2.5.6.1). 
 
Table 2.7 – Standard OE-PCR reaction using Phusion® High-Fidelity DNA polymerase. 
 Component Volume (µL) Final concentration 
Phase 
1 
5x Phusion HF buffer 10 1x 
10 mmol L-1 dNTPs 1 200 µmol L-1 
Template PCR-1 Variable 
100 ng 
Template PCR-2 Variable 
2 units/µL Phusion® High-
Fidelity DNA polymerase 
0.5 1 unit 
H2O Up to 45 µL  
Phase 
2 
10 µmol L-1 forward primer 2.5 0.5 µmol L-1 









Table 2.8 – Standard OE-PCR thermo-cycling reaction conditions for use with 
Phusion® High-Fidelity DNA polymerase. 
 Step Temperature (°C) Time Cycles 
Phase 
1 
Initial denaturation 98 30 seconds 1 
Denaturation 98 10 seconds 
15 cycles Primer annealing 45 – 72 40 seconds 
Extension 72 15 seconds per kbp 
Pause to add primer oligonucleotides 
Phase 
2 
Denaturation 98 10 seconds 
20 cycles Primer annealing 45 – 72 40 seconds 
Extension 72 15 seconds per kbp 
Final extension 72 5 minutes 1 
 
 
2.5.6 Electrophoresis of DNA 
DNA was analysed by agarose gel electrophoresis, or capillary gel 
electrophoresis. 
  
2.5.6.1 Agarose gel electrophoresis 
DNA grade agarose (Severn Biotech Ltd., United Kingdom) was suspended 
in 100 mL Tris-Acetate-EDTA (TAE) buffer (40 mmol L-1 Tris, 20 mmol L-1 Acetic 
acid, 1 mmol L-1 EDTA) and dissolved by microwave heating. 7 µL SYBR® Safe 
DNA Gel Stain (Thermo Fisher Scientific, USA) was added to enable visualisation of 
the DNA. The gel was cast with the required well size determined by the volume of 
the DNA containing solution following addition of gel loading dye, purple (NEB, USA) 
to 1x concentration. Once set, the DNA containing solution was added and the 
loaded gel underwent electrophoresis at 100 V for 30 – 45 minutes. DNA bound with 
SYBR® Safe DNA Gel Stain was visualised with the Safe Imager™ 2.0 Blue Light 
Transilluminator (Thermo Fisher Scientific, USA) system (excitation: 470 nm, 
emission: 530 nm). DNA band sizes were determined by comparison with 2-Log 




2.5.6.2 Capillary gel electrophoresis  
Analytical DNA analysis, were DNA did not need to be recovered, was 
performed using the Agilent 2200 TapeStation System (Agilent Technologies, USA). 
DNA bands are separated on a capillary agarose column, increasing the speed with 
which samples can be analysed. Furthermore, the sensitivity of DNA detection is 
increased to 5 pg/µL if required. DNA sizes up to 1 kbp were analysed with the 
D1000 Screentape and electronic DNA ladder. DNA sizes up to 5 kbp were 
analysed with the D5000 Screentape and comparison with the D5000 DNA marker. 
As per the manufacturer’s instructions, 1 µL of the DNA containing sample was 
mixed with 3 µL (D1000) or 10 µL (D5000) of the appropriate buffer.  Results were 
analysed using the 2200 TapeStation Controller Software (Agilent Technologies, 
USA), and Agilent TapeStation Analysis software (Agilent Technologies, USA). The 
buffers contain a low bp DNA marker and a high bp DNA marker with which the 
analysis software can directly compare between different capillaries. 
 
2.5.7 Purification of DNA from agarose gel 
DNA isolated by agarose gel electrophoresis (Section 2.5.6.1) was excised 
using a scalpel. Excess agarose gel not harbouring DNA was removed and the DNA 
was subsequently purified using the Monarch® DNA Gel Extraction Kit (NEB, USA). 
This kit utilises the standard bind/wash/elute workflow with a silica DNA binding 
matrix which lowers buffer transfer when compared to other common comparable 
kits. The gel slice was added to a pre-weighed 1.5 mL tube, the subsequent weight 
was measured and 4 volumes of Monarch Gel Dissolving Buffer was added (1 mg of 
gel equates to 1 µL buffer). The mix was incubated at 55 °C until the gel slice had 
fully dissolved, and subsequently added to a spin column. The DNA was bound to 
the silica by centrifugation at 16,000 rcf for 1 minute. The DNA was then washed 
twice with 200 µL DNA Wash Buffer, centrifuging for 1 minute at 16,000 rcf after each 
buffer addition. The DNA was eluted in into a fresh 1.5 mL tube with 10 µL molecular 




2.5.8 Digestion of DNA with restriction nucleases 
DNA fragments can be digested by restriction endonucleases in a blunt or 
staggered manner to expose blunt or ‘sticky ends’. Type IIP restriction 
endonucleases cleave the DNA within their targeting region, leaving a consistent 
region to facilitate cloning of DNA fragments. Type IIS restriction endonucleases on 
the other hand cleave the DNA outside their recognition site. Thus the ‘sticky end’ 
can be different between different DNA fragments cut with the same type IIS 
restriction endonucleases. Ligases allow the joining of DNA fragments at a 
compatible site. For example, bluntly cleaved DNA can be ligated to any other 
bluntly cleaved DNA fragment, provided a free phosphate group is available to 
facilitate the joining of the DNA backbone. Compatible ‘sticky ends’ are required for 
ligases to combine DNA fragments cut in such a manner121. DNA to be digested with 
restriction endonucleases were carried out following the manufacturer’s 
recommendations. Unless otherwise stated, all restriction nucleases were obtained 
from NEB.  
Parental CRISPR plasmid backbone preparations during gRNA protospacer 
cloning underwent restriction digestion reactions using AarI (Thermo Fisher 
Scientific, USA) or SapI. The AarI reaction mixture outlined in Table 2.9 was 
prepared and incubated for 5 hours at 37 °C, before the enzyme was heat 
inactivated at 65 °C for 20 minutes. 
 
Table 2.9 – Typical reaction mixture for the preparation of parental CRISPR plasmid 
backbones, based on pBAC0008, during gRNA protospacer cloning. 
Component Volume (µL) Final concentration 
Plasmid DNA Variable Up to 1 µg 
10x Buffer AarI 2 1x 
50x AarI Oligonucleotide 0.4 1x 
2 units/µL AarI 0.5 1 unit 




2.5.9 Dephosphorylation of DNA 
Backbone DNA for use in cloning was 5´ dephosphorylated using Alkaline 
Phosphatase, Calf Intestinal (CIP) (NEB, USA) to prevent self-ligation with 
compatible ends. The manufacturer’s protocol was followed to set up 20 µL reactions 
as per Table 2.10. This was incubated at 37 °C for 30 minutes before the DNA was 
isolated and purified by agarose gel electrophoresis. 
 
Table 2.10 – DNA dephosphorylation reaction using Alkaline Phosphatase, Calf 
Intestinal (CIP). 
Component Volume (µL) Final concentration 
Linear DNA Variable Up to 1 pmol 
Cutsmart Buffer (10x) 2 1x 
1 units/µL CIP 1 1 unit 
H2O Up to 20 µL  
 
 
2.5.10 Ligation of DNA fragments 
DNA fragments were ligated using T4 DNA Ligase (NEB, USA). The reaction 
mixture, with a total DNA amount of 100 ng, is described in Table 2.11. Reactions 
were incubated at room temperature for 2 hours, heat inactivation of the ligase at 
65 °C for 10 minutes and used to transform E. coli cells (Section 2.4.1). 
 
Table 2.11 – Ligation reaction conditions using T4 DNA Ligase. 
Component Volume (µL) Final concentration 
Backbone DNA Variable Variable (mol L-1) 
Insert DNA Variable 5x mol L-1 of backbone DNA 
10x T4 DNA Ligase Buffer 2 1x 
400 units/µL T4 DNA Ligase 1 400 units 




2.5.11 Gibson DNA Assembly 
The Gibson Assembly technology was used to assemble multiple DNA 
fragments with overlapping regions in a one-pot isothermal reaction122. Typically, 
20 bp of homology between adjacent fragments were designed. NEBuilder HiFi 
DNA Assembly Master Mix (NEB, USA) was used for all assembly reactions. The 
reaction master mix was diluted in an equal volume of the DNA fragments to be 
assembled. Insert DNA was combined with the vector in a 3:1 molar ratio. All 
reactions were incubated at 50 ºC for 60 min before being used to transform E. coli 
cells (Section 2.4.1). 
 
2.5.12 InABLE® DNA Assembly 
The InABLE® DNA assembly method was used to construct the initial 
parental plasmids to be subsequently used alongside traditional cloning methods for 
final plasmid construction and use within CRISPR experiments (Section 2.5)123. 
Individual 5´ truncated parts were prepared by PCR and subjected to restriction 
digestion at 5´ and 3´ regions with SapI. These parts were ligated to phosphorylated 
and annealed oligonucleotides at each terminus, containing 3 nt and 16 nt single 
strands at the 5´ and 3´ ends, respectively. The part- oligonucleotides fusions were 
annealed at the homologous 16 nt overhangs for 1 hour at 37 °C, and used to 
transform electrocompetent E. coli (Section 2.4.1).  
 
2.5.13 Ligation Independent cloning 
Ligation independent cloning (LIC) was used for the introduction of PliaG for 
gfpmut3 expression on the plasmid pGFPbglS, yielding plasmid pBAC0091124. The 
method outlined by Bisicchia et al. was followed124. pGFPbglS contains a LIC site: 
TTTTACCGCGGGCTTTCCCGGGAAGGAGGAACT. pGFPbglS is linearised with 
SmaI (recognition sequence in bold) and 4 pmol is treated with 20 units of T4 
polymerase (NEB) in the presence of 1x NEBbuffer 2.1 and 2.5 mmol L-1 dATP 
(Thermo Fisher Scientific) for 20 minutes at 22 °C followed by 20 minutes at 75 °C 
to inactivate the enzyme. This generates single-stranded overhangs on either side 
of the SmaI site extending to the underlined A bases.  
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A PliaG containing fragment was prepared by PCR using oligonucleotides 
oMAP0298/0299, introducing a 5´-CCGCGGGCTTTCCCAGC-3´ tail sequence via 
oMAP0298 and a 5´-GTTCCTCCTTCCCACC-3´ tail sequence via oMAP0299. 
0.2 pmol PCR fragments were then treated with 0.4 units of T4 DNA polymerase in 
the presence of 1x NEBuffer 2.1 and 2.5 mmol L-1 dTTP at 22 °C for 20 minutes, 
and the enzyme was inactivated at 75 °C for 30 minutes. This generates an insert 
fragment with complementary single-stranded regions to those generated in 
pGFPbglS. 
5 ng of the treated pGFPbglS was mixed with 15 ng of the treated PCR 
product and incubated at room temperature for 10 minutes before transformation of 
E. coli by electroporation (section 2.4.1). 
 
2.6 DNA sequencing 
DNA Sanger sequencing was primarily carried out by Source Bioscience 
(Cambridge, United Kingdom). Sequencing for CRISPR enabled DNA deamination 
base editing was performed either by Source Bioscience, GeneWiz (Beijing, China) 
or General Biosystems (Beijing, China). 
 
2.7 CRISPR-Cas9 mediated gene editing in Bacillus subtilis 
2.7.1 sgRNA protospacer design 
The protospacer regions were initially identified using the online tool 
CRISPR-ERA: a comprehensive designer tool for CRISPR genome editing, (gene) 
repression, and activation, and selected based on the proximity to the desired 
modification125. This tool is only applicable for Cas9 based CRISPR experiments. 
Latterly, a widely used online tool, CHOPCHOP, was adapted for use with B. 
subtilis and was used for protospacer design126,127. This tool is applicable for both 
Cas9 and AsCpf1 protospacer identification. Due to the similarities between the 
PAM sites for AsCpf1 and MAD7, CHOPCHOP can also identify appropriate sites 
for MAD7 based experiments, however gRNA scores relevant for AsCpf1 may not 




2.7.2 sgRNA selection 
When a gene or locus input is loaded to the protospacer identification 
software, all candidates are scored and listed based on% GC, predicted efficiency, 
the detection of any off-target effects, and the level of self-complementarity to 
identify any stem-loops in the subsequent RNA. Additionally, the position where the 
protospacer is situated is experiment dependent. 
 
2.7.2.1 CRISPR enabled gene editing and DNA deaminase base editing 
When a region was to be deleted, a PAM site was selected equidistance 
from the 5´ and 3´ ends of the relevant area. PAM sites used for point mutations or 
DNA insertions were selected for their proximity to the intended editing/insertion site. 
 
2.7.2.2 CRISPRi 
PAM sites were selected for their proximity to the gene promoter or 5´ region 
of the target gene. 
 
2.7.2.3 CRISPRa 
Protospacers were selected at regions extending upstream of the start 
codon, as was exemplified in E. coli by Bikard et al.59. Protospacers within the 
promoter act as controls for the binding of the Cas9 fusion protein to show the 
knock-down of the target gene.  
 
2.7.3 Cloning of protospacer region into parental plasmids 
Parental plasmids were digested with either AarI or SapI, depending on the 
parental plasmid used (Section 2.5.8), before being dephosphorylated to prevent 
self-ligation (Section 2.5.9). Two DNA oligonucleotides were annealed and 
phosphorylated (Section 2.5.4.1). The annealed oligonucleotides consisted of the 
protospacer region for targeting of the Cas proteins and 4 nt or 3 nt on the 5´ and 3´ 
ends to generate a single stranded overhang for compatibility with the AarI or SapI, 
respectively, digested parental plasmid. These were subsequently ligated (Section 
2.5.10) with the prepared parental plasmid. Insertion was confirmed by cPCR 
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(Section 2.5.5.2) and sequencing with oMAP0148. All final plasmids used for 















Oligonucleotides used for 




Start codon -35 promoter element 




pBAC0035 pBAC0015 Cas9 NT - - - oMAP0145/0147 


























pBAC0092 pBAC0082 dCas9-ω(Bs) gfpmut3 CGG - 
113 bp upstream  (Pveg 
and PrrnB P1) 
oMAP0224/0225 
pBAC0093 pBAC0082 dCas9-ω(Bs) gfpmut3 AGG - 
131 bp upstream  (Pveg 
and PrrnB P1) 
oMAP0226/0227 
pBAC0094 pBAC0082 dCas9-ω(Bs) gfpmut3 AGG - 
139 bp upstream  (Pveg 
and PrrnB P1) 
oMAP0228/0229 
pBAC0095 pBAC0082 dCas9-ω(Bs) gfpmut3 TGG - 
163 bp upstream  (Pveg 
and PrrnB P1) 
oMAP0230/0231 
pBAC0096 pBAC0082 dCas9-ω(Bs) gfpmut3 AGG - 
200 bp upstream  (Pveg 
and PrrnB P1) 
oMAP0232/0233 
pBAC0097 pBAC0067 dCas9-ω(Es) gfpmut3 AGG - 163 bp upstream (PliaG) oMAP0324/0325 
pBAC0098 pBAC0067 dCas9-ω(Es) gfpmut3 GGG - 125 bp upstream (PliaG) oMAP0326/0327 
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pBAC0099 pBAC0067 dCas9-ω(Es) gfpmut3 AGG - 145 bp upstream (PliaG) oMAP0328/0329 
pBAC0100 pBAC0067 dCas9-ω(Es) gfpmut3 TGG - 154 bp upstream (PliaG) oMAP0330/0331 
pBAC0101 pBAC0067 dCas9-ω(Es) NT - - - oMAP0145/0147 
pBAC0102 pBAC0082 dCas9-ω(Bs) gfpmut3 GGG - 
80 bp upstream (PliaG) 
16 bp upstream    (Pveg 
and PrrnB P1) 
oMAP0320/0321 
pBAC0103 pBAC0082 dCas9-ω(Bs) gfpmut3 AGG - 
97 bp upstream (PliaG) 
33 bp upstream    (Pveg 
and PrrnB P1) 
oMAP0322/0323 
pBAC0104 pBAC0082 dCas9-ω(Bs) NT - - - oMAP0145/0147 
pBAC0110 pBAC0090 dCas9-Φ29 gfpmut3 GGG - 80 bp upstream (PliaG) oMAP0320/0321 
pBAC0111 pBAC0090 dCas9-Φ29 gfpmut3 AGG - 97 bp upstream (PliaG) oMAP0322/0323 
pBAC0112 pBAC0090 dCas9-Φ29 gfpmut3 GGG - 125 bp upstream (PliaG) oMAP0326/0327 
pBAC0113 pBAC0090 dCas9-Φ29 gfpmut3 AGG - 145 bp upstream (PliaG) oMAP0328/0329 
pBAC0114 pBAC0090 dCas9-Φ29 gfpmut3 TGG - 154 bp upstream (PliaG) oMAP0330/0331 
70 
 
pBAC0115 pBAC0090 dCas9-Φ29 NT - - - oMAP0145/0147 
pBAC0120 pBAC0082 dCas9-ω(Bs) gfpmut3 CGG - 84 bp upstream (PliaG) oMAP0336/0337 
pBAC0121 pBAC0082 dCas9-ω(Bs) gfpmut3 GGG - 73 bp upstream (PliaG) oMAP0338/0339 
pBAC0122 pBAC0082 dCas9-ω(Bs) gfpmut3 TGG - 68 bp upstream (PliaG) oMAP0340/0341 
pBAC0123 pBAC0082 dCas9-ω(Bs) gfpmut3 TGG - 56 bp upstream (PliaG) oMAP0342/0343 
pBAC0124 pBAC0082 dCas9-ω(Bs) gfpmut3 CGG - 45 bp upstream (PliaG) oMAP0344/0345 
pBAC0125 pBAC0082 dCas9-ω(Bs) gfpmut3 CGG - 30 bp upstream (PliaG) oMAP0346/0347 
pBAC0126 pBAC0082 dCas9-ω(Bs) gfpmut3 CGG - 23 bp upstream (PliaG) oMAP0350/0351 
pBAC0127 pBAC0082 dCas9-ω(Bs) gfpmut3 CGG - 11 bp upstream (PliaG) oMAP0354/0355 




pBAC0132 pBAC0082 dCas9-ω(Bs) gfpmut3 CGG - 
20 bp upstream 
(Pveg) 
oMAP0406/0407 
pBAC0133 pBAC0082 dCas9-ω(Bs) gfpmut3 GGG - 61 bp upstream oMAP0326/0327 
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(Pveg and PrrnB P1) 
pBAC0134 pBAC0082 dCas9-ω(Bs) gfpmut3 AGG - 
20 bp downstream 
(PrrnB P1) 
oMAP0412/0413 
pBAC0135 pBAC0082 dCas9-ω(Bs) gfpmut3 GGG - 
9 bp upstream 
(PrrnB P1) 
oMAP0414/0415 
pBAC0160 pBAC0159 AsCpf1 NT - - - oMAP0553/0554 








pBAC0163 pBAC0158 MAD7 NT - - - oMAP0555/0556 



















oMAP0563/0564 and  




NT - - - 






























pBAC0189 pBAC0163 dMAD7 NT - - - oMAP0555/0556 












pBAC0194 pBAC0035 dCas9 NT - - - oMAP0145/0147 






















pBAC0201 pBAC0158 MAD7 bpr TTTT 1 bp upstream - oMAP0724/0725 
pBAC0202 pBAC0158 MAD7 nprB TTTT 2 bp upstream - oMAP0731/0732 
pBAC0203 pBAC0158 MAD7 mpr TTTG 1 bp upstream - oMAP0738/0739 




































































































2.7.4 Donor DNA (dDNA) preparation 
Linear dDNA was prepared by OE-PCR (Section 2.5.5.3), where the 
modifications of interest were introduced into the primers used for the initial PCR 
products. In the event that the modifications of interest have been introduced into a 
strain during a previous experiment, the gDNA for this strain (following curing of the 
editing plasmid) was purified, and used for PCR amplification.  
 
2.7.5 Co-transformation of B. subtilis 
Naturally competent B. subtilis (Section 2.4.2), were transformed with 200 ng 
of the editing plasmid alongside 1 µg of dDNA at ~2 kbp in length.  
 
2.7.6 Curing of editing plasmid from B. subtilis 
The CRISPR editing plasmids were removed from the edited strain by 
promoting plasmid loss in LB supplemented with 1 mmol L-1 IPTG overnight. Here 
the presence of IPTG encourages curing by introducing the pressure of protein 
expression without the presence of the appropriate antibiotic to retain the plasmid 
within the cell.  
Plasmid loss was confirmed by counter plating on LB agar plates with and 
without chloramphenicol before a subsequent round of editing, or other uses for the 
strain. Counter plating was performed by first patching a sterilised velvet cloth from 
an LB agar plate harbouring the colonies to be screened. This was then used to 
inoculate first an additional LB agar plate, and an LB agar plate with the appropriate 
antibiotics. Following growth at 37 °C, colonies which grew on LB agar without 
antibiotics, but not on the plate containing chloramphenicol, were judged to have lost 
the plasmid. This was confirmed by growing the colony in LB media only, and LB 
media with chloramphenicol. 
 
2.8 Protein analysis by Sodium Dodecyl Sulphate-
Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Proteins were visualised using sodium dodecyl sulphate-polyacrylamide gel 





2.8.1 Protein sample preparation 
Proteins expressed intracellularly were prepared for SDS-PAGE analysis in 
the following manner. 1 mL cell culture of a known OD600 was harvested by 
centrifugation at 16,000 xg for 1 minute. The supernatant was discarded and the cell 
pellet was resuspended in 32.2 µL cell lysis master mix / mL culture / OD600. The cell 
lysis master mix was made up of 30 µL BugBuster® Protein Extraction Reagent, 
2 µL 30 mg/mL lysozyme from chicken egg white and 0.2 µL 2.5 units/µL 
Benzonase® Nuclease (Merck, USA). This was incubated at 37 °C for 20 minutes to 
lyse the cells before being centrifuged at 16,000 xg for 10 minutes to separate the 
soluble and insoluble intracellular protein fractions. The soluble fraction 
(supernatant) was separated, and the insoluble fraction was resuspended in the 
same volume of deionised H2O. SDS-PAGE samples were prepared by adding 
10 µL of the soluble or insoluble fraction to 12.5 µL 4x BOLT LDS Sample Buffer 
(Thermo Fisher Scientific, USA), 5 µL 9% (w/v) dithiothreitol, and 22.5 µL deionised 
H2O before being incubated at 100 °C for 5 minutes. The sample was subsequently 
briefly centrifuged to ensure the full volume was in the base of the tube, before 
being mixed by vortexing.  
Extracellular protein samples and protein purification samples were analysed 
directly by mixing 32.5 µL of the cell culture supernatant, or purification fraction, with 
the SDS-PAGE sample components as above, without the addition of H2O. The 
samples were boiled, centrifuged and vortexed as above. 
 
2.8.2 Separation of samples by SDS-Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) 
Proteins within the prepared SDS-PAGE sample were separated based on 
their molecular weight using the Bolt™ Bis-Tris Plus Gel system (Thermo Fisher 
Scientific, USA) with 1 mm gel thickness and a gradient of 4-12% polyacrylamide 
concentration. Intracellular protein samples were analysed by the addition of 10 µL 
SDS-PAGE sample to each well. Extracellular protein samples and protein 
purification samples were analysed by the addition of 35 µL SDS-PAGE sample to 






2.8.3 InstantBlue™ protein visualisation 
Protein samples separated using the Bolt™ Bis-Tris Plus Gel system were 
visualised using 20 mL of InstantBlue™ Protein Stain (Expedeon, USA). This was 
added directly to the gel and incubated at room temperature, with gentle agitation, 
for 15 minutes. Following incubation, the InstantBlue™ Protein Stain was discarded, 
and the gel was washed with deionised H2O. 
 
2.9 Enzymatic activity detection 
2.9.1 Analysis of α-amylase activity in solid phase 
The starch degrading α-amylase enzyme can be characterised through the 
use of iodine to stain non-degraded starch27. As such, α-amylase secretion can be 
detected from a colony on an LB agar plate supplemented with 1% (w/v) soluble 
potato starch. Colonies were first used to inoculate a fresh LB plate before adding 
5 mL H2O to the plate and washing off the colonies to allow a clear identification of a 
degraded starch halo. 2.5 mL of 3.57 mmol L-1 iodine solution was added to each 
plate to stain the non-degraded starch a dark blue. When the α-amylase was 
secreted from the colony, a clear halo can be observed.  
 
2.9.2 Analysis of α-amylase activity in liquid phase 
Using biological triplicates, 2 mL LB B. subtilis cultures, supplemented with 
the relevant antibiotics and 1 mmol L-1 IPTG for dcas9 or dmad7 expression 
induction, were grown for 24 hours of growth at 37 °C, 250 rpm. 100 µL samples 
were harvested at 2250 rcf for 5 minutes and the supernatant, containing the 
secreted α-amylase enzyme, was stored at -20 °C until required. In a 96-well MTP, 
biological triplicates were analysed by mixing 25 µL of the thawed supernatant with 
100 µL of ice-cold assay solution (0.05% (w/v) soluble potato starch, 50 mmol L-1 tris 
hydrochloride, 25 mmol L-1 calcium chloride dihydrate, pH 6.8). This was incubated 
at 37 °C for 30 minutes before the reaction was stopped by the addition of 50 µL of 
stop solution (0.01% (w/v) iodine, 0.1% (w/v) potassium iodide, 1 mol L-1 tris 
hydrochloride). Each well was analysed at 620 nm using the FLUOstar Omega 




A medium blank treated in the same way was used as a base line for the reaction. 
Several serial dilutions were carried out to ensure the absorbance was in the linear 
range of the spectrophotometer.  
Amylase activity is shown by a decrease in absorbance. In the presence of 
KI, I2 forms I3- which is a soluble complex that enters the coil of the starch causing 
an intense blue-black colour. Therefore, when starch is degraded by amylase a 
lighter colour is obtained. The values obtained were inverted to make it clear where 
greater amylase activity was identified. 
 
2.9.3 Analysis of protease activity  
Subtilisin E variants and WT activity was determined by casein degradation 
as described by Cupp-Enyard128. Experiments were carried out with three technical 
replicates. The protocol was modified for use with MTP to increase the experimental 
rigor and throughput. 20 µL samples were added to 115 µL 0.65% (w/v) casein 
solution (prepared in 50 mmol L-1 potassium phosphate dibasic trihydrate, pH 7.5), 
mixed well and incubated at 37 °C for 30 minutes. 115 µL 110 mmol L-1 
trichloroacetic acid was added and incubated at 37 °C for 10 minutes to stop the 
reaction. The MTP was centrifuged at 2000 xg for 10 minutes. 50 µL of the 
supernatant was added to 125 µL 500 mmol L-1 sodium carbonate, before the 
further addition of 25 µL 0.5 N Folin & Ciocalteu’s phenol reagent which reacts 
primarily with free tyrosine released by the protease. This was mixed well and 
incubated at 37 °C for 30 minutes. The MTP was centrifuged at 2000 xg for 
10 minutes before transferring 100 µL of the supernatant into a fresh MTP and 
recording the absorbance value at 660 nm using the FLUOstar Omega Microplate 
Reader (BMG LABTECH, Germany). 
 
2.9.3.1 Residual protease enzyme activity assay 
The residual protease activity was measured in the same manner as in 
section 2.9.3. However, prior to the addition of the enzyme fraction, the samples 





2.10 GFPmut3 detection 
B. subtilis 168 was modified to express GFPmut3 which was subsequently 
used as a reporter protein for various methods.  
 
2.10.1 Qualitative detection 
The presence of expressed GFPmut3 within colonies or liquid culture was 
qualitatively detected using the Safe Imager™ 2.0 Blue Light Transilluminator and 
Amber Filter (Thermo Fisher Scientific, USA) system (excitation: 470 nm, emission: 
530 nm).  
 
2.10.2 Quantitative detection by plate reader 
Using biological triplicates, 2 mL LB cultures, containing the relevant 
antibiotics and 1 mmol L-1 IPTG for where appropriate, were grown overnight at 
37 °C, 250 rpm. In the same medium, the overnight cultures were used to inoculate 
2 mL cultures in 24 well plates to OD600 0.05 and grown to exponential growth phase 
at 37 °C, 250 rpm to normalise the cell state between cultures. These were 
subsequently used to inoculate a further 2 mL culture of the same medium to 
OD600 0.05. OD600 levels were measured and 100 µL samples were used to measure 
GFPmut3 using the FLUOstar Omega Microplate Reader (BMG LABTECH, 
Germany) 24 hours after assay culture inoculation (GFPmut3 excitation: 485 nm, 
emission: 520 nm, gain: 1000). The relative expression levels of gfpmut3 were 
quantitatively determined by normalisation of the GFPmut3 levels (A.U.) by OD600. 
 
2.11 In silico design for protein engineering of B. subtilis 168 
subtilisin E 
The crystal structures for B. subtilis subtilisin E (PDB ID: 1SCJ) and its 






2.12 Subtilisin E purification by size exclusion 
chromatography 
The three subtilisin E variants and WT protein were overexpressed in the 
aprE knock-out strain BAC0114. This strain was then transformed with plasmids 
pBAC0059/0060/0068/0069, resulting in strains BAC0119/0120/0121/0122 
respectively. These strains were grown for 24 hours at 37 °C, 250 rpm in 20 mL LB 
supplemented with chloramphenicol and 1 mmol L-1 IPTG for aprE variant 
expression. The supernatant was clarified by centrifugation (850 rcf, 10 minutes, 4 
°C) and dialysed overnight into 100 mmol L-1 tris hydrochloride  with 150 mmol L-1 
sodium chloride at pH 8. The dialysed supernatant was concentrated to 5 mL with 
Amicon Ultra-15 (10 kDa membrane (Merck, USA)), filtered through a 0.2 µm filter 
(Sartorius, Germany). This was loaded onto a HiPrep Sephacryl S-200 HR, 120 mL 
16/60 size exclusion column (GE Healthcare, USA), eluted in the same buffer 
composition used for dialysis and fractions found to contain subtilisin E were pooled.  
 
2.12.1 Protein concentration determination 
Protein concentration was determined by absorbance at 280 nm. Samples 
were loaded into a quartz cuvette and analysed using the Cary 60 UV-Vis 
spectrophotometer (Agilent Technologies, USA), and the Simple Reads software 
(Agilent Technologies, USA). The spectrophotometer was blanked with the same 
buffer used during protein purification. The Beer-Lambert law (Equation 2-2) was 
used to determine the protein concentration using the absorbance at 280 nm, the 
molar extinction co-efficient (ε) of AprE (32430 for all variants), and the known 
pathlength (l) of 1 cm.   
 
Equation 2-2 – Beer-Lambert Law   
𝑨𝒃𝒔𝟐𝟖𝟎  =  𝜺 ×  𝑪 ×  𝑰 
 
2.13 Thermal shift assay 
The fluorescence-based thermal shift assay was used to determine the 




reaction was prepared in a total volume of 20 µL (18 µL purified subtilisin E variant 
in purification buffer (section 2.11), 1 µL 100 mmol L-1 calcium acetate and 1 µL 
1:50 SYPRO® Orange). The assay was performed with six technical replicates for 
each variant. The reaction was analysed using the PikoReal™ Real-Time PCR 
System (Thermo Fisher Scientific, USA) which recorded changes in fluorescence 
with increasing temperature (40 °C - 80 °C in increments of 0.2 °C, held for 6 
seconds at each point). 
 
2.14 Real-time quantitative reverse transcription PCR (RT 
qRT-PCR) 
Real-time quantitative reverse transcription PCR (RT qRT-PCR) was used to 
detect differences in gfpmut3 expression levels during CRISPRa experiments in 
B. subtilis. The analysis was performed with biological triplicates and technical 
duplicates using two reference genes (gapA and sdhA) to allow standardisation of 
the samples as per the Minimum Information for Publication of Quantitative 
Real-Time PCR Experiments (MIQE)133. Strain BAC0297 harbouring a non-targeting 
CRISPRa plasmid was used as the relative quantification reference. 
 
2.14.1 Harvesting of samples 
To allow reliable comparison between replicates, samples were taken during 
exponential phase of the assay culture following growth synchronisation using a 
pre-culture. Growth was monitored with dilutions of the cell culture in 96-well 
U-bottom plates (Greiner Bio-One, Austria) using the FLUOstar Omega Microplate 
Reader (BMG LABTECH, Germany). 
In 24-deep well plates, three single colonies were used to inoculate 1 mL LB 
medium supplemented with the appropriate antibiotic and 1 mmol L-1 IPTG. These 
were grown overnight at 37 °C, 250 rpm. The following morning, these cultures were 
used to inoculate pre-cultures (LB medium supplemented with the appropriate 
antibiotic and 1 mmol L-1 IPTG, 1 mL final volume) to OD600 0.05 and grown until 
mid-exponential phase (OD600 0.4 – 0.8). The pre-cultures were diluted to 
OD600 0.05 in pre-warmed LB medium supplemented with the appropriate antibiotic 




monitored and at mid-exponential phase 50 µL (corresponding the manufacturer’s 
recommended biomass amount for RNA purification) of the culture was removed for 
immediate RNA purification.  
 
2.14.2 RNA purification 
The total RNA for each sample was prepared using the Monarch® Total RNA 
Miniprep Kit (NEB, USA). The purification was carried out in a biological safety 
cabinet, and RNAseZap® (Thermo Fisher Scientific, USA) was used to clean the 
biological safety cabinet, pipettes and gloves prior to the experiment to avoid 
contamination by RNAse enzymes. The manufacturer’s protocol was followed 
throughout.  
Cells were harvested by centrifugation (500 xg, 1 minute) and the 
supernatant was removed. Two volumes of RNA Lysis Buffer was mixed with 
lysozyme from chicken egg white at a final concentration of 3 mg/mL. This 
underwent vigorous vortexing for 10 seconds, incubated at 25 °C for 10 minutes and 
centrifuged for 2 minutes at 16,000 xg. The supernatant was transferred to a gDNA 
Removal Column. All subsequent centrifugation steps were performed at 16,000 xg. 
The gDNA removal column was centrifuged for 30 seconds and to the 
supernatant was added an equal volume of 100% (v/v) ethanol. This was mixed by 
pipetting before being added to an RNA Purification Column and centrifuging for 
30 seconds. The flow-through was discarded and 500 µL RNA Wash Buffer was 
added to the column. This was centrifuged for 30 seconds and 80 µL DNase I 
reaction mix was loaded to the column for an on-column DNase I treatment to 
remove residual DNA. Following incubation at room temperature for 15 minutes, 
500 µL RNA Priming Buffer was added to the column before centrifugation for 
30 seconds. 500 µL RNA Wash Buffer was loaded before centrifugation for 
30 seconds. A further 500 µL RNA Wash Buffer was added before centrifugation for 
2 minutes. The RNA was eluted with 50 µL Nuclease-free Water and stored 
at -80 °C until required. 
 
2.14.3 RNA quantification 
RNA concentration was quantified with two replicates using the Qubit® 2.0 




Assay Kit (Thermo Fisher Scientific, USA). The manufacturer’s instructions were 
followed. The Qubit® RNA HS working solution was prepared by mixing 1 µL of the 
Qubit® RNA HS Reagent with 199 µL Qubit® RNA HS Buffer, per sample to be 
analysed as well as for two additional standards. 199 µL of this was added to each 
tube for analysis of samples, while 190 µL was added to each tube for standard 
analysis. 1 µL sample was added to each sample tube, while 10 µL of each 
standard (0 ng/µL and 10 ng/µL) were added to each standard tube. Following 
2 minutes incubation at room temperature and ensuring no bubbles were present in 
the base of the tube, these were analysed using the Qubit® 2.0 Fluorometer on the 
RNA HS setting. 
 
2.14.4 Reverse transcription 
RNA was reverse transcribed to cDNA using the ProtoScript® II Reverse 
Transcriptase (NEB, USA). In duplicate reactions, the following was added: 6 µL 
purified RNA; 2 µL of the supplied Random Primer Mix  at 60 µmol L-1; 10 µL 
Protoscript® II Reaction Mix; 2 µL Protoscript® II Enzyme Mix. This mixture was 
incubated for 5 minutes at 25 °C, followed by 60 minutes at 42 °C. The subsequent 
cDNA was used for quantitative PCR reactions. 
 
2.14.5 Real-time quantitative reverse transcription PCR (RT qRT-PCR) 
primer identification and validation 
RT qRT-PCR reaction primers were developed to allow accurate 
quantification of gfpmut3, gapA and sdhA transcription levels. Two primer sets were 
tested for each target transcript. Primer set 1 for gapA was previously reported by 
Song et al. (2016) to be effective for RT qRT-PCR in B. subtilis. All other primer sets 
were designed using Primer3Plus using the following parameters: a product range 
of 100-150 bp; the primer length should be a minimum of 18 bp, a maximum of 
27 bp and an optimum of 20 bp; primer melting temperature should be a minimum of 
57 °C, a maximum of 58 °C and an optimum of 57.5 °C; and the GC content should 
be a minimum of 45%, a maximum of 55% and an optimum of 50%134. Primers were 
resuspended with sterile PCR grade H2O in a biological safety cabinet and stored at 




Primers were validated using gDNA isolated from strain BAC0288 (B. subtilis 
168 ΔbglS::aphAI Pveg gfpmut3) as described in section 2.5.3. gDNA concentration 
was measured in triplicate (Section 2.5.2). RT qPCR reactions were set up as in 
Table 2.13. Reactions were set up using undiluted, 1 in 10, 1 in 100, 1 in 1000 and 1 
in 10000 template DNA dilutions alongside a no gDNA control reaction. All reactions 
were performed using the PikoReal™ Real-Time PCR System (Thermo Fisher 
Scientific, USA), using the program outlined in Table 2.14, which allowed for the 
detection of an increase in fluorescence when more DNA was amplified.  
 
Table 2.13 – RT qPCR reaction conditions used for primer validation. 
Component Volume (µL) Final concentration 
PowerUp SYBR Green Master Mix [2x] 
(Thermo Fisher Scientific, USA) 
5 1x 
10 µmol L-1 forward primer 0.5 0.5 µmol L-1 
10 µmol L-1 reverse primer 0.5 0.5 µmol L-1 
Template gDNA 2 variable 
Sterile PCR grade H2O 2  
 
Table 2.14 – RT qPCR thermo-cycling reaction conditions used for primer validation. 
Step Temperature (°C) Time Cycles 
Uracil-DNA glycosylase activation 50 2 minutes 1 
Dual-Lock™ DNA polymerase activation 95 2 minutes 1 
Denaturation 95 15 seconds 
40 cycles 
Primer annealing and extension 60 1 minute 
Final Extension 60 30 seconds 1 
Melting Curve 60 - 95 0.2 °C / s 1 
 
RT qPCR reactions were analysed by melt curve analysis to validate only a 
single product is amplified and Cq (quantification cycle) results. Cq is determined by 




determined by the PikoReal™ Real-Time PCR System as 10 times greater than that 
of the standard deviation of the baseline. Using the Cq results from the dilutions of 
the gDNA template DNA, a calibration curve was established and allowed the 
determination of the amplification factor, and therefore the PCR efficiency, for each 
primer set. To determine the amplification factor, Equation 2-3 was used. PCR 
primers with 100% efficiency would yield an amplification factor of 2 and would 
correspond to a calibration curve slope value of -3.32. The primer set for each target 
gene with the PCR efficiency (%) closest to 100% was selected for use in 
subsequent RT qRT-PCR experiments.  
 





2.14.6 Real-time quantitative reverse transcription PCR (RT qRT-PCR) 
RT qRT-PCR reactions were set up as outlined in Table 2.15. All reactions 
were performed using the PikoReal™ Real-Time PCR System (Thermo Fisher 
Scientific, USA), using the program outlined in Table 2.14. Two technical replicates 
were performed for each of three biological replicate samples. Non-template 
controls were analysed alongside the samples to ensure there was no 
contaminating DNA introduced during the assay set up. Assay gene and reference 
genes were analysed in parallel. Assay strains were run alongside the control strain. 
 
Table 2.15 – RT qRT-PCR reaction conditions used for gfpmut3 transcriptional 
alteration analysis. 
Component Volume (µL) Final concentration 
PowerUp SYBR Green Master Mix [2x] 
(Thermo Fisher Scientific) 
5 1x 
10 µmol L-1 forward primer 0.5 0.5 µmol L-1 
10 µmol L-1 reverse primer 0.5 0.5 µmol L-1 
cDNA 3  





2.14.7 Data processing 
The RT qRT-PCR reactions each gave a Cq and Tm value. Cq values were 
used to compare the transcription levels of gfpmut3, gapA and sdhA transcription 
between the control strain and assay strains. Tm values are used to ensure the 
same PCR product is compared between reactions.  
The ΔΔCq method was used to determine differences in transcription levels 
between assay and control strains. The difference in Cq values (ΔCq), averaged by 
technical replicates, between control and assay strains, as well as gfpmut3 and 
gapA or sdhA was calculated as in Table 2.16.  
 
Table 2.16 – ΔCq values derived from RT qRT-PCR reactions. BAC0297 acts as the 
control strain. 
ΔCq1 Cq (gfpmut3, assay strain) - Cq (gapA, assay strain) 
ΔCq2 Cq (gfpmut3, assay strain) - Cq (sdhA, assay strain) 
ΔCq3 Cq (gfpmut3, BAC0297) - Cq (gapA, BAC0297) 
ΔCq4 Cq (gfpmut3, BAC0297) - Cq (sdhA, BAC0297) 
 
The normalised target gene transcription level was calculated for the assay 
and control strains using Equation 2-4, which assumes 100% product amplification 
efficiency. Lastly the normalised gfpmut3 transcription level was calculated relative 
to gapA using Equation 2-5, and sdhA using Equation 2-6 (ΔΔCq). The standard 
deviation of the average final relative transcription value, between the biological 
replicates, was calculated. 
 
Equation 2-4 – Normalised gfpmut3 transcription level  
𝟐−∆𝑪𝒒 
 













2.15 CRISPR enabled DNA base editing in Bacillus subtilis 
Plasmids harbouring dCas9-AID, nCas9-AID, TadA-dCas9 and TadA-nCas9 
were used to transform naturally competent B. subtilis (Section 2.4.2) and 
successful transformants were identified on LB agar plates supplemented with 
chloramphenicol and 1 mmol L-1 IPTG. dCas9 and nCas9 plasmids targeting the 
same region were used as controls to show base editing was caused by the fused 
deaminase. 
 
2.15.1 TadA base editing 
cPCR and sequencing was carried out of the target region within 
transformants. Three transformants were used to inoculate 5 mL LB broth 
supplemented with chloramphenicol and 1 mmol L-1 IPTG and grown to exponential 
growth phase at 37 °C, 250 rpm. This was used to inoculate 10 mL LB broth 
supplemented with chloramphenicol and 1 mmol L-1 IPTG to OD600 0.05 and grown 
for 48 hours at 37 °C, 250 rpm. At 16, 24 and 48 hours of growth, 10 µL of this 
culture was struck only on an LB agar plate supplemented with chloramphenicol 
only and grown overnight. Colonies were analysed by cPCR and sequenced to 
determine if base editing had successfully occurred at the target region. 
 
2.15.2 AID base editing 
2.15.2.1 AID base editing of a single target nucleotide 
cPCR and sequencing of the transformants identified a mixed population of 
edited and non-edited cells in analysed colonies. Transformants were struck out to 
obtain single colonies on LB agar supplemented with chloramphenicol only. The 
proportion of the original transformation colony with successful base editing was 





2.15.2.2 AID base editing of multiple target nucleotides 
Triplicate transformants were used to inoculate 5 mL LB broth supplemented 
with chloramphenicol and 1 mmol L-1 IPTG and grown to exponential growth phase 
at 37 °C, 250 rpm. This was used to inoculate 10 mL LB broth supplemented with 
chloramphenicol and 1 mmol L-1 IPTG to OD600 0.05 and grown for 24 hours at 37 
°C, 250 rpm. 10 µL of this culture was struck only on an LB agar plate supplemented 
with chloramphenicol and 1 mmol L-1 IPTG and grown overnight. Colonies were 
analysed by cPCR and sequenced to determine if base editing had successfully 
occurred. 
 
2.16 In silico data analysis 
All data calculations were carried out using Microsoft Excel (Microsoft, USA). 
This data was subsequently represented in graphs using GraphPad Prism 6 
(GraphPad Software, USA). 
In silico DNA manipulations were performed using Clone Manager 9 (SciEd 
Software, USA). Following DNA sequencing, alignment with reference sequences 
was performed using Clone Manager 9 (SciEd Software, USA) while DNA 
chromatograms were interpreted using the ApE – A plasmid Editor. Vector schemes 
were prepared in Vector NTI® (Thermo Fisher Scientific, USA). 
 
2.17 In silico CRISPR array library construction 
To determine the theoretical maximum number of inserts for the construction 
of a CRISPR array library, the Edinburgh Genome Foundry CUBA software was 
utilised. Specifically, the design overhangs tool allowed the identification of 









CRISPR-Cas9 systems of adaptive immunity in bacteria have become widely 
used across all fields of biology as a genome editing tool since demonstration of its 
use as a RNA-guided DNA endonuclease in 201243. This method employs the Cas9 
endonuclease being guided to a target region, neighbouring a 5´-NGG-3´ 
protospacer adjacent motif (PAM) site, by an sgRNA consisting of a targeting 
protospacer region, the ‘handle’ to which the Cas9 binds (tracrRNA when not fused 
to crRNA within an sgRNA), and a stem loop combining these features61. The 
technique, based on the type II CRISPR-Cas9 system from Streptococcus 
pyogenes, makes use of the host DNA double-strand break (DSB) repair machinery 
to introduce mutations within the DNA sequence. The repair of these DSBs, 
generally by homology directed repair (HDR) mechanisms, allows the introduction of 
selected modifications in the presence of an engineered template with chromosome 
homology regions flanking the desired mutations.  
Following the establishment of the CRISPR-Cas9 system in B. subtilis in 
2016, it was striking that the initial methods employed involved the editing of a strain 
harbouring a chromosomal integration of cas9, followed by a co-transformation of an 
sgRNA expression cassette and dDNA (both of which would be integrated onto the 
chromosome)105,135. Chromosomal integration of cas9 and sgRNA expression 
cassettes were utilised since the use of plasmids within B. subtilis is lower than 
other hosts, such as E. coli, due to their historically comparative instability. Such 
instabilities have been overcome however, in part through the incorporation of repA 
within plasmids such as pHT01 (MoBiTec) allowing efficient theta plasmid 
replication136. These systems are burdened with an inflexibility to their wide scale 
implementation due to the additional work required to validate the insertion of cas9. 
A further example of the CRISPR-Cas9 system, developed by Altenbuchner, 
employed the use of a single plasmid for chromosomal editing, showing that prior 
chromosomal integration of cas9 was not essential63. This plasmid harboured the 
cas9 gene, sgRNA expression cassette, and dDNA. While the flexibility of this 




both sgRNA and dDNA plasmid cloning increases the time for experiments to be 
completed.  
To address these concerns, this chapter describes the development of a 
system, based on the B. subtilis – E. coli shuttle vector, pHT01, where sgRNA and 
cas9 are expressed on a single plasmid. This final plasmid, used alongside a 
separate PCR product as dDNA for B. subtilis co-transformation, allows 
chromosomal modifications through either homologous recombination (HR) or HDR. 
Cas9 is unable to cleave the target site following successful chromosomal 
integration of the dDNA due to a synonymous PAM site mutation preventing further 
cleavage. The editing plasmid is then subsequently removed from the cell, leaving 
the successfully edited strain for downstream applications.  
The use of PCR products as dDNA was shown by Westbrook et al. to be less 
efficient for transformations compared to when the dDNA was contained on a 
separate plasmid135. However, the flexibility of PCR products as dDNA (compared to 
the time and resources required for plasmid construction), combined with the 
increased flexibility of a plasmid based cas9 and sgRNA expression system, rather 
than chromosomal integration, was preferable and is used in this study. 
Furthermore, the reliably high transformation efficiencies obtained with the adapted 
naturally competent B. subtilis 168 method, developed by Bennallack et al., ensures 
that a co-transformational approach is viable24. 
Due to the known high rate of homologous recombination in B. subtilis, it was 
hypothesised that the primary mode of action for CRISPR-Cas9 enabled genomic 
modifications was due to homologous recombination occurring first, with the 
CRISPR-Cas9 system acting as a counterselection method for these recombination 
events. It has remained unclear if the Cas9 induced DSB induces DNA repair. To 
test this hypothesis, the tryptophan auxotrophy of B. subtilis 168 was exploited. This 
auxotrophy is caused by the absence of a single isoleucine codon in the trpC2 
gene63. The reintroduction of this codon restores prototrophy and enables growth on 
M9 minimal medium without the addition of L-tryptophan.   
A consideration for commercial applications of CRISPR-Cas9 has been the 
intellectual property (IP) landscape surrounding its use. While the IP landscape for 
use in bacteria appears to be relatively clear when compared to its use in 
eukaryotes and medical applications, the requirement for licence and royalty 




CRISPR nuclease family, known as Cpf1 or Cas12a, were initially identified in 46 
different organisms, with 16 being characterised for PAM specificities and 8 found to 
efficiently induce DNA DSB137. These nucleases utilise alternative mechanisms to 
identify their targets and induce DNA cleavage. T rich PAM sites were characterised 
as well as the DNA being cut with a 5-8 base staggered cut rather than a blunt cut 
as performed by Cas9137. Patents covering the use of Cpf1 were quickly filed 
following its discovery, thus making its use similarly unattractive. 
The release of a further alternative CRISPR nuclease, MAD7 (isolated from 
Eubacterium rectale and also known as ErCas12a71), in 2018 represented a 
potential way to bypass the use of the Cas9 or Cpf1 nucleases. The developers of 
this nuclease, Inscripta (USA), claim MAD7 is free to use for both academic and 
industrial research applications. They also state that any strain developed using 
MAD7 is royalty free for commercial applications, provided that the final strain does 
not contain the MAD7 nuclease itself70. While Inscripta have released data 
confirming MAD7 as active for genomic editing in E. coli, S. cerevisiae, mouse and 
human HEK293T cells, and Wesley et al. recently exemplified its activity in 
zebrafish, data on its activity levels in B. subtilis was lacking71.  
In this chapter the CRISPR-Cas9 method outlined above is developed, as 
well as comparing this system with the alternative CRISPR nucleases, 
Acidaminococcus sp. BV3L6 Cpf1 (AsCpf1) and MAD7. Furthermore, the driving 
mechanism behind CRISPR genome editing within B. subtilis 168 was investigated 
and a licence free protease knock-out library is designed and partially constructed. 
The work in this chapter relating to MAD7 was published in February 2020 
and a copy of this publication can be found in Appendix G. 
 
3.2 Materials and methods 
3.2.1 Plasmids and strains 
The plasmids and strains used in this chapter are outlined below in Table 








Table 3.1 – Strains and plasmids used in this chapter. 
Strain/Plasmid Description/Genotype Reference 
Strains   
B. subtilis 168 trpC2 Laboratory 
stock 
BAC0040 B. subtilis 168 with pBAC0008. This chapter. 
BAC0050 B. subtilis 168 with pBAC0015. This chapter. 
BAC0111 B. subtilis 168 ΔbglS::aph(3´)-lIIa-LIC site-gfpmut3. This chapter. 
BAC0288 BAC0111 ΔbglS::aph(3´)-lIIa-Pveg-gfpmut3. This chapter. 
BAC0369 B. subtilis 168 ΔaprE This chapter. 
BAC0371 B. subtilis 168 ΔnprE This chapter. 
BAC0371 B. subtilis 168 ΔhtrA This chapter. 
BAC0372 B. subtilis 168 Δbpr This chapter. 
BAC0373 B. subtilis 168 Δmpr This chapter. 
BAC0374 B. subtilis 168 Δepr This chapter. 
Plasmids   
pHT01 E. coli/B. subtilis shuttle vector carrying Pgrac and lacI, 
bla, cat. 
MoBiTec 
pGFPbglS bla; 5´ bglS; aph(3´)-lIIa; LIC site; gfpmut3; 3´ bglS 124 




















ColE1 ori; bla; PCMV; PT7; AsCpf1-NLS; f1 ori; aph(3´)-
II. 
137 
pBAC0001 pHT01 with SapI sites removed. This chapter. 
pBAC0003 pBAC0001 with rrnB T1 T2; sgRNA Cas9 handle; 
protospacer cloning site; PJ23110. 
This chapter. 
pBAC0008 pBAC0001 with rrnB T1 T2; sgRNA Cas9 handle; 
protospacer cloning site; Pveg. 
This chapter. 
pBAC0009 pBAC0001 with rrnB T1 T2; sgRNA Cas9 handle; 
protospacer cloning site; PrrnB P1. 
This chapter. 
pBAC0015 pBAC0008 with cas9 (S. pyogenes). Cas9 
expression regulated by the Pgrac. 
This chapter. 
pBAC0027 pBAC0015 with sgRNA targeting 147 bp downstream 
of the start codon within B. subtilis 168 amyE.  
This chapter. 
pBAC0035 pBAC0015 with a non-targeting protospacer.  This chapter. 
pBAC0041 pBAC0015 with sgRNA targeting 25 bp downstream 
of the start codon within B. subtilis 168 amyE. 
This chapter. 
pBAC0047 pBAC0015 with sgRNA targeting 83 bp downstream 
of the start codon within B. subtilis 168 amyE. 
This chapter. 
pBAC0085 pBAC0015 with sgRNA targeting 347 bp downstream 
of the start codon within B. subtilis 168 trpC2.  
This chapter. 
pBAC0129 pBAC0015 with sgRNA targeting 18 bp upstream of 





pBAC0154 pBAC0001 with rrnB T1 T2; crRNA AsCpf1 handle; 
protospacer cloning site; Pveg 
This chapter. 
pBAC0155 pBAC0001 with rrnB T1 T2; crRNA MAD7 handle; 
protospacer cloning site; Pveg 
This chapter. 
pBAC0158 pBAC0155 with MAD7 cloned between BamHI and 
XbaI sites. The MAD7 gene was isolated from BamHI 
and XbaI restriction digested pBAC0145. 
This chapter. 
pBAC0159 pBAC0154 with Ascpf1 cloned between BamHI and 
XbaI sites. The Ascpf1 gene was isolated from 
pBAC0146 using oligonucleotides oMAP0500/0501.  
This chapter. 
pBAC0160 pBAC0159 with a non-targeting gRNA.  This chapter. 
pBAC0161 pBAC0159 with gRNA targeting 21 bp downstream of 
the start codon within B. subtilis 168 amyE.  
This chapter. 
pBAC0162 pBAC0158 with gRNA targeting 21 bp downstream of 
the start codon within B. subtilis 168 amyE.  
This chapter. 
pBAC0163 pBAC0158 with a non-targeting gRNA.  This chapter. 
pBAC0165 pBAC0015 with sgRNA targeting 27 bp downstream 
of the start codon within BAC0288 gfpmut3.  
This chapter. 
pBAC0166 pBAC0158 with gRNA targeting 21 bp downstream of 
the start codon within BAC0288 gfpmut3.  
This chapter. 
pBAC0167 pBAC0159 with gRNA targeting 21 bp downstream of 
the start codon within BAC0288 gfpmut3.  
This chapter. 
pBAC0185 pBAC0015 with sgRNA targeting 368 bp downstream 
of the start codon within B. subtilis 168 trpC2.  
This chapter. 
pBAC0197 pBAC0158 with gRNA targeting 12 bp downstream of 
the start codon within B. subtilis 168 aprE. 
This chapter. 
pBAC0198 pBAC0158 with gRNA targeting 6 bp downstream of 





pBAC0199 pBAC0158 with gRNA targeting 22 bp downstream of 
the start codon within B. subtilis 168 htrA. 
This chapter. 
pBAC0200 pBAC0158 with gRNA targeting 25 bp downstream of 
the start codon within B. subtilis 168 htrB. 
This chapter. 
pBAC0201 pBAC0158 with gRNA targeting 1 bp upstream of the 
start codon within B. subtilis 168 bpr. 
This chapter. 
pBAC0202 pBAC0158 with gRNA targeting 2 bp upstream of the 
start codon within B. subtilis 168 nprB. 
This chapter. 
pBAC0203 pBAC0158 with gRNA targeting 1 bp upstream of the 
start codon within B. subtilis 168 mpr. 
This chapter. 
pBAC0204 pBAC0158 with gRNA targeting 6 bp downstream of 
the ATG start codon within B. subtilis 168 epr. 
This chapter. 
pBAC0205 pBAC0158 with gRNA targeting 15 bp downstream of 
the start codon within B. subtilis 168 wprA. 
This chapter. 
pBAC0206 pBAC0158 with gRNA targeting 7 bp downstream of 
the start codon within B. subtilis 168 vpr. 
This chapter. 
pBAC0218 pBAC0158 with gRNA targeting 299 bp downstream 
of the start codon within B. subtilis 168 trpC2. 
This chapter. 
 
3.2.1.1 Plasmid construction 
pBAC0001 was constructed by the Gibson DNA assembly method (Section 
2.5.11) to remove the SapI sites present in pHT01 (MoBiTec) to allow compatibility 
with the inABLE® DNA assembly method122. PCR products (Section 2.5.5) for 
Gibson assembly were prepared from pHT01 using oligonucleotides 
oMAP0002/0003/0004/0005. 
Plasmids pBAC0003/0008/0009/0154/0155 were constructed using the 
inABLE® DNA assembly technique (Section 2.5.12). 
pBAC0008, designed for use in experiments where S. pyogenes Cas9, or its 




vector backbone from pBAC0001; 2. the LacI repressor and 
isopropyl β-D-1-thiogalactopyranoside (IPTG) inducible Pgrac promoter from 
pBAC0001, including a multiple cloning site; 3. the bidirectional strong rrnB T1 and 
T2 terminators; 4. the sgRNA expression module consisting of a kanamycin 
resistance gene (aphAI) flanked by AarI sites expressed under the control of the Pveg 
promoter, and the 'Cas9 handle' section of the sgRNA. 5´ truncated parts were 
prepared by PCR from the indicated template and oligonucleotides: 1. pBAC0001 
with oMAP0010/0011; 2. pBAC0001 with oMAP0018/0019; 3. pING0001 with 
oMAP0024/0025; 4. pING0002 with oMAP0030/0031. Parts were ligated at 5´ and 
3´ respectively with annealed oligonucleotides: 1. oMAP0008/0009 and 
oMAP0014/0015; 2. oMAP0016/0017 and oMAP0020/0021; 3. oMAP0022/0023 and 
oMAP0048/0049; 4. oMAP0050/0051 and oMAP0052/0053. 
pBAC0003 and pBAC0009 plasmids were identical to pBAC0008 with the 
exception that Pveg was replaced by PJ23110 and PrrnB P1 respectively for sgRNA 
expression. 5´ truncated parts were prepared in the same manner. pBAC0003/0009 
parts 1., 2. and 3. were ligated with the same sets of annealed oligonucleotides as 
pBAC0008. The remaining part 4. for pBAC0003 was ligated at 5´ and 3´ 
respectively with annealed oligonucleotides oMAP0050/0051 and oMAP0012/0013 
to introduce PJ23110. The remaining part 4. for pBAC0009 was ligated at 5´ and 3´ 
respectively with annealed oligonucleotides oMAP0050/0051 and oMAP0054/0055 
to introduce PrrnB P1. 
pBAC0154, designed for use in experiments where Acidaminococcus Cpf1, 
or its derivatives, would be used, consisted of four parts: 1., 2. and 3. were the same 
corresponding parts as used in pBAC0008; 4. gRNA expression module consisting 
of non-coding spacer DNA flanked by SapI sites and the 'AsCpf1 handle' section of 
the gRNA under the control of the Pveg promoter. Due to its size, this part was 
prepared using only phosphorylated and annealed oligonucleotides 
(oMAP0490/0491), thus allowing SapI sites to be introduced into the part for later 
cloning steps (Parts were ligated at 5´ and 3´ respectively with annealed 
oligonucleotides: 1. and 2. as in pBAC0008; 3. oMAP0022/0023 and 
oMAP0486/0487; 4. oMAP0488/0489 and oMAP0498/0499.). 
pBAC0155, designed for use in experiments where MAD7 (Inscripta Inc., 
USA), or its derivatives, would be used, consisted of four parts: 1., 2. and 3. were 




consisting of non-coding spacer DNA flanked by SapI sites and the 'Mad7 handle' 
section of the gRNA under the control of the Pveg promoter. Due to its size, this part 
was prepared using only phosphorylated and annealed oligonucleotides 
(oMAP0492/0493), thus allowing SapI sites to be introduced into the part for later 
cloning steps (Parts were ligated at 5´ and 3´ respectively with annealed 
oligonucleotides: 1. and 2. as in pBAC0008; 3. oMAP0022/0023 and 
oMAP0486/0487; 4. oMAP0488/0489 and oMAP0498/0499). 
pBAC0013 was constructed by converting the catalytically inactive dcas9 
gene from pdCas9-bacteria to active cas9. This was done by introducing mutations 
A10D, A840H and removing a BamHI site by PCR (oligonucleotides 
oMAP0062/0063/0064/0065/0066/0067) and a subsequent 3-part Gibson Assembly 
(pdCas9-bacteria was a gift from Stanley Qi (Addgene plasmid # 44249))122,138. 
The catalytically active cas9 gene was PCR amplified from pBAC0013 with 
primers oMAP0073/0074, introducing a BsaI site and XbaI restriction enzyme 
recognition sites at the 5´ and 3´ end of the gene, respectively. The amplified cas9 
was digested (Section 2.5.8) with BsaI-HF and XbaI, and ligated (Section 2.5.10) 
with the BamHI-HF and XbaI digested pBAC0008 backbone, yielding pBAC0015. 
BsaI was used due to WT S. pyogenes cas9 containing a BamHI recognition site.  
To analyse the alternative CRISPR nucleases, MAD7, pBAC0158 was 
constructed by digesting pBAC0155 and pMK-RQ-MAD7 (MAD7, codon optimised 
for B. subtilis and flanked by BamHI and XbaI recognition sites, synthesised by 
Thermo Fisher Scientific) with BamHI-HF and XbaI restriction enzymes, and ligating 
the pBAC0155 backbone with the MAD7 gene.  
pBAC0159 was constructed by PCR amplifying AsCpf1 from pY010 
(pcDNA3.1-hAsCpf1) with oligonucleotides oMAP0500/0501, digesting this and 
pBAC0154 with BamHI-HF and XbaI restriction enzymes and ligating the pBAC0154 
backbone with the AsCpf1 gene. pY010 (pcDNA3.1-hAsCpf1) was a gift from Feng 
Zhang (Addgene plasmid # 69982)137. 
Plasmids used for Cas9, AsCpf1 or MAD7-mediated editing were prepared 
from the pBAC0015, pBAC0159 or pBAC0158 parental plasmids respectively, using 
phosphorylated and annealed oligonucleotide pairs as described in Section 2.5.4.1. 
Information on the oligonucleotides used in construction, target gene and PAM site 
for the following plasmids used in this chapter can be found in Table 2.12: 




pBAC0162; pBAC0165; pBAC0166; pBAC0167; pBAC0185; pBAC0197; 
pBAC0198; pBAC0199; pBAC0200; pBAC0201; pBAC0202; pBAC0203; 
pBAC0204; pBAC0205; pBAC0206; pBAC0218. 
As a positive control for transformation efficiency, an sgRNA designed not to 
target the B. subtilis 168 chromosome was inserted into the AarI digested and 
dephosphorylated pBAC0015 backbone with the phosphorylated and annealed 
oligonucleotide pair oMAP0145/0147, yielding pBAC0035. Similar non-targeting 
gRNAs were inserted into the SapI digested and dephosphorylated pBAC0159 
(oMAP0553/0554) and pBAC0158 (oMAP0555/0556) yielding pBAC0160 (AsCpf1) 
and pBAC0163 (MAD7) transformation positive control plasmids respectively.  
 
3.2.1.2 Strain construction 
BAC0111 was constructed by transforming naturally competent B. subtilis 
168 (Section 2.4.2) with the integration plasmid pGFPbglS16,24,124. Transformants 
were selected on LB agar plates supplemented with kanamycin.  
Using the approach described in section 2.7, CRISPR-Cas9 mediated 
chromosome editing was used to insert the Pveg promoter upstream of the gfpmut3 
gene in BAC0111 to construct strain BAC0288. Linear dDNA in the form of overlap 
extension PCR (OE-PCR) products, amplified from BAC0111 gDNA with 
oligonucleotide sets oMAP0388/0393/0394/0395 (Section 2.5.5.3) was used 
alongside pBAC0129. The CRISPR-Cas9/sgRNA plasmid was removed from the 
edited strain as described in Section 2.7.6. The insertion of Pveg was verified by PCR 
amplification from BAC0288 gDNA with oMAP0803/0804 and sequencing. 
Furthermore, GFPmut3 was confirmed by fluorescence emission analysis using 
Safe Imager 2.0 Blue Light Transilluminator and Amber Filter (Thermo Fisher 
Scientific) system (excitation: 470 nm, emission: 530 nm).  
A single OE-PCR product was used to allow a direct comparison between 
Cas9, AsCpf1 and MAD7 editing efficiencies at the amyE locus. The OE-PCR 
product generated using the oligonucleotide set oMAP0121/0551/0552/0122 was 
co-transformed alongside the editing plasmids pBAC0041, pBAC0161 and 
pBAC0162 for Cas9, AsCpf1 and MAD7 editing respectively. Similarly, a single 
dDNA was generated for gfpmut3 editing in conjunction with each nuclease. This 




pMK-RQ-gfpmut3-dDNA as template, and transformed alongside the editing 
plasmids pBAC0165, pBAC0167 and pBAC0166 for Cas9, AsCpf1 and MAD7 
editing respectively. When targeting gfpmut3, transformants were spread on LB agar 
plates supplemented with chloramphenicol and IPTG (1 mmol L-1). Effective 
knock-out of gfpmut3 by stop codon introduction was determined by analysis of 
fluorescence emission using Safe Imager 2.0 Blue Light Transilluminator and Amber 
Filter (Thermo Fisher Scientific) system (excitation: 470 nm, emission: 530 nm). 
Genotypes were confirmed by colony PCR with oligonucleotides hybridising to the 
chromosome (oMAP0393/0814) outside of the dDNA homology arm region, and 
sequenced with primer oMAP0815 to ensure accurate coverage of the targeted 
region. When targeting amyE, transformants were spread on LB agar plates 
supplemented with chloramphenicol, IPTG (1 mmol L-1) and 1% w/v soluble potato 
starch (VWR). Effective knock-out of amyE by stop codon introduction was 
determined by staining transformation plates with iodine1,27. Genotypes were 
confirmed by colony PCR with oligonucleotides hybridising to the chromosome 
(oMAP0811/0812) outside of the dDNA homology arm region, and sequenced with 
primer oMAP0813 to ensure accurate coverage of the targeted region. 
To construct the protease knock-out strain library, 200 ng of plasmids 
pBAC0197-0206 (targeting protease encoding genes outlined in Table 3.1) were 
co-transformed with 1 µg of the appropriate dDNA in the form of a OE-PCR product 
prepared from B. subtilis 168 gDNA with the following oligonucleotide sets: 
oMAP0198/0703/0704/0195 (pBAC0197), oMAP0255/0707/0708/0252 (pBAC0198), 
oMAP0261/0711/0712/0258 (pBAC0199), oMAP0267/0715/0716/0264 (pBAC0200), 
oMAP0726/0727/0728/0729 (pBAC0201), oMAP0733/0734/0735/0736 (pBAC0202), 
oMAP0740/0741/0742/0743 (pBAC0203), oMAP0747/0748/0749/0750 (pBAC0204), 
oMAP0754/0755/0756/0757 (pBAC0205), oMAP0719/0720/0721/0722 (pBAC0206). 
  
3.3 Results 
3.3.1 Construction and assessment of a single-plasmid approach for 
CRISPR-Cas9-mediated gene editing in B. subtilis 
To ensure the plasmid construction for final editing plasmids is as simple as 
possible, a single plasmid editing approach was developed which allows rapid in situ 




single cloning step, and without previous genome modifications. During the editing 
process, this plasmid transcribes a sgRNA and cas9. The dDNA is co-transformed 
with the plasmid in the form of a linear PCR product constructed using overlap 
extension PCR (OE-PCR). The dDNA includes the desired genome mutations as 
well as a synonymous mutation to remove the PAM site and prevent further cutting 
by the nuclease. In each dDNA, mutations are flanked either side by regions of 
~1 kbp homologous to the chromosome either side of the targeted PAM site. 
CRISPR-Cas9 editing plasmids were designed based on the commercially available 
E. coli - B. subtilis shuttle vector, pHT01.  
 
3.3.1.1 Promoter selection for sgRNA expression 
Accuracy of the sgRNA transcriptional start site is important for high editing 
efficiency. This is due to the 5´ region of the sgRNA being the 20 nt protospacer 
region and errors within the transcriptional start site can reduce the capacity for 
targeting Cas9 to the relevant site61. It was decided that constitutive promoters 
would be used for sgRNA expression to ensure an excess of sgRNA and prevent 
this being a limiting factor, maximising editing efficiency. Three constitutive 
promoters (synthetic PJ23101(constitutive), and native Pveg (constitutive) and PrrnB P1 
(active during exponential growth phase)) with well characterised transcriptional 
start sites had previously been identified139,140 and had the additional benefit of being 
short enough to be included on oligonucleotides used during plasmid preparation 
with the inABLE® approach (section 3.2.1.1).  
To ensure these promoters had sufficient activity for sgRNA expression, the 
kanamycin resistance aphAI gene was introduced between AarI restriction enzyme 
recognition sites within pBAC0003 (PJ23101), pBAC0008 (Pveg) and pBAC0009 
(PrrnB P1). B. subtilis 168 was transformed with each plasmid, with successful 
transformants being selected on LB agar supplemented with chloramphenicol. 
Subsequently, three transformants were struck onto LB agar supplemented with 
chloramphenicol and kanamycin. Growth was observed with all colonies containing 
the pBAC0008 and pBAC0009 plasmids, but not pBAC0003. As such, PJ23101 was 
judged to be insufficiently active for sgRNA expression. Pveg, was selected to be 
taken forward for sgRNA expression due to it being more commonly used for 
expression within B. subtilis118. While Pveg is natively 237 bp in length, Sojka et al. 




sites to give a medium rather than strong promoter strength which was used in this 
study140. 
 
3.3.1.2 Validation that cas9 is expressed to allow editing 
Since S. pyogenes Cas9 is the most widely reported and well characterised 
CRISPR nuclease to date it was utilised throughout this study141. Due to the 
reported toxicity of Cas9 to some organisms, it was decided to utilise the IPTG 
inducible Pgrac promoter (present in pHT01) for cas9 expression which would allow 
the tuning of expression levels should it be required142,143.  
Cas9 was cloned into pBAC0008 as described in section 3.2.1.1, yielding 
pBAC0015. Following transformation of B. subtilis 168 with plasmids pBAC0008 and 
pBAC0015, producing strains BAC0040 and BAC0050 respectively, protein 
expression analysis was performed. The strains were grown to a normalised cell 
state to ensure comparability between cultures (Section 2.2.1) and subsequently 
grown with and without IPTG for 18 hours before harvesting, preparing samples and 
performing SDS-PAGE analysis (Section 2.8). The gel was stained with Instant 
Blue™ (Section 2.8.3) and scanned (Figure 3.1). 
 
 
Figure 3.1 - cas9 expression SDS-PAGE analysis. 
SDS-PAGE gel analysis of strains B. subtilis 168, BAC0040 (empty vector control) and 
BAC0050 (pBAC0015 for cas9 expression) for the confirmation of cas9 expression. Soluble 
and insoluble expression bands are shown following chemical cell lysis (Section 2.8.1). 
Strains were grown in the presence (+) or absence (-) of IPTG. Protein size was determined 
by comparison Blue pre-stained protein standard, broad range (M). The predicted band size 





Cas9 (158 kDa) expression can be observed in BAC0050 in the presence of 
IPTG, with the majority of expression within the insoluble fraction. No other obvious 
differences were observed between the empty vector control strain, and the Cas9 
containing strain.  
 
3.3.1.3 Cloning strategy for the simple, rapid completion of CRISPR-Cas9 
editing plasmids 
To complete the cloning of each editing plasmid, the parental plasmid, such 
as pBAC0015, requires the cleavage of two type IIS restriction enzyme sites yielding 
non-compatible overhangs (Figure 3.2). This removes the aphAI gene which confers 
the kanamycin resistance used to identify suitable sgRNA promoters (section 
3.3.1.1). Furthermore, the removal of the 858 bp DNA fragment between the AarI 
sites acts as an indicator to successful DNA cleavage. To ensure no self-ligation in 
cases where only one of the two AarI sites has successfully been cleaved, the 
digested DNA is dephosphorylated (Section 2.5.9). 
A 20 bp DNA fragment is inserted to complete the sgRNA. The DNA for 
insertion is simply prepared by the phosphorylation and annealing of two 24 nt DNA 
oligonucleotides with compatible overhangs to the cut plasmid (Figure 3.2C). The 
subsequent completed CRISPR plasmid, once confirmed by sequencing with 
oMAP0148, is ready for genome editing to proceed. This system represents a 
simple, rapid approach to target Cas9 to any site within the genome provided a 











Figure 3.2 – Cloning strategy for final CRISPR-Cas9 editing plasmids. 
A) Schematic of the ‘parental’ CRISPR-Cas9 editing plasmid, pBAC0015. B) Protospacer 
cloning region prior to digestion with the AarI restriction enzyme. AarI recognition sites are 
indicated and the corresponding cut sites and exposed ssDNA overhangs are indicated by 
red lines. The ribosome binding site (RBS) and amino acid sequence for the N-terminus and 
C-terminal ends of the kanamycin resistance gene, aphAI, are indicated within the blue 
brackets. The 5´ region of the downstream Cas9 Handle are also represented. The 3’ region 
of Pveg is indicated by the green arrow. * = transcriptional start site for Pveg. C) Protospacer 
cloning region post AarI digestion. 4 nt ssDNA overhangs are exposed, allowing cloning to 
proceed. Two phosphorylated and annealed complimentary oligonucleotides (harbouring the 
protospacer to guide Cas9 to its target site) with 4 nt 5´ ssDNA overhangs with 
complementarity to the AarI digested and dephosphorylated pBAC0015 backbone and 
subsequently be ligated to complete the cloning procedure. 
 
3.3.1.4 Assessment of the CRISPR-Cas9-enabled genome editing 
efficiency within B. subtilis 168 
In order to determine the efficiency of genome editing with the developed 
system, three PAM sites were identified at the 5´ end of the gene encoding the 
starch degrading α-Amylase enzyme, amyE. This was chosen due to the simple 
identification of knock-out mutants following growth on media containing starch. 
When starch is exposed to iodine, a deep blue colour is obtained. Since this enzyme 
is secreted into the extracellular environment, when agar containing soluble starch is 
stained with iodine, the absence of a halo where a colony was formed indicates the 
absence of secreted α-Amylase. Thus, through the introduction of stop codons at 
the 5´ end of the gene to disrupt translation of the mRNA, knock-out mutants could 




These three protospacers were cloned into pBAC0015 (as per the approach 
outlined in Figure 3.2) yielding plasmids pBAC0027/0041/0047 (Table 2.12). The 
cloning of the protospacers was confirmed by colony PCR, using the sense strand 
protospacer oligonucleotide as the forward primer and a reverse primer hybridising 
in the plasmid backbone (oMAP0148) and sequencing of the plasmid DNA. An 
example of such a colony PCR reaction is shown in Figure 3.3 where 2 of 3 clones 
screened successfully had the protospacer inserted.  
dDNA for use with pBAC0027/0041/0047 was developed by OE-PCR using 
the oligonucleotide sets oMAP0121/0122/0123/0124, oMAP0121/0122/0128/0129 
and oMAP0121/0122/0143/0144 respectively. Each dDNA was designed to 
introduce a stop codon together with a synonymous PAM mutation to eliminate 
Cas9 cleavage at the edited site after homologous recombination. Naturally 
competent B. subtilis 168 was co-transformed with the plasmid/dDNA pairs and 
grown in the presence or absence of IPTG to determine if leaky expression of cas9 
from Pgrac was sufficient for genome editing and if editing efficiency could be 
increased with a higher level of nuclease present. The non-targeting plasmid, 
pBAC0035 was transformed alongside these experiments as a control to show 
cleavage would only take place in the presence of the sgRNA and nuclease.  
 
 
Figure 3.3 – Capillary gel electrophoresis following colony PCR to detect clones with 
successful insertion of protospacer DNA. 
D1000 ScreenTape analysis with the Agilent 2200 TapeStation system (Section 2.5.6.2). 
DNA band sizes (bp) were compared to an electronic ladder (L). 1 – clone 1; 2 – clone 2; 3 – 





The results (Figure 3.4) show effective knock-out colonies are only obtained 
in the presence of dDNA. In the absence of IPTG, an editing rate for 
pBAC0027/0041/0047 of 89.3%, 89.5% and 82.4% was achieved respectively. In 
the presence of IPTG the rates were 83.8%, 85.3% and 86.8% indicating that higher 
levels of nuclease expression do not have a significant effect on editing rate. This 
suggests that the rate of editing is independent of Cas9 levels, with only a 
requirement of basal ‘leaky’ expression for counterselection by cleaving and 
preventing growth of the non-edited cells. While knock-out colonies could have been 
obtained through the use of dDNA only, the lack of a selection mechanism would 
cause the formation of a lawn following transformation in the absence of antibiotic 
selection for plasmid incorporation. The level of editing in the absence of antibiotic 
selection and Cas nuclease counterselection is discussed more in section 3.3.3. 
Additionally, the base level editing efficiency with antibiotic selection for plasmid 
incorporation but without Cas nuclease counterselection is investigated in section 
3.3.2. 
Since no deletion phenotypes were identified in the absence of dDNA, we 
have shown that CRISPR-Cas9 editing does not occur due to NHEJ in B. subtilis 
168. Instead we have shown that editing is bound to either HDR or HR (with Cas9 







Figure 3.4 – Editing efficiency using three sgRNAs targeting amyE. 
A) White (- IPTG) and grey (+IPTG) bars represent the number of CFU obtained following 
transformation of three amyE targeting plasmids (pBAC0027/0041/0047) with or without 
editing template (dDNA) to introduce stop codons and repair the sgRNA-targeted Cas9 DSB. 
A plasmid containing a non-targeting sgRNA (pBAC0035) was transformed to monitor 
transformation efficiency. The blue (- IPTG) and red (+ IPTG) bars represent the editing 
efficiency of the obtained CFU determined by observing the presence or absence of a halo 
following iodine staining of the starch-containing transformation plates. Error bars indicate 
the standard deviation between three transformations. B) DNA sequencing results for the 
target region of four colonies with knock-out (KO) phenotypes from each target plasmid + 
dDNA transformation. DNA for sequencing was isolated by PCR amplification of genomic 
DNA for each target. KO candidates are compared to a similarly prepared and sequenced 




3.3.2 Analysis of CRISPR-enabled genome editing efficiencies with 
alternative nucleases 
Following the release of MAD7 for academic or industrial research and strain 




workhorse B. subtilis was investigated. As such a side by side comparison of S. 
pyogenes Cas9, Acidaminococcus sp. BV3L6 Cpf1 (AsCpf1) and MAD7 was carried 
out to determine if MAD7 could act as a CRISPR nuclease for commercial strain 
development. AsCpf1 was also selected for this comparison as it has the greatest 
level of identity (31%) to MAD770. The different characteristics of these nucleases 
are outlined in Table 3.2. MAD7 was codon optimised (sequence comparison in 
Appendix D) for B. subtilis and synthesised (Thermo Fisher Scientific), while the 
readily available human codon optimised AsCpf1 from pY010 was utilised. 
 
Table 3.2 – Different characteristics of the alternative CRISPR nucleases tested for 
activity in B. subtilis.  




Nuclease Type Type II Type V 
Cut type Blunt Staggered 
Native guide RNA 2 RNA molecules 1 RNA molecule 
PAM 
5´ NRG 3’ 
(R = G or A) 
5´ TTTV 3’ 
(V = G, C or A) 
5´ YTTN 3’ 
(Y = T or C) 
Amino acid length 1368 1307 1263 
 
 ‘Base CRISPR-MAD7 and CRISPR-AsCpf1 plasmids were constructed in a 
similar manner to the ‘base CRISPR-Cas9 plasmid, pBAC0008 (section 3.2.1.1). 
The primary difference between these plasmids is that the handle through which the 
Cas9 associates to the sgRNA was replaced with the specific gRNA handles for 
MAD7 and AsCpf1 respectively. As Pveg was shown to be well suited to sgRNA 
expression, this was retained within the editing plasmids and aphAI, conveying 
kanamycin resistance, was not introduced. Furthermore, two SapI restriction 
enzyme recognition sites were used to replace the AarI sites to facilitate protospacer 
cloning. While SapI yields 3 nt ssDNA overhangs, instead of the 4 nt following AarI 




MAD7 and AsCpf1 were inserted into pBAC0155 and pBAC0154 respectively, 
yielding pBAC0158 and pBAC0159 (section 3.2.1.1).  
To compare the genome editing efficiencies between Cas9, AsCpf1 and 
MAD7 in B. subtilis, the amyE and gfpmut3 genes were selected for knock-out due 
to their ease of analysis to identify successfully edited colonies. Due to their 
similarity in PAM site specificities, AsCpf1 (5´ TTTV 3’ (V = G,C or A)) and MAD7 (5´ 
YTTN 3’ (Y = T or C)) targeted the same sites for both individual gene targets (amyE – 
TTTG; gfpmut3 – TTTC). This site was selected based on its proximity to the Cas9 
PAM site to allow as close a comparison as possible. A single dDNA was designed 
for each target to introduce a stop codon at the 5´ of the gene and remove the PAM 
site. Editing of amyE and gfpmut3 was performed in B. subtilis 168 and BAC0288 
respectively.  
Plasmids carrying non-targeting gRNA were prepared for each nuclease to 
measure transformation efficiency and the potential toxicity towards B. subtilis. The 
transformation efficiency of the non-targeting AsCpf1 plasmid (1.3 x102 CFU/µg 
DNA in B. subtilis 168 and 4.5 x101 CFU/µg in BAC0288) was lower than that of 
Cas9 (1.3 x104 CFU/µg DNA in B. subtilis 168 and 2.5 x103 CFU/µg in BAC0288) 
and MAD7 (9.4 x103 CFU/µg DNA in B. subtilis 168 and 2.4 x103 CFU/µg in 
BAC0288). This suggests a toxicity effect of AsCpf1 towards B. subtilis which is not 
observed with Cas9 nor MAD7.  
 
3.3.2.1 Comparison of the editing efficiencies obtained following editing 
of amyE with Cas9, AsCpf1 and MAD7 
The pBAC0041 Cas9 editing plasmid (section 3.3.1.4) was utilised alongside 
plasmids pBAC0161 and pBAC0162 for AsCpf1 and MAD7 enabled genome editing 
of amyE respectively. A single dDNA was designed for each target to introduce a 
stop codon at the 5´ of the gene and remove the PAM sites (Figure 3.5A). Cas9, 
AsCpf1 and MAD7 yielded amyE knock-out efficiencies of 91%, 1.6% and 98%, 
respectively when B. subtilis 168 was co-transformed with the editing plasmids and 
dDNA (Figure 3.5B/C). Thus, in this case, MAD7 was found to have an editing 
efficiency of a least as good as Cas9. The 1.6% editing observed with AsCpf1, in 
combination with the low transformation efficiency obtained, was thought to be due 
to serendipitously dDNA being incorporated into the chromosome by homologous 




successfully edited colonies were observed for any nuclease in the absence of 
dDNA. 
To identify the benefit of having the targeting nucleases present in this 
system, the non-targeting Cas9 plasmid (pBAC0035) and the MAD7 equivalent 
(pBAC0163) were transformed alongside the dDNA, as well as separate 
co-transformations utilising the targeting plasmid (Figure 3.5D). AsCpf1 was not 
analysed since it had not exhibited a high efficiency of editing. The results indicate 
the clear advantage for editing efficiency in the presence of the targeting plasmid 
with efficiencies increasing from 0% to 98% for Cas9 and 0% to 93% for MAD7 
(Figure 3.5D). Following phenotypic analysis, the genotypes of a selected population 
of the transformants were confirmed by colony PCR and sequencing. Primers used 
during colony PCR (oMAP0811/0812) hybridised outside of the homology arm 
region on the chromosome. All colonies screened confirmed the expected genotype 
following phenotypic analysis (Cas9 – WT: 2/2 colonies; knock-out: 9/9 colonies. 
MAD7 – WT: 2/2 colonies; knock-out: 10/10 colonies).  
Following editing with MAD7, a higher average number of CFU was obtained 
than with Cas9. This is thought to represent a potential advantage over Cas9 
genome editing, potentially due to its smaller size having less burden on the cell. 
However, following an unpaired t test with Welch’s correction, it was established that 






Figure 3.5 – Editing efficiencies obtained following CRISPR-Cas9/AsCpf1/MAD7-
mediated amyE editing. 
A) Non-edited (WT) and edited sequences. The ATG start codon is underlined. The targeted 
PAM sites are indicated for Cas9, AsCpf1 and MAD7. The modified base pairs are 
highlighted in bold and the introduced stop codons are marked with red boxes. 
B) Co-transformational editing approach where the plasmid expressing the gRNA and 
nuclease are used to transform B. subtilis 168 alongside a linear editing template (dDNA) 
containing the editing region. C) Transformations and co-transformations comparing editing 
efficiencies when utilising Cas9, AsCpf1 or MAD7 nucleases in the presence or absence of 
editing template (dDNA). D) Transformations identifying the benefit in editing efficiency to 
having the nuclease and targeting gRNA present. Bars represent the average number of 
CFU obtained following transformation of the amyE targeting editing plasmid for each 
nuclease (Cas9 – pBAC0041; AsCpf1 – pBAC0161; MAD7 – pBAC0162), or non-targeting 
(NT) plasmids for Cas9 (pBAC0035) or MAD7 (pBAC0163), with or without dDNA to 
introduce a stop codon and remove the PAM site. The circled number above each bar 
represents the total number of transformants phenotypically screened by observing the 
presence or absence of a halo following iodine staining of the starch-containing 







3.3.2.2 Comparison of the editing efficiencies obtained following editing 
of gfpmut3 with Cas9, AsCpf1 and MAD7 
As an additional target for genome editing efficiency, strain BAC0288 
expressing the gfpmut3 gene under the control of Pveg was prepared (section 
3.2.1.2). pBAC0165, pBAC0167 and pBAC0166 were used to transform BAC0288 
with and without dDNA to test Cas9, AsCpf1 and MAD7 editing efficiencies 
respectively through the introduction of stop codons and synonymous PAM site 
mutations to prevent further cutting by each nuclease (Figure 3.6A/B). A single 
dDNA was used for all nucleases. When knocking out gfpmut3, editing efficiencies 
of 83%, 0% and 100% were observed in strain BAC0288 for Cas9, AsCpf1 and 
MAD7, respectively (Figure 3.6C). No successfully edited colonies were observed 
for any nuclease in the absence of dDNA. As for amyE, the base level editing rate 
for Cas9 and MAD7 targeting modification of gfpmut3 was investigated using 
non-targeting plasmids and the same dDNA (Figure 3.6D). The results showed a 
similar benefit to editing efficiency when the targeting plasmid was utilised with rates 
increasing from 0.18% to 75% for Cas9 and 0.23% to 100% for MAD7 (Figure 3.6D). 
Following phenotypic analysis, the genotypes of all colonies exhibiting the knock-out 
phenotype, from the targeting and non-targeting CRISPR plasmid 
co-transformations with dDNA, and a selected population of the transformants 
exhibiting the WT phenotype were confirmed by colony PCR and sequencing. 
Primers used during colony PCR (oMAP0393/0814) hybridised outside of the 
homology arm region on the chromosome. All colonies screened confirmed the 
expected genotype following phenotypic analysis (Cas9 – WT: 7/7 colonies; 
knock-out: 5/5 colonies. MAD7 – WT: 6/6 colonies; knock-out: 4/4 colonies). 
BAC0288 proved to be considerably less competent than B. subtilis 168 with 
a transformation efficiency of 5.2-fold less for the Cas9 control plasmid (pBAC0035) 
and 3.9-fold less for the MAD7 control plasmid (pBAC0163). As a result, while the 
capacity to edit the target site efficiently is apparent, these results on their own are 
not statistically robust due to the low CFU obtained and should be taken as 
supporting evidence with the efficiencies obtained in the amyE editing experiment in 







Figure 3.6 – Editing efficiencies obtained following CRISPR-Cas9/AsCpf1/MAD7-
mediated gfpmut3 editing. 
A) Non-edited (WT) and edited sequences. The ATG start codon is underlined. The targeted 
PAM sites are indicated for Cas9, AsCpf1 and MAD7. The modified base pairs are 
highlighted in bold and the introduced stop codons are marked with red boxes. 
B) Co-transformational editing approach where the plasmid expressing the gRNA and 
nuclease are used to transform B. subtilis 168 alongside a linear editing template (dDNA) 
containing the editing region. C) Transformations and co-transformations comparing editing 
efficiencies when utilising Cas9, AsCpf1 or MAD7 nucleases in the presence or absence of 
dDNA. D) Transformations identifying the benefit in editing efficiency to having the nuclease 
and targeting gRNA present. Bars represent the average number of CFU obtained following 
transformation of the gfpmut3 targeting editing plasmid for each nuclease (Cas9 – 
pBAC0165; AsCpf1 – pBAC0167; MAD7 – pBAC0166), or non-targeting (NT) plasmids for 
Cas9 (pBAC0035) or MAD7 (pBAC0163), with or without dDNA to introduce a stop codon 
and remove the PAM site. The circled number above each bar represents the total number 
of transformants phenotypically screened by observing the presence or absence of 
GFPmut3 following blue light analysis. Error bars indicate the standard deviation between 






3.3.2.3 Development of a protease knock-out strain library with MAD7 
As it had been established that MAD7 was as or more efficient than Cas9 for 
genome editing in B. subtilis 168, an industrially relevant use for this new tool was 
sought. The extracellular protease deficient BRB strains, developed by Pohl et al., 
underwent sequential whole gene deletion of the seven extracellular proteases 
(NprB, AprE, Epr, Bpr, NprE, Mpr and Vpr) present in B. subtilis 168 cultures40. 
Further deletions were subsequently made of the membrane bound proteases 
WprA, HtrA and HtrB which are involved in quality control of proteins secreted into 
the extracellular environment40,144,145. These strains, or similar alternative strains, 
have since been used for heterologous protein production, and recently also in 
stably tethering proteins to the cell wall to enable future uses in biocatalysis, 
bioremediation or lignocellulose degradation40,41,146. 
It was decided to produce a MAD7 developed version of these strains were 
frame shift mutations for each protease creates effective knock-outs with final 
strains free for commercial use and with minimal genomic modifications utilised 
instead of the full gene deletions employed for the construction of the BRB strains. 
Industrially, these new strains could be utilised in a 24-well plate format to screen 
the strains with increasing number of silenced genes with any extracellular 
heterologous protein target to identify which strain produces the highest amount of 
the target protein (Figure 3.7). Alternatively, each strain could be further modified 
using CRISPR tools to investigate the effect of further gene knock-outs, or 
knock-ins. 
Sequential deletions such as those defined here can be rapidly carried out 
with CRISPR tools. Once all genetic elements are available, two rounds of editing 
can be carried out in five days. This includes quality control checks by colony PCR 
and sequencing to ensure the mutation was introduced as designed, as well as 
subsequent plasmid loss before the next round of mutations. This is possible due to 
high efficiency of the CRISPR systems making it rare to select a non-edited colony, 
and as such plasmid loss and quality control checks can be ran in parallel. 
Furthermore, if there had been unforeseen delays in the sequencing, the use of the 
editing plasmid from the previous round allows a clear report that the synonymous 
PAM mutation had been introduced, and as such there is a high likelihood that the 






Figure 3.7 – Protease knock-out strain library. 
A) The proposed workflow for new heterologous protein expression targets in B. subtilis. 
Target proteins for secretion can be introduced either on replicative plasmids, or 
incorporated onto the chromosome using the CRISPR approach described here. 
Downstream assays for identification of the highest producing strain is dependent on the 
target protein for production. B) The intended strain genotype for each well.  
 
The strain library construction was initiated with plasmids pBAC0197-0206 
being combined with their relevant dDNA (section 3.2.1.2) and co-transforming 
naturally competent B. subtilis 168. Transformants were selected on LB agar 
supplemented with chloramphenicol and IPTG. When only the targeting plasmid was 
transformed, a drastic drop in transformation efficiency was observed for six of the 
ten targets (Table 3.3). These genes (aprE, nprE, htrA, bpr, mpr, and epr) were 
found to have been knocked out as planned following colony PCR and sequencing. 
No successful mutants were obtained for the remaining targets (htrB, nprB, wprA 
and vpr). 
It was hypothesised that the remaining targets had not worked as planned 




PAM site introduced following HR of the dDNA (vpr and htrB). Data provided by 
Inscripta indicated that TTTT PAM sites are generally functional (as shown here with 
bpr and vpr targets) though not in all cases (potentially observed here with nprB and 
wprA)67. Future targeting of these genes will utilise the same dDNA, but the target 
PAM will be moved by a single base to ensure a TTTV (V = A, G or C) PAM site.  
No knock-out colonies were identified for vpr or htrB targets. As in both 
cases the PAM site was altered to TCTA, and other bases within the YTTN (Y = C 
or T) PAM site can tolerate C bases, it is hypothesised that this represents a 
potential additional PAM site67. However, due to time constraints and following 
discussions with my supervisor, this hypothesis was not further investigated. 
This strain library (Figure 3.7) could not be completed within the time 
limitations of this study. However, once completed and successfully used to identify 
the optimum background strain for a target heterologous protein, subsequent rounds 
of editing would be desirable to produce a final strain for use in large-scale 
fermentation processes. The repair of the trpC2 gene to return the strain to a 
prototrophic state, as described in section 3.3.3, is desirable to allow the use of 
cheaper chemically defined media without the need for tryptophan supplementation. 
Next, to prevent the strain entering sporulation and maximise protein production, the 
sporulation master regulator, spo0A should be targeted for knock-out147. 
Alternatively, sigma factor F (spoIIAC) is also known to be responsible for 
transcription of forespore proteins and as such is an alternative/additional target for 
deletion41.  Deletion of other highly expressed secreted proteins, such as α-Amylase 
(amyE) could aid downstream protein purification, as well as potentially increasing 
the rate with which proteins are expressed and secreted by not blocking the relevant 
cellular machinery.  Lastly, to avoid excessive foaming in large-scale fermentation 
processes, thereby lowering costs and reducing potential loss of culture, the 










Table 3.3 – Colonies obtained following the first round of protease knock-out library 
construction. 
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3.3.3 Homologous recombination vs. DNA double-strand break repair 
as the driving mechanism for CRISPR genome editing in 
B. subtilis 168 
To elucidate the mechanism with which CRISPR-mediated editing takes 
place in B. subtilis 168,  we made use of this strain’s tryptophan auxotrophy to 
compare the efficiency in restoring prototrophy when a linear dDNA is transformed 
on its own, or in the presence of either a Cas9 or MAD7 non-targeting or 
trpC2-targeting plasmid. The linear dDNA was designed to simultaneously introduce 
an additional isoleucine residue adjacent to I110 residue of TrpC2, returning the 
strain to a prototrophic state, and a synonymous mutation to eliminate the PAM 
recognition site and prevent continuous cutting by the trpC2-targeting plasmid 
(Figure 3.8A/B)63.  By selecting transformants in M9 minimal medium supplemented 
with or without either chloramphenicol (plasmid selection) or tryptophan, we could 
clarify whether HR drives genome editing, preventing a DSB, or if the DSB induces 
DNA repair by HR. 
In the absence of tryptophan there is not a significant difference in CFU 
obtained when transforming the linear dDNA to restore tryptophan prototrophy on its 
own or in the presence of either the trpC2 targeting or non-targeting plasmids 
(Figure 3.8). Furthermore, when cells with restored prototrophy were also selected 
in the presence of chloramphenicol, there was no significant difference between the 
co-transformation of dDNA with either the trpC2-targeting or non-targeting 
CRISPR-Cas9 plasmids (Figure 3.8). Both these results indicate that HR is the main 
driving force for CRISPR-Cas9 editing in the presence of dDNA. When tryptophan 
was supplemented to M9, the absence of a selective pressure for restored 
prototrophy results in a significantly lower number of CFU when co-transforming the 
dDNA and the trpC2-targeting plasmid compared to the co-transformation of dDNA 
with the non-targeting plasmid (Figure 3.8). In this case, the lethal cut induced by 
the nuclease counterselects the transformants in which HR of dDNA has not 
occurred. As such, while the high efficiency of HR is the main driving force for 
genome editing, the nuclease induced DSB is essential to obtain high editing 






Figure 3.8 – Restoration of B. subtilis prototrophy using CRISPR-Cas9 and CRISPR-
MAD7 for genome editing. 
A) and B) show the non-edited (WT) and edited sequences for Cas9 and MAD7 editing 
respectively. The modified base pairs are highlighted in bold and the inserted isoleucine 
codon, adjacent to I110, is marked with red boxes. C) Co-transformational editing approach 
where the CRISPR plasmid expressing the gRNA and nuclease is transformed alongside a 
linear editing template (dDNA) containing the editing region. D) and E) Graphs show the 
number of transformants following transformations with the indicated combinations of dDNA 
and targeting (pBAC0185 for Cas9 and pBAC0218 for MAD7) or non-targeting plasmid 
(pBAC0035 for Cas9 and pBAC0163 for MAD7) to restore B. subtilis 168 prototrophy, with 
Cas9 and MAD7 respectively. Bars represent the average number of colony forming units 
(CFU) normalised by the transformation efficiency of pBAC0035 (Cas9) selected on LB agar 
supplemented with chloramphenicol or pBAC0163 (MAD7) selected on LB agar 
supplemented with chloramphenicol and IPTG. Error bars indicate the standard deviation 






3.4.1 Limitations and inefficiencies within the CRISPR-Cas genome 
editing approach 
In this chapter, CRISPR systems were developed and characterised for use 
with B. subtilis 168. This approach, where a single plasmid for cas9 and sgRNA 
expression, and a linear OE-PCR product as dDNA are co-transformed, relies on 
the preparation of highly competent B. subtilis cells. Provided the promoter and 
origin or replication genetic elements are active, the transformation efficiency is the 
key limitation with this approach being utilised in other Bacilli or strains of B. subtilis 
where a drastic drop in natural competence efficiency has occurred. In such cases, 
it may be best to introduce the dDNA into the plasmid to remove the need for two 
transformation events to take place, as exemplified by Altenbuchner63. However, this 
was not investigated in this study. 
Editing in the presence of higher colony numbers did not reach 100% since a 
low number of CFUs were obtained when only the editing plasmid is present. These 
would appear to be instances when the colony has escaped cutting. Such ‘escaper’ 
colonies could have formed due to random mutations interrupting the PAM site. 
However, as the spontaneous mutation frequency for B. subtilis is between 10-8 and 
10-7, and, by using the pBAC0035 control plasmid CFUs, an average of 1763 cells 
with IPTG, and 1989 cells without IPTG were transformed with the editing plasmid, it 
appears unlikely that PAM sites were interrupted by random mutagenesis in the 
‘escaper’ colonies8. Given that there is a strong selection for cell survival in the 
presence of the plasmid due to the plates being supplemented with 
chloramphenicol, it is more likely that these transformants are instances where the 
plasmid incorporated has a mutation inactivating either the nuclease or gRNA thus 
preventing cleavage and allowing colony formation.  
We have provided evidence that, in B. subtilis 168, CRISPR-Cas9 and 
CRISPR-MAD7 genome editing efficiency is driven primarily by HR of dDNA 
preventing the lethal Cas9 or MAD7-induced DNA DSB, rather than HDR following 
the DSB. Mougiakos et al. reported the endogenous HR machinery within 
Bacillus smithii incorporating plasmid borne dDNA while Cas9 was inactive at 
≥42 °C. Counterselection of the cells which had not undergone HR was then 
performed at 37 °C where the Cas9 was once again functional. Here we have 




active and growth is optimal117. The presence of the CRISPR-Cas9 or 
CRISPR-MAD7 system was not required to detect successful HR due to 
prototrophic selection on M9 minimal medium. However, where such a selection is 
not possible, the CRISPR-Cas9 or CRISPR-MAD7 systems act as a powerful 
counterselection for unedited cells. The lack of a significant increase in editing 
efficiency following addition of IPTG to drive cas9 expression, and as sgRNA 
expression is known to be under the strong constitutive promoter, Pveg, indicated 
editing rates are decoupled from Cas9 expression levels with leaky Pgrac promoter 
activity being sufficient to induce the lethal DSB.  Moreover, as the natural 
competency master regulator ComK activates transcription of the primary 
component of HR, recA, and DNA uptake is single stranded, yielding a substrate 
with which RecA can bind, HR can readily proceed at the target site prior to the DSB 
taking place148,149.  
 
3.4.2 Toxicity of AsCpf1 to Bacillus subtilis 
It was not clear why AsCpf1 appeared to have a degree of toxicity to 
B. subtilis following transformations utilising non-targeting plasmids and 
transformation efficiencies ~100 fold less than MAD7 or Cas9 equivalent 
transformations. Further experiments to elucidate this were not carried out as the 
primary goal was to compare the new, commercially free-to-use MAD7 with the well 
characterised and established Cas9. As a hypothesis however, it is possible that the 
toxicity is linked to AsCpf1 being codon optimised for humans in pY01068. As such, 
the codon usage ratio (frequency per thousand codons of B. subtilis/AsCpf1) was 
analysed and showed the human codon optimised AsCpf1 utilises 800/1307 codons 
used at least 50% less often in B. subtilis (Figure 3.9). Considering the high number 
of rarely used codons, it may be the case that the mRNA translation is being 
continually paused, causing an accumulation of misfolded or incomplete insoluble 
protein, which is known to be toxic to the cell150.  
 Future analysis of genome editing with AsCpf1 should synthesise a 
B. subtilis codon optimised gene to enable clear comparison with other nucleases. 
Furthermore, comparison assays with the catalytically inactive dAsCpf1 variant 
would elucidate if in fact a random catalytic activity of AsCpf1 is the toxic element 
observed here. The developed parental plasmid for use with AsCpf1, pBAC0154, 






Figure 3.9 – Ratio of codon usage in B. subtilis to AsCpf1 codon optimised for 
humans. 
White bars show all used codons with ratio >1 and unlikely to be limited for expression in 
B. subtilis. Similarly, grey bars represent a ratio of 0.5 – 1 where codons are more limited, 
and black bars represent a ratio < 0.5 where codons could be severely limited. The numbers 




CRISPR-Cas9 mediated genome editing of B. subtilis 168 was found to be a 
highly efficient process at 87.1% in the absence of IPTG and 85.2% in the presence 
of IPTG. Such high editing efficiencies make it feasible to proceed with strain 
development in a rapid manner with several rounds of editing. Similar high editing 
rates were observed with the alternative CRISPR nuclease, MAD7. Since B. subtilis 
is used widely as an industrial workhorse, the use of MAD7 may be more attractive 
than Cas9 for commercial strain construction. However, significant questions 
regarding application of MAD7 remain. A significant case study, and potentially a 
challenge to the MAD7 IP, owned by Inscripta, may be required before industry fully 
trusts the claims made by Inscripta that MAD7 is free to use for commercial R&D 
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Chapter 4 – CRISPR-Cas9 In Situ engineering of 
subtilisin E in Bacillus subtilis 
 
4.1 Introduction 
As a proof that CRISPR-Cas9 was a valuable tool for rapid genome editing 
for the development of an industrially significant protein production target, the 
extracellular protease Subtilisin E (encoded by the aprE gene) was selected as it is 
used globally within the detergent, food, pharmaceutical and leather industries151. 
Subtilisin E serves in nature to degrade other proteins utilising a nucleophilic S327 
residue in its catalytic triad (D138, H170, S327) for hydrolysis of the target peptide 
bond39,152. 
As the wild type Subtilisin E enzyme can be broken down by detergent 
formulations and heat, subtilisin variants with improved thermostability and pH 
tolerance have long been of interest. Subtilisin E has been widely used as a target 
for protein engineering experiments which can be split into 8 categories for designed 
improvements: Catalytic mechanism, substrate specificity, new activities, general 
proteolytic activity general stability, stability in exotic environments, surface activity 
and folding mechanisms. These are reviewed in detail by Bryan39. 
A salt-bridge triad (Arg19-Glu271-Arg275), identified in the subtilisin E 
homolog from Bacillus clausii (M-protease), was found to be a contributor for the 
characteristic thermotolerance of this enzyme through site-directed mutagenesis 
experiments153. Mutation of these sites (R19Q-E271Q-R275Q) allowed a similar 
level of activity retention following incubation at 55 °C, while ≥60 °C caused an 
increased rate of activity reduction when compared the WT enzyme. Following 
incubation at 60 °C, a 50% drop in activity was observed following 12.9 minutes 
incubation, whereas the WT enzyme required 37.8 minutes incubation for the same 
reduction in activity153.  
In this chapter, we use CRISPR-Cas9 mediated genome editing to replace 
the respective residues in subtilisin E (Gln125-Gln377-Gln381), and evaluate the 
effect of the salt bridge on the thermostability and activity of the new variant and two 




system for B. subtilis rapid, in situ protein engineering, which is at the core of 
industrial biotechnology to provide new, suitable and competitive biocatalysts.  
The work in this chapter was published in January 2019 and a copy of this 
publication can be found in Appendix E. 
 
4.2 Materials and methods 
4.2.1 Plasmids and strains 
The plasmids and strains used in this chapter are outlined below in Table 
4.1. The oligonucleotides used in this chapter can be found in Appendix C. 
 






B. subtilis 168 trpC2 Laboratory 
stock 
BAC0094 B. subtilis 168 with aprE Q125R variant.  This chapter. 
BAC0095 B. subtilis 168 with aprE Q377E and Q381R 
variant. 
This chapter. 
BAC0097 BAC0095 with  aprE Q125R, Q377E and Q381R 
variant 
This chapter. 
BAC0114 B. subtilis 168 ΔaprE::aad9 This chapter. 
BAC0116 BAC0114 with pHT01. This chapter. 
BAC0117 BAC0114 with pBAC0057. This chapter. 




BAC0119 BAC0114 with pBAC0059. This chapter. 
BAC0120 BAC0114 with pBAC0060. This chapter. 
BAC0121 BAC0114 with pBAC0068. This chapter. 
BAC0122 BAC0114 with pBAC0069. This chapter. 
Plasmids 
  
pHT01 E. coli/B. subtilis shuttle vector carrying Pgrac and 
lacI, bla, cat. 
MoBiTec 
pDR111 bla; 5´ amyE; aad9; Pspac;lacI; 3’ amyE 154 
pBAC0015 pBAC0008 with cas9 (S. pyogenes). Cas9 
expression regulated by the Pgrac. 
Section 
3.2.1.1 
pBAC0054 pBAC0015 with sgRNA targeting 359 bp 
downstream of the start codon within B. subtilis 
168 aprE.  
This chapter. 
pBAC0055 pBAC0015 with sgRNA targeting 1163 bp 
downstream of the start codon within B. subtilis 
168 aprE.  
This chapter. 
pBAC0057 pHT01 with aprE (native) from B. subtilis 168 
with native GTG start codon.  
This chapter. 
pBAC0058 pHT01 with aprE (Q125R, Q377E and Q381R 
variant) from BAC0097 with native GTG start 
codon. 
This chapter. 
pBAC0059 pHT01 with aprE (native) from B. subtilis 168 
with ATG start codon.  
This chapter. 
 
pBAC0060 pHT01 with aprE (Q125R, Q377E and Q381R 





pBAC0068 pHT01 with aprE (Q125R variant) from 
BAC0094 with ATG start codon.  
This chapter. 
pBAC0069 pHT01 with aprE (Q377E and Q381R variant) 
from BAC0095 with ATG start codon.  
This chapter. 
 
4.2.2 Plasmid construction 
Plasmids used for Cas9 -mediated editing were prepared from the 
pBAC0015 parental plasmid, using phosphorylated and annealed oligonucleotide 
pairs as described in Section 2.5.4.1. Information on the oligonucleotides used in 
construction, target gene and PAM site for the following plasmids used in this 
chapter can be found in Table 2.12: pBAC0054; pBAC0055. 
Plasmids pBAC0057/0058/0059/0060/0068/0069 were constructed by PCR 
amplifying the variant of aprE from the gDNA of the strain specified in Table 4.1. The 
PCR primers used for each variant amplification and introduction of BamHI and 
XmaI restriction enzyme sites, were: pBAC0057 – oMAP0199/0186; pBAC0058 – 
oMAP0199/0200; pBAC0059 – oMAP0203/0186; pBAC0060 – oMAP0203/0200; 
pBAC0068 – oMAP0203/0186; pBAC0069 – oMAP0203/0200. Each PCR product 
underwent BamHI-HF and XmaI restriction enzyme digestion (Section 2.5.8) and 
ligation (Section 2.5.10) with the similarly digested pHT01 vector. 
 
4.2.3 Strain construction 
Using the approach described in Section 2.7, CRISPR-Cas9 mediated 
editing of the aprE gene in B. subtilis 168 was carried out to construct strains 
BAC0094 and BAC0095. dDNA OE-PCR products, amplified from B. subtilis 168 
gDNA with oligonucleotide sets oMAP0152/0153/0154/0155 and 
oMAP0158/0159/0160/0161 were used alongside pBAC0054 and pBAC0055 
respectively. Editing was confirmed by PCR of the aprE gene with oligonucleotides 
oMAP0152/0161, followed by sequencing using oligonucleotides oMAP0158 and 
oMAP0155 for candidates edited with pBAC0054 and pBAC0055 respectively. The 
CRISPR-Cas9/sgRNA plasmid was removed from the edited strain as described in 




introduced previously were confirmed by sequencing (as above) of the newly 
constructed strain, BAC0097. 
BAC0114 was constructed by transformation of B. subtilis 168 with OE-PCR 
product containing a spectinomycin resistance cassette (PCR amplified from 
pDR111 with primers oMAP0221/0222) flanked by homology arms upstream and 
downstream of aprE (PCR amplified from B. subtilis 168 gDNA with oligonucleotides 
oMAP0217/0218 and oMAP0219/0220). Confirmation of aprE deletion was obtained 
by purification of the genomic DNA for BAC0114 and PCR of ΔaprE::aad9 locus with 
oligonucleotides oMAP0670 (hybridising to aad9) and oMAP0671 (hybridising to the 
genome, upstream of the homology arm region). Additionally, PCR with 
oligonucleotide pair oMAP0217/0220 (hybridising to the extremities of the homology 
arm region) revealed the expected increase in product size for ΔaprE::aad9 relative 
to the WT PCR product.  
BAC0114 was transformed with plasmids 
pBAC0057/0058/0059/0060/0068/0069, resulting in strains 
BAC0017/0018/0119/0120/0121/0122 respectively.  
 
4.3 Results 
4.3.1 Identification of target residues for modification in subtilisin E 
The crystal structures for B. subtilis subtilisin E (PDB ID 1SCJ) and its 
B. clausii homolog, M-protease (PDB ID 1WSD), were overlaid using Swiss-Pdb 
viewer (Figure 4.1)129–131. The residues corresponding to the salt-bridge triad 
(R19-E271-R275) that have previously been shown to contribute towards 






Figure 4.1 - Design and CRISPR-Cas9 editing process of aprE.  
A) B. subtilis 168 subtilisin E crystal structure (green) and overlay with B. clausii M protease 
crystal structure (cyan), with the associated salt bridge (dashed yellow line). B) Design of the 
sgRNA and dDNA OE-PCR product for CRISPR-Cas9 genome editing. The two rounds of 
editing are described in blue and red, the PAM recognition sequences for each sgRNA was 
also targeted for disruption in each dDNA. C) Description of editing process where the 
second round of editing occurs following a blunt DSB by sgRNA guided Cas9. 
 
4.3.2 In situ modification of aprE with CRISPR-Cas9 
A CRISPR-Cas9 mediated chromosome editing strategy was designed to 
introduce the mutations Q125R, Q377E and Q381R (Figure 4.1). pBAC0015 was 
altered to include the oligonucleotide pairs oMAP0150/oMAP0151 or 
oMAP0156/oMAP0157, yielding plasmids pBAC0054 (targeting Q125R locus) and 
pBAC0055 (targeting Q377E and Q381R locus) respectively. Due to their proximity, 
Q377E and Q381R modifications were combined into a single CRISPR-Cas9 




step. The desired edits, included the synonymous PAM mutation to prevent 
continuous cutting by the RNA-guided Cas9 endonuclease, were introduced in the 
homology overlap of the two DNA fragments prepared using PCR. These were 
subsequently combined using OE-PCR and co-transformed alongside the respective 
plasmid (Figure 4.1). OE-PCR products from oligonucleotides sets 
oMAP0152/0153/0154/0155 and oMAP0158/0159/0160/0161 were used alongside 
pBAC0054 and pBAC0055 respectively. Following an efficient curing process in 
which the editing plasmid was lost from the successfully edited strain by growth in 
the absence of chloramphenicol for plasmid selection, and in the presence of IPTG 
to increase the burden of Cas9 expression on cells retaining the plasmid, yielding 
strains BAC0094 (Q125R) and BAC0095 (Q377E and Q381R) respectively, a 
second round of editing using the second set of editing plasmid and dDNA yielded 
the final strain (BAC0097) containing all three modified residues. All screened 
colonies were found to contain the desired mutations following sequencing. 
This system represents a rapid technique for in situ protein modifications 
within B. subtilis 168. Once the Cas9-sgRNA expression plasmid is prepared, the 
same region on the unmodified chromosome can be targeted with a library of 
alternative, rapidly prepared, linear dDNA templates conveying novel modifications 
of interest. As such it is feasible to target a region of a protein of interest, such as a 
substrate binding pocket, and introduce a library of modifications to identify 
beneficial variants of the target protein. 
 
4.3.3 Purification of subtilisin E variants 
4.3.3.1 Variant expression plasmid and strain preparation 
The CRISPR-Cas9 method had been shown to allow rapid, in situ, protein 
engineering, applicable to target strains already in commercial production. However, 
the native subtilisin E is expressed at low levels, even when expression is induced 
on the multicopy plasmid, pHT01 in strain BAC0117 (Figure 4.2). To ensure 
accurate protein characterisation could be performed on the variants obtained in 
strains BAC0094, BAC0095 and BAC0097, each variant was cloned into the pHT01 
vector, yielding plasmids pBAC0068, pBAC0069 and pBAC0060 respectively, 
allowing IPTG inducible expression and secretion of each variant. The native aprE 
gene was also cloned into pHT01, yielding plasmid pBAC0059, to act as a control 




with an ATG start codon to maximise protein expression levels. In B. subtilis ATG, 
TTG and GTG start codons are used in 78%, 13% and 9% of coding sequences 
respectively155. Furthermore, it has previously been shown that GTG start codons 
are three to five-fold less efficient than ATG start codons for translational initiation in 
B. subtilis156. In each newly constructed plasmid, each variant is expressed under 
control of the IPTG inducible Pgrac promoter.  
 
 
Figure 4.2 – Subtilisin E variant expression analysis.  
Comparison of the spent media of strains expressing native and variant subtilisin E proteins 
to an empty vector control strain. All plasmids were introduced into the BAC0114 (B. subtilis 
168 ΔaprE::aad9) strain. Subtilisin E (27.7 kDa) position on the gel is indicated by red 
triangles. All samples are derived from the clarified supernatant of the strains grown in 
presence (+) or absence (-) of IPTG for subtilisin E expression. For each variant, the 
subtilisin E start codon (s.c.) utilised is indicated. Strains used: Empty vector = BAC0116; 
Q125R ATG s.c. = BAC0121; Q377E Q381R ATG s.c. = BAC0122; Native ATG s.c. = 
BAC0119; Q125R Q377E Q381R ATG s.c. = BAC0120; Native GTG s.c. = BAC0117; 
Q125R Q377E Q381R GTG s.c. = BAC0118. M = Blue Prestained Protein Standard, Broad 
Range (11-190 kDa) (New England Biolabs). 
 
These plasmids were used to transform strain BAC0114 which had 
undergone a full deletion of the wild-type aprE gene through introduction of the 
spectinomycin resistance gene, aad9 (section 4.2.3). BAC0114 was utilised instead 
of B. subtilis 168 wild-type to ensure recombination of the expression plasmids into 
the wild-type aprE locus did not occur and to ensure a single protein purification 





4.3.3.2 Validation of subtilisin E variant overexpression 
To ensure pBAC0059/0060/0068/0069 yielded detectable levels of each 
secreted variant in the BAC0114 background, each strain was grown in the 
presence or absence of IPTG and the supernatant was analysed by SDS-PAGE 
(Figure 4.2). These were compared to a negative control strain containing the empty 
pHT01 plasmid. In the presence of IPTG a strong additional band is observed 
indicating the successful expression and secretion of each variant. Furthermore, 
BAC0114 was transformed with pBAC0057 and pBAC0058, expressing the native 
(B. subtilis 168) and triple variant (BAC0097) respectively with the native GTG start 
codon. Direct comparison of these strains to those with an ATG start codon shows 
the direct benefit of the altered start codon in obtaining higher levels of subtilisin E 
expression (Figure 4.2).  
 
4.3.3.3 Size exclusion chromatography protein purification 
Size exclusion chromatography (SEC) was utilised to purify the native 
subtilisin E, as well as each of the three variants. SEC separates proteins based on 
their size by isocratic elution, with larger proteins being eluted from the column 
before smaller proteins. Clarified and concentrated supernatant was loaded to the 
column and eluted (Section 2.12). The UV280 nm absorbance of eluted proteins was 
monitored (Figure 4.3), and 5 mL fractions were collected throughout the purification 
process using the ӒKTA start protein purification system (GE healthcare). Following 
each purification, the fractions were analysed by SDS-PAGE to determine if the 
protein had been successfully isolated (Figure 4.3). In each case, fractions 16 and 
17 yielded the pure subtilisin E variant, as observed in Figure 4.2, with no other 
proteins detectable by SDS-PAGE. As such the proteins were purified to a 








Figure 4.3 – Subtilisin E variant purifications by SEC (previous page).  
ӒKTA Purification chromatographs (Blue line = UV280 nm; Red lines and numbers = collection 
fractions) and their corresponding SDS-PAGE gels following purification of subtilisin E 
variants from strains A) BAC0119; B) BAC0121; C) BAC0122; D) BAC0120. Lanes on each 
SDS-PAGE gel represent: M – Blue Prestained Protein Standard, Broad Range (11-190 
kDa) (New England Biolabs); 1 – clarified supernatant post dialysis; 2 – flow-through during 
concentration post dialysis; 3 – concentrated sample, pre filtration; 4 – concentrated sample, 
post filtration; 5 – fractions 6 & 7; 6 – fractions 8 & 9; 7 - fractions 10 & 11; 8 - fractions 12 & 
13; 9 - fractions 14 & 15; 10 - fractions 16 & 17; 11 - fractions 18 & 19; 12 - fractions 20 & 21; 
13 - fractions 22-28. 
 
4.3.4 Thermotolerance of subtilisin E variants 
The thermotolerance of the purified subtilisin E variants and native protein 
were analysed by the thermal shift assay (Figure 4.4)132. This assay utilises the 
SYPRO® Orange Protein Gel Stain (Merck) which non-specifically binds to 
hydrophobic residues. As the temperature increases in the reaction, the protein 
tertiary structure relaxes and exposes the hydrophobic core residues. This displaces 
the fluorescence quenching water molecules from the SYPRO® Orange molecule 
allowing fluorescence detection (excitation: 470 nm; emission: 570 nm) in a suitable 
instrument, such an RT-qPCR thermocycler157. Variants Q377E + Q381R and 
Q125R + Q377E + Q381R showed increased thermotolerance when compared to 
the native and Q125R proteins, confirming the importance of residues E377 and 
R381 for protein stability at higher temperatures. In contrast, the Q125R variant 
showed no increase in thermotolerance, most likely as there is no other mutated 
residue with which it can form a salt bridge.  
The average Tm for each variant was established by performing a melt curve 
analysis of the thermal shift assay data (Figure 4.4). An increase in Tm of up to 
1.4 °C was established and verified as statistically significant by use of an unpaired t 
test with Welch’s correction (Figure 4.5). The greatest increase in Tm of 1.4 °C was 
found in the Q377E + Q381R variant (54.8 °C, P value = < 0.0001), while the full salt 
bridge triad variant showed an increase of 1.2 °C (54.6 °C, P value = < 0.0001). The 
Q125R variant showed no significant difference in Tm when compared to the WT 






Figure 4.4 - Thermal shift assay of the thermostability of each subtilisin E variant and 
WT.  
Increase in fluorescence was detected as hydrophobic regions of the protein were exposed 
as the protein denatured. The protein melting temperature of each variant and WT was 
calculated with a melt curve analysis, determining the peak rate of protein unfolding per 
temperature increase. Error bars indicate the standard deviation between six replicates. 
 
 
Figure 4.5 - Average Tm between Subtilisin variants and WT replicates.  
The Tm of each subtilisin E variant and WT was calculated as the temperature at which the 
peak rate of protein unfolding was observed for each of six replicated. Error bars indicate the 






4.3.5 Activity retention of subtilisin E variants 
To ensure the introduced mutations had not negatively affected catalytic 
efficiency of the enzyme, the activity for each variant and the WT was established 
under neutral conditions (pH 7.5, 37 °C) by measuring the degradation of casein 
using Folin’s reagent (Figure 4.6)128. Both the Q125R and Q125R + Q377E + 
Q381R variants were 60% less active when compared to the WT, suggesting that 
the Q125R residue is important for catalytic activity. The Q377E + Q381R variant on 
the other hand showed an increase in protease activity of 46.5% (P value = < 
0.0001).  
Residual enzyme activity was measured following incubation of the enzyme 
variants at 55 °C (Figure 4.7). Variant Q377E + Q381R was found to be the best at 
retaining its enzymatic activity when incubated for over 20 minutes. An improvement 
of 12.1% and 15.1% in activity relative to the WT following incubation for 40 and 
60 minutes respectively was noted. The Q125R + Q377E + Q381R variant showed 
a 34.9% decrease in activity relative to the WT following 20 minutes incubation. 




Figure 4.6 - Protease activity assay.  
Protease activity at pH 7.5, 37 °C for 10 minutes. Normalised for protein concentration 
determined by absorbance at 280 nm. Absorbance units (AU) determined at 660 nm. **** = p 
value summary (p = < 0.0001) following unpaired t test with Welch’s correction. Error bars 






Figure 4.7 - Residual protease activity assay.  
Residual protease activity under neutral conditions following incubation at 55 °C for various 
lengths of time, determined by a casein degradation enzymatic assay. Error bars indicate 




In this chapter we have applied the CRISPR-Cas9 tools developed in 
Chapter 3 to perform rapid protein engineering. In under a week we carried out two 
rounds of in situ CRISPR-Cas9 editing of the subtilisin E gene, aprE. A salt bridge 
was introduced in two variants, Q377E + Q381R and Q125R + Q377E + Q381R. 
with the Q337E + Q381R variant showing an increase of 46.5% in subtilisin E 
activity, as well as a 1.4 °C increase in thermostability. To the best of our knowledge 
these modifications have not been combined before in B. subtilis subtilisin E.  
Interestingly, the Q125R + Q377E + Q381R variant did not retain its activity 
levels to the same level as the Q377E + Q381R variant. Indeed, in both variants 
where the Q125R mutation is introduced a drastic drop in enzyme activity was 
observed (Figure 4.6 and Figure 4.7), indicating a vital catalytic activity role for 
residue Q125 within B. subtilis subtilisin E. A similar study of salt bridges in subtilisin 




bridge based on X-ray crystal structure, but resulted in a 1.2 °C drop in 
thermotolerance158. Future analysis of the variants prepared in this study should also 
incorporate an empty vector negative control reaction which will ensure that the 
response observed in the protease activity assays were not due to a small 
contamination of a highly active protease. 
This method for genomic modifications by CRISPR-Cas9 allows rapid, in situ 
protein engineering of industrially relevant strains. Furthermore, discovery and 
optimisation of molecular biology tools such as the work presented here, increases 
the speed and efficiency at which novel biocatalysts can be developed for 
sustainable bioprocesses. This method could be used for in situ directed evolution of 
protein regions through the construction of a dDNA library and the targeting of a 





Chapter 5 – Transcriptional regulation via CRISPR 
tools in Bacillus subtilis 
 
5.1 Introduction 
The CRISPR-Cas9 toolbox for transcriptional interference (CRISPRi) within 
B. subtilis was first developed by Westbrook et al. through the use of chromosomally 
integrated dcas9 and sgRNAs106. Latterly, Peters et al. validated their similarly 
integrated in the genome, dCas9 based CRISPRi system in B. subtilis as titratable 
for downregulation, sterically hindering the progression of the RNA polymerase 
(RNAP). This system was used to analyse all essential genes within B. subtilis 
16873. Both these systems utilised chromosomal integrations of dcas9 and sgRNA 
expression cassettes as it was thought that plasmid-based systems could be less 
stable. However, plasmids based on theta replication, such as pHT01, have been 
shown to be highly stable in B. subtilis159. Additionally, plasmid-based systems have 
a level of flexibility lacking in chromosomal integration methods. In cases where 
CRISPRi is utilised to identify targets for deletion, these integrated components 
would require removal prior to gene knock-out with the catalytically active Cas9 or 
other Cas9-based downstream applications. This is due to the risk of integration of 
Cas9 into dCas9 by homologous recombination.   
Furthermore, multiplexing has been achieved through the use of individual 
sgRNA expression constructs73. Natural CRISPR-Cas9 systems utilise two RNA 
guiding components - tracrRNA and crRNA. Here we develop and exemplify a 
CRISPR system, compatible with B. subtilis, for the simultaneous multiplexed 
targeting of amyE and gfpmut3 through the utilisation of a plasmid system where the 
sgRNA has been split to individually expressed tracrRNA, and the expression of a 
crRNA array to allow simple cloning of multiple targeting protospacers (Figure 5.1). 
The transcriptional alteration systems described above only focus on the 
downregulation of gene expression by disruption of RNAP binding or RNA 
elongation. Transcriptional activation with CRISPR tools (CRISPRa) has been 
widely used in mammalian cell research, as well as in S. cerevisiae, and generally 
consist of a activation domain bound to dCas9 in order to attract the RNAP to the 
target gene72. No such dCas9 fusions had been reported within B. subtilis, in 




Bacterial RNAP (Figure 5.2) consists of 4 primary subunits: two α (RpoA) 
subunits; one β (RpoB) subunit; and one β’ (RpoC) subunit. Combined, these form 
the α2ββ’ complex which elongates RNA when it associates to a σ factor specific to 
the promoter elements upstream of a gene or operon161,162. Other small subunits, 
termed δ, ε, and ω are known to associate with the RNAP and aid in its assembly, 
increasing transcriptional specificity and influencing the recycling of RNAP162.  
 
 
Figure 5.1 – Schematic diagram of CRISPR-Cas9 guiding RNA cloning sites. 
Diagram showing the single guide RNA (sgRNA) (A) or tracrRNA-crRNA complex (B) bound 
to dCas9 enabling identification of the target PAM site. The elements of dCas9 are shown 
(recognition lobe – green; catalytically inactivated nuclease lobe – pink; catalytically 
inactivated HNH domain – grey). C) Diagram of the sgRNA cloning site. The kanamycin 
resistance gene (aphAI – not to scale) is removed by the type IIS restriction enzyme, AarI. A 
20 bp protospacer region can then be introduced between the cleavage sites to complete the 
sgRNA (D). E) Diagram of the crRNA array cloning site. Protospacer regions, flanked by 
direct repeats (DR) are introduced (F) following cleavage with the type IIS restriction enzyme 





In E. coli, the ω subunit has been shown to associate with, and ensure 
correct folding of the β’ subunit of RNAP (Figure 5.2). Furthermore, ω promotes the 
binding of β’ with the α2β complex161,162. E. coli and Mycobacterium smegmatis with 
rpoZ (ω) deleted were found to have misfolded and degraded β’ subunits161. Dove 
and Hochschild found that the E. coli ω subunit could promote a 70-fold increase in 
transcription of a target genes, when fused to the DNA binding cI repressor from 
bacteriophage λ, within an E. coli ΔrpoZ strain163.  Bikard et al. exemplified 
CRISPRa in E. coli through the use of dCas9 fused to the ω subunit (Figure 5.2)59. A 
maximum transcriptional increase of 23-fold was observed when ω was fused to the 
N-terminus of dCas9 (dCas9-ω) and targeted to the template DNA strand, 59 nt 
upstream of the -35 promoter element, controlling expression of a GFP reporter 
protein59. 
In this chapter we attempt to translate the CRISPRa method successfully 
exemplified in E. coli by Bikard et al. into B. subtilis 16859, as well as attempting 
CRISPRa with an alternative transcriptional activator derived from the B. subtilis 
specific bacteriophage Φ29 protein 4, which is known to activate transcription of the 
viral genome at the A3 promoter through interactions with the RNAP α subunit 
(Figure 5.2).  
Lastly, this chapter describes the first reported identification of a catalytically 
inactive variant of the MAD7 nuclease (isolated from Eubacterium rectale and also 
known as ErCas12a71), termed dMAD7. This tool is based on MAD7 which, 
according to Inscripta, is free to use for industrial and academic R&D70. MAD7 has 
been shown to be functional for genome editing within E. coli, S. cerevisiae, mouse 
and human HEK293T cells67, zebrafish71, as well as B. subtilis in this study (Section 
3.3.2). MAD7, like other related Cpf1 (Cas12a) nucleases, has a T-rich PAM site 
preference of 5´-YTTN-3’ (Y = T or C)67 and natively utilises a single gRNA 
molecule, as opposed to the crRNA-tracrRNA complex utilised by Cas9 nucleases 
(Figure 5.1B). 
We propose dMAD7 can be used to identify targets, which could 
subsequently be deleted from the chromosome using MAD7 enabled editing. The 
resulting strain, according to Inscripta70, would not incur any read through royalties 
otherwise associated with Cas9 or Cpf1 nucleases, provided the final strain does not 




The work in this chapter relating to dMAD7 was published in February 2020 




Figure 5.2 – Schematic representation of CRISPRa within bacteria. 
A) the system employed by Bikard et al. where dCas9 is fused to the RNA polymerase 
(RNAP) ω subunit (known to interact with the  β’ subunit) to attract the RNAP complex 
(consisting of two α subunits, and one of each β, β’ and σ subunits) to activate transcription 
at a specific promoter (-35 and -10) element. The subsequent transcriptional start site is 
indicated with an arrow. The complex is targeted to the correct site using a single guide RNA 
(sgRNA), containing a protospacer targeting DNA next to a protospacer adjacent motif 
(PAM) site. B) Similar to the system employed by Bikard et al., the bacteriophage Φ29 
protein 4 is fused to dCas9 to interact with the RNAP α subunit and act as an alternative 






5.2 Materials and methods 
5.2.1 Plasmid and strain construction 
The plasmids and strains used in this chapter are outlined below in Table 
5.1. The oligonucleotides used in this chapter can be found in Appendix C. 
 
Table 5.1 – Strains and plasmids used in this chapter. 
Strain/Plasmid Description/Genotype Reference 
Strains   
B. subtilis 168 trpC2 Laboratory 
stock 
BAC0110 ΔrpoZ This chapter. 
BAC0111 B. subtilis 168 ΔbglS::aph(3’)-lIIa-LIC site-gfpmut3 Section 3.2.1.2 
BAC0205 B. subtilis 168 ΔbglS::aph(3’)-lIIa-PliaG-gfpmut3 This chapter. 
BAC0206 BAC0110 ΔbglS::aph(3’)-lIIa- PliaG-gfpmut3 This chapter. 
BAC0238 BAC0205 with pBAC0097 This chapter. 
BAC0239 BAC0205 with pBAC0098 This chapter. 
BAC0240 BAC0205 with pBAC0099 This chapter. 
BAC0241 BAC0205 with pBAC0100 This chapter. 
BAC0242 BAC0205 with pBAC0101 This chapter. 
BAC0243 BAC0205 with pBAC0102 This chapter. 
BAC0244 BAC0205 with pBAC0103 This chapter. 
BAC0245 BAC0205 with pBAC0104 This chapter. 
BAC0246 BAC0205 with pBAC0110 This chapter. 




BAC0248 BAC0205 with pBAC0112 This chapter. 
BAC0249 BAC0205 with pBAC0113 This chapter. 
BAC0250 BAC0205 with pBAC0114 This chapter. 
BAC0251 BAC0205 with pBAC0115 This chapter. 
BAC0252 BAC0206 with pBAC0097 This chapter. 
BAC0253 BAC0206 with pBAC0098 This chapter. 
BAC0254 BAC0206 with pBAC0099 This chapter. 
BAC0255 BAC0206 with pBAC0100 This chapter. 
BAC0256 BAC0206 with pBAC0101 This chapter. 
BAC0257 BAC0206 with pBAC0102 This chapter. 
BAC0258 BAC0206 with pBAC0103 This chapter. 
BAC0259 BAC0206 with pBAC0104 This chapter. 
BAC0260 BAC0206 with pBAC0110 This chapter. 
BAC0261 BAC0206 with pBAC0111 This chapter. 
BAC0262 BAC0206 with pBAC0112 This chapter. 
BAC0263 BAC0206 with pBAC0113 This chapter. 
BAC0264 BAC0206 with pBAC0114 This chapter. 
BAC0265 BAC0206 with pBAC0115 This chapter. 
BAC0279 BAC0205 with pBAC0120 This chapter. 
BAC0280 BAC0205 with pBAC0121 This chapter. 
BAC0281 BAC0205 with pBAC0122 This chapter. 




BAC0283 BAC0205 with pBAC0124 This chapter. 
BAC0284 BAC0205 with pBAC0125 This chapter. 
BAC0285 BAC0205 with pBAC0126 This chapter. 
BAC0286 BAC0205 with pBAC0127 This chapter. 
BAC0288 BAC0111 ΔbglS::aph(3’)-lIIa-Pveg-gfpmut3 Section 3.2.1.2 
BAC0289 BAC0111 ΔbglS::aph(3’)-lIIa-PrrnB P1-gfpmut3 This chapter. 
BAC0295 BAC0288 with pBAC0132 This chapter. 
BAC0296 BAC0288 with pBAC0133 This chapter. 
BAC0297 BAC0288 with pBAC0104 This chapter. 
BAC0298 BAC0288 with pBAC0102 This chapter. 
BAC0299 BAC0288 with pBAC0103 This chapter. 
BAC0300 BAC0288 with pBAC0092 This chapter. 
BAC0301 BAC0288 with pBAC0093 This chapter. 
BAC0302 BAC0288 with pBAC0094 This chapter. 
BAC0303 BAC0288 with pBAC0095 This chapter. 
BAC0304 BAC0288 with pBAC0096 This chapter. 
BAC0305 BAC0289 with pBAC0133 This chapter. 
BAC0306 BAC0289 with pBAC0104 This chapter. 
BAC0307 BAC0289 with pBAC0102 This chapter. 
BAC0308 BAC0289 with pBAC0103 This chapter. 
BAC0309 BAC0289 with pBAC0092 This chapter. 




BAC0311 BAC0289 with pBAC0094 This chapter. 
BAC0312 BAC0289 with pBAC0095 This chapter. 
BAC0313 BAC0289 with pBAC0096 This chapter. 
BAC0314 BAC0289 with pBAC0134 This chapter. 
BAC0315 BAC0289 with pBAC0135 This chapter. 
BAC0330 BAC0288 with pBAC0164 This chapter. 
BAC0331 BAC0288 with pBAC0168 This chapter. 
BAC0348 BAC0288 with pBAC0194 This chapter. 
BAC0349 BAC0288 with pBAC0195 This chapter. 
BAC0350 BAC0288 with pBAC0189 This chapter. 
BAC0351 BAC0288 with pBAC0190 This chapter. 
BAC0352 B. subtilis 168 with pBAC0194 This chapter. 
BAC0353 B. subtilis 168 with pBAC0184 This chapter. 
BAC0354 B. subtilis 168 with pBAC0189 This chapter. 
BAC0355 B. subtilis 168 with pBAC0188 This chapter. 
BAC0360 B. subtilis 168 with pBAC0212 This chapter. 
BAC0361 B. subtilis 168 with pBAC0213 This chapter. 
BAC0362 B. subtilis 168 with pBAC0214 This chapter. 
BAC0363 B. subtilis 168 with pBAC0215 This chapter. 
BAC0364 BAC0288 with pBAC0207 This chapter. 
BAC0365 BAC0288 with pBAC0208 This chapter. 




BAC0367 BAC0288 with pBAC0210 This chapter. 
BAC0368 BAC0288 with pBAC0211 This chapter. 
BAC0377 BAC0288 with pBAC0222 This chapter. 
BAC0378 BAC0288 with pBAC0220 This chapter. 
BAC0380 BAC0288 with pBAC0219 This chapter. 
BAC0381 BAC0288 with pBAC0212 This chapter. 
BAC0382 BAC0288 with pBAC0215 This chapter. 
Plasmids   
pdCas9-bacteria tetR; dCas9 (S. pyogenes); rrnB T1; p15a ori; cat 138 
pGFPbglS bla; 5´ bglS; aph(3’)-lIIa; LIC site; gfpmut3; 3’ bglS 124 
pMK-RQ-
dMAD7 









ColE1 ori; aphAI; pHT01 MCS; trpA terminator; PrrnB 
P1; tracrRNA; T7 terminator; trpA terminator; DR; 





pWJ66 cat; p15A ori; tracrRNA; dcas9-ω(Ec); crRNA cloning 
site 
59 
pBAC0001 pHT01 with SapI sites removed Section 
3.2.1.1 
pBAC0008 pBAC0001 with rrnB T1 T2; sgRNA Cas9 handle; 
protospacer cloning site; Pveg 
Section 
3.2.1.1 
pBAC0015 pBAC0008 with cas9 (S. pyogenes). Cas9 






pBAC0018 pBAC0008 with dcas9 (S. pyogenes). dcas9 
expression regulated by the Pgrac 
This chapter. 
pBAC0035 pBAC0015 with non-targeting sgRNA DNA Section 
3.2.1.1 
pBAC0041 pBAC0015 with sgRNA targeting 25 bp downstream 
of the start codon within B. subtilis 168 amyE 
Section 
3.2.1.1 
pBAC0065 pBAC0015 with sgRNA targeting 143 bp downstream 
of the start codon within B. subtilis 168 rpoZ 
This chapter. 
pBAC0067 pBAC0008 with dcas9-ω(Ec). dcas9-ω(Ec) 
expression regulated by the Pgrac 
This chapter. 
pBAC0082 pBAC0018 with dcas9-ω(Bs). dcas9-ω(Bs) 
expression regulated by the Pgrac 
This chapter. 
pBAC0090 pBAC0018 with dcas9-Φ29. dcas9-Φ29 expression 
regulated by the Pgrac 
This chapter. 
pBAC0091 pGFPbglS with PliaG inserted at LIC site This chapter. 
pBAC0092 pBAC0082 with sgRNA targeting 113 bp upstream of 
the Pveg and PrrnB P1 -35 promoter element for gfpmut3 
expression in BAC0288/0289 
This chapter. 
pBAC0093 pBAC0082 with sgRNA targeting 131 bp upstream of 
the Pveg and PrrnB P1 -35 promoter element for gfpmut3 
expression in BAC0288/0289 
This chapter. 
pBAC0094 pBAC0082 with sgRNA targeting 139 bp upstream of 
the Pveg and PrrnB P1 -35 promoter element for gfpmut3 
expression in BAC0288/0289 
This chapter. 
pBAC0095 pBAC0082 with sgRNA targeting 163 bp upstream of 
the Pveg and PrrnB P1 -35 promoter element for gfpmut3 





pBAC0096 pBAC0082 with sgRNA targeting 200 bp upstream of 
the Pveg and PrrnB P1 -35 promoter element for gfpmut3 
expression in BAC0288/0289 
This chapter. 
pBAC0097 pBAC0067 with sgRNA targeting 105 bp upstream of 
the PliaG -35 promoter element for gfpmut3 
expression in BAC0205/0206 
This chapter. 
pBAC0098 pBAC0067 with sgRNA targeting 125 bp upstream of 
the PliaG -35 promoter element for gfpmut3 
expression in BAC0205/0206 
This chapter. 
pBAC0099 pBAC0067 with sgRNA targeting 145 bp upstream of 
the PliaG -35 promoter element for gfpmut3 
expression in BAC0205/0206 
This chapter. 
pBAC0100 pBAC0067 with sgRNA targeting 154 bp upstream of 
the PliaG -35 promoter element for gfpmut3 
expression in BAC0205/0206 
This chapter. 
pBAC0101 pBAC0067 with non-targeting sgRNA DNA This chapter. 
pBAC0102 pBAC0082 with sgRNA targeting 80 bp upstream of 
the PliaG, and 16 bp upstream Pveg and PrrnB P1, -35 
promoter elements for gfpmut3 expression in 
BAC0205/0206/0288/0289 
This chapter. 
pBAC0103 pBAC0082 with sgRNA targeting 80 bp upstream of 
the PliaG, and 16 bp upstream Pveg and PrrnB P1, -35 
promoter elements for gfpmut3 expression in 
BAC0205/0206/0288/0289 
This chapter. 
pBAC0104 pBAC0082 with non-targeting sgRNA DNA This chapter. 
pBAC0110 pBAC0090 with sgRNA targeting 80 bp upstream of 
the PliaG -35 promoter element for gfpmut3 





pBAC0111 pBAC0090 with sgRNA targeting 97 bp upstream of 
the PliaG -35 promoter element for gfpmut3 
expression in BAC0205/0206 
This chapter. 
pBAC0112 pBAC0090 with sgRNA targeting 125 bp upstream of 
the PliaG -35 promoter element for gfpmut3 
expression in BAC0205/0206 
This chapter. 
pBAC0113 pBAC0090 with sgRNA targeting 145 bp upstream of 
the PliaG -35 promoter element for gfpmut3 
expression in BAC0205/0206 
This chapter. 
pBAC0114 pBAC0090 with sgRNA targeting 154 bp upstream of 
the PliaG -35 promoter element for gfpmut3 
expression in BAC0205/0206 
This chapter. 
pBAC0115 pBAC0090 with non-targeting sgRNA DNA This chapter. 
pBAC0120 pBAC0082 with sgRNA targeting 84 bp upstream of 
the PliaG -35 promoter element for gfpmut3 
expression in BAC0205 
This chapter. 
pBAC0121 pBAC0082 with sgRNA targeting 73 bp upstream of 
the PliaG -35 promoter element for gfpmut3 
expression in BAC0205 
This chapter. 
pBAC0122 pBAC0082 with sgRNA targeting 68 bp upstream of 
the PliaG -35 promoter element for gfpmut3 
expression in BAC0205 
This chapter. 
pBAC0123 pBAC0082 with sgRNA targeting 56 bp upstream of 
the PliaG -35 promoter element for gfpmut3 
expression in BAC0205 
This chapter. 
pBAC0124 pBAC0082 with sgRNA targeting 45 bp upstream of 
the PliaG -35 promoter element for gfpmut3 





pBAC0125 pBAC0082 with sgRNA targeting 30 bp upstream of 
the PliaG -35 promoter element for gfpmut3 
expression in BAC0205 
This chapter. 
pBAC0126 pBAC0082 with sgRNA targeting 84 bp upstream of 
the PliaG -35 promoter element for gfpmut3 
expression in BAC0205 
This chapter. 
pBAC0127 pBAC0082 with sgRNA targeting 11 bp upstream of 
the PliaG -35 promoter element for gfpmut3 
expression in BAC0205 
This chapter. 
pBAC0129 pBAC0015 with sgRNA targeting 18 bp upstream of 
the start codon within BAC0111 gfpmut3. 
This chapter. 
pBAC0132 pBAC0082 with sgRNA targeting 16 bp upstream of 
the Pveg -35 promoter element for gfpmut3 expression 
in BAC0288 
This chapter. 
pBAC0133 pBAC0082 with sgRNA targeting 61 bp upstream of 
the Pveg and PrrnB P1 -35 promoter element for gfpmut3 
expression in BAC0288/0289 
This chapter. 
pBAC0134 pBAC0082 with sgRNA targeting 20 bp downstream 
of the PrrnB P1 -35 promoter element for gfpmut3 
expression in BAC0289 
This chapter. 
pBAC0135 pBAC0082 with sgRNA targeting 9 bp upstream of 
the PrrnB P1 -35 promoter element for gfpmut3 
expression in BAC0289 
This chapter. 
pBAC0155 pBAC0001 with rrnB T1 T2; T7 terminator; 
protospacer cloning site; gRNA MAD7 handle; Pveg 
Section 
3.2.1.1 
pBAC0157 pBAC0001 with tracrRNA-crRNA array cloned 
between BamHI and SmaI sites 
This chapter. 







pBAC0162 pBAC0158 with gRNA targeting 21 bp downstream of 
the start codon within B. subtilis 168 amyE 
Section 
3.2.1.1 
pBAC0163 pBAC0158 with non-targeting gRNA DNA Section 
3.2.1.1 
pBAC0164 pBAC0157 with dcas9 cloned between BamHI and 
XbaI sites 
This chapter. 
pBAC0165 pBAC0015 with sgRNA targeting 27 bp downstream 
of the start codon within BAC0288 gfpmut3 
Section 
3.2.1.1 
pBAC0166 pBAC0158 with sgRNA targeting 21 bp downstream 
of the start codon within BAC0288 gfpmut3 
Section 
3.2.1.1 
pBAC0168 pBAC0164 with crRNA array DNA targeting (in order) 
47 bp downstream of the start codon within BAC0288 
amyE and 68 bp upstream of the start codon within 
BAC0288 gfpmut3 
This chapter. 
pBAC0184 pBAC0041 with dcas9 replacing cas9 This chapter. 
pBAC0187 pBAC0155 with dMAD7 from pMK-RQ-dMAD7. 
dMAD7 expression regulated by Pgrac 
This chapter. 
pBAC0188 pBAC0162 with dMAD7 replacing MAD7 This chapter. 
pBAC0189 pBAC0163 with dMAD7 replacing MAD7 This chapter. 
pBAC0190 pBAC0166 with dMAD7 replacing MAD7 This chapter. 
pBAC0194 pBAC0035 with dcas9 replacing cas9 This chapter. 
pBAC0195 pBAC0165 with dcas9 replacing cas9 This chapter. 
pBAC0207 pBAC0187 with sgRNA targeting 9 bp downstream of 
the start codon within BAC0288 gfpmut3 
This chapter. 
pBAC0208 pBAC0187 with sgRNA targeting 16 bp downstream 





pBAC0209 pBAC0187 with sgRNA targeting 43 bp downstream 
of the start codon within BAC0288 gfpmut3 
This chapter. 
pBAC0210 pBAC0187 with sgRNA targeting 78 bp downstream 
of the start codon within BAC0288 gfpmut3 
This chapter. 
pBAC0211 pBAC0187 with sgRNA targeting 80 bp downstream 
of the start codon within BAC0288 gfpmut3 
This chapter. 
pBAC0212 pBAC0187 with sgRNA targeting 4 bp downstream of 
the start codon within B. subtilis 168 amyE 
This chapter. 
pBAC0213 pBAC0187 with sgRNA targeting 11 bp downstream 
of the start codon within B. subtilis 168 amyE 
This chapter. 
pBAC0214 pBAC0187 with sgRNA targeting 27 bp downstream 
of the start codon within B. subtilis 168 amyE 
This chapter. 
pBAC0215 pBAC0187 with sgRNA targeting 51 bp downstream 
of the start codon within B. subtilis 168 amyE 
This chapter. 
pBAC0219 pBAC0187 with crRNA array DNA targeting (in order) 
80 bp and 21 bp downstream of the start codon 
within BAC0288 gfpmut3 
This chapter. 
pBAC0220 pBAC0187 with crRNA array DNA targeting (in order) 
80 bp downstream of the start codon within BAC0288 
gfpmut3 and 4 bp downstream of the start codon 
within BAC0288 amyE 
This chapter. 
pBAC0222 pBAC0187 with crRNA array DNA targeting (in order) 
4 bp and 51 bp downstream of the start codon within 
BAC0288 amyE 
This chapter. 
LIC = Ligation Independent Cloning; MCS = Multiple Cloning Site; DR = direct 
repeat. 
 
5.2.1.1 Plasmid construction 
The construction of plasmids pBAC0008/0155 using the inABLE® assembly 




pBAC0008 (yielding pBAC0015) and MAD7 into pBAC0155 (yielding pBAC0158) is 
also described in detailed in Section 3.2.1.1. 
The catalytically inactive dcas9 gene was PCR amplified (Section 2.5.5.1) 
from pdCas9-bacteria138 with primers oMAP0073/0074, introducing a BsaI site and 
XbaI restriction enzyme recognition sites at the 5´ and 3’ end of the gene, 
respectively. The amplified dcas9 was digested (Section 2.5.8) with BsaI and XbaI, 
and ligated (Section 2.5.10) with the BamHI-HF and XbaI digested pBAC0008 
backbone, yielding pBAC0018. BsaI was used due to S. pyogenes dcas9 containing 
a BamHI recognition site.  
The dcas9-ω(Ec) fusion was similarly cloned into the BamHI and XbaI 
digested pBAC0008 backbone following PCR amplification from pWJ66, yielding 
plasmid pBAC006759. pWJ66 was a gift from Luciano Marraffini (Addgene plasmid 
#46570).  
pBAC0082 carrying the dcas9-ω(Bs) fusion was cloned by PCR amplification 
of the 3’ region of dCas9 from pBAC0018 with oMAP0223 (introducing a PmlI 
restriction enzyme recognition site) and oMAP0214. In parallel, the B. subtilis rpoZ 
gene (encoding the B. subtilis RNA polymerase ω subunit) was PCR amplified from 
B. subtilis 168 gDNA (gDNA preparation described in section 2.5.3) with primers 
oMAP0215 (introducing a 20 bp region of homology with oMAP0214) and 
oMAP0216 (introducing an XbaI restriction enzyme recognition site). These two 
PCR products were fused using OE-PCR (Section 2.5.5.3) with primers 
oMAP0216/0223, and the subsequent product was digested with PmlI and XbaI. 
pBAC0018 was also digested with PmlI and XbaI and ligated with the digested 3’ 
dCas9-rpoZ OE-PCR product.  
pBAC0090 carrying the dCas9-Φ29 fusion protein was cloned in the same 
manner as pBAC0082 with the 3’ region of dCas9 PCR amplified with the same 
primers.  The genome sequence of Φ29 is available (NC_011048.1) and as such P4 
was synthesised (codon optimised for B. subtilis) as linear dsDNA by Twist 
Bioscience (USA). Φ29P4 was PCR amplified using primers oMAP0317/0318. 
pBAC0187 was constructed by digesting pBAC0155 and pMK-RQ-dMAD7 
(dMAD7 (MAD7 gene with D877A (codon GCT to GAT), E962A (codon GCA to GAA), 
D1213A (codon GCT to GAT) modifications) flanked by BamHI and XbaI recognition 
sites, synthesised by Thermo Fisher Scientific), with BamHI-HF and XbaI. The 




Plasmids used for Cas9-mediated editing were prepared from the pBAC0015 
parental plasmid using phosphorylated and annealed oligonucleotide pairs as 
described in section 2.5.4.1. Plasmids used for analysis of the effector fusion 
proteins dCas9-ω(Ec), dCas9-ω(Bs) or dCas9-Φ29 were prepared from the 
pBAC0067, pBAC0082 or pBAC0090 parental plasmids respectively, using 
phosphorylated and annealed oligonucleotide pairs as described in section 2.5.4.1. 
Plasmids used for dMAD7 CRISPRi analysis were prepared from the pBAC0158 
parental plasmid using phosphorylated and annealed oligonucleotide pairs as 
described in section 2.5.4.1. Information on the oligonucleotides used in 
construction, target gene and PAM site for the following CRISPR plasmids used in 
this chapter can be found in Table 2.12: pBAC0035; pBAC0041; pBAC0065; 
pBAC0097; pBAC0098; pBAC0099; pBAC0100; pBAC0101; pBAC0092; 
pBAC0093; pBAC0094; pBAC0095; pBAC0096; pBAC0102; pBAC0103; 
pBAC0104; pBAC0120; pBAC0121; pBAC0122; pBAC0123; pBAC0124; 
pBAC0125; pBAC0126; pBAC0127; pBAC0129; pBAC0132; pBAC0133; 
pBAC0134; pBAC0135; pBAC0110; pBAC0111; pBAC0112; pBAC0113; 
pBAC0114; pBAC0115; pBAC0162; pBAC0163; pBAC0165; pBAC0166; 
pBAC0207; pBAC0208; pBAC0209; pBAC0210; pBAC0211; pBAC0212; 
pBAC0213; pBAC0214; pBAC0215; pBAC0219; pBAC0220; pBAC0222. 
pBAC0157 was constructed by ligating the BamHI and SmaI cut pBAC0001 
with the BamHI and PmlI cut pMK-RQ-tracrRNA-crRNA array (Thermo Fisher 
Scientific). pBAC0157 contains a tracrRNA expression cassette, controlled by PrrnB 
P1, and a crRNA array expression cassette, controlled by Pveg, and retained the Pgrac 
controlled expression site successfully used for cas9 expression (Section 3.3.1.2). 
dcas9 was inserted following PCR amplification using oMAP0073/0074, digesting 
this with BsaI and XbaI, and ligating with pBAC0157 cut with BamHI and XbaI, 
yielding pBAC0164. pBAC0168 was designed to simultaneously target gfpmut3 and 
amyE. A third, non-targeting crRNA was also included to ensure maturation of the 
first two crRNAs. The crRNA array to yield these targeting molecules was split 
between two sets of oligonucleotides due to their length. Each set, once 
phosphorylated and annealed (Section 2.5.4.1), contained a 3 nt overhang for 
ligation with the SapI digested pBAC0164 backbone, as well as a 4 nt overhang for 
ligation to the other oligonucleotide set. The three fragments were combined in a 
single ligation reaction. SapI replaced AarI in plasmids derived from pBAC0008 due 




could be used here since the crRNA array cloning region was synthesised, and the 
InABLE® DNA assembly method was not utilised (in which SapI digestion is 
generally required, preventing the downstream use of SapI). 
pBAC0184/0194/0195 were prepared by digesting pBAC0041/0035/0165 
respectively with BamHI-HF and XbaI to remove cas9 and subsequently ligating 
these backbones with dcas9 which was PCR amplified from pdCas9-bacteria with 
primers oMAP0073/0074. This PCR product was digested with BsaI and XbaI and 
ligated with the prepared backbones. 
pBAC0188/0189/0190 were prepared by digesting pBAC0162/0163/0166 
respectively with BamHI-HF and XbaI to remove MAD7 and subsequently ligating 
these backbones with dMAD7 which was isolated from pMK-RQ-dMAD7 with the 
same restriction enzymes.  
Ligation independent cloning (LIC) was used for the introduction of PliaG for 
gfpmut3 expression on the plasmid pGFPbglS124. The method outlined by Bisicchia 
et al. was followed124. Oligonucleotides oMAP0244/0245 were used to PCR amplify 
PliaG from B. subtilis 168 gDNA and yielded the final integration plasmid pBAC0091. 
 
5.2.1.2 Strain construction 
Using the approach described in section 2.7, CRISPR-Cas9 mediated 
chromosome editing was used to delete rpoZ from B. subtilis 168. dDNA OE-PCR 
products, amplified from B. subtilis 168 gDNA with oligonucleotide set 
oMAP0210/0211/0212/0213 was used alongside pBAC0065. Cas9/sgRNA plasmid 
was removed from the edited strain as described in section 2.7.6, yielding BAC0110. 
The deletion of rpoZ was verified by PCR amplification from gDNA with 
oMAP0210/0213 and D5000 Tapestation analysis as described in section 2.5.6.2. 
Similarly, CRISPR-Cas9 mediated chromosome editing was used to insert 
the Pveg or PrrnB P1 promoters upstream of the gfpmut3 gene in BAC0111 (Section 
3.2.1.2) to construct stain BAC0288 (Section 3.2.1.2) and BAC0289 respectively. To 
construct BAC0289, dDNA OE-PCR products, amplified from BAC0111 gDNA with 
oligonucleotide set oMAP0388/0393/0396/0397 was used alongside pBAC0129. 
The CRISPR-Cas9/sgRNA plasmid was removed from the edited strain as 
described in section 2.7.6. The insertion of PrrnB P1 was verified by PCR amplification 




Furthermore, GFPmut3 was detected by fluorescence emission analysis using Safe 
Imager 2.0 Blue Light Transilluminator and Amber Filter (Thermo Fisher Scientific) 
system (excitation: 470 nm, emission: 530 nm).  
All remaining strains described in Table 5.1 were prepared by making their 
parental strain naturally competent (section 2.4.2) and transforming with 200 ng of 
the plasmid also described in Table 5.1. 
 
5.3 Results 
5.3.1 Evaluation of CRISPRa within B. subtilis 
5.3.1.1 Effector protein selection 
Following the successful exemplification of CRISPRa in E. coli ΔrpoZ using a 
dCas9 fusion to the ω subunit of this organism (ω(Ec)), this dCas9-effector 
combination was chosen to attempt CRISPRa within B. subtilis alongside two other 
effector proteins. These were the ω subunit (RpoZ) of RNAP in B. subtilis (ω(Bs)), 
and the Φ29 bacteriophage protein P4, known to interact with the α subunit of RNAP 
of B. subtilis to activate transcription of the viral genome at the viral A3 
promoter59,164. It was hypothesised that this interaction could be harnessed for 
transcriptional activation through interactions between the Φ29 subunit and the 
native RNAP α subunit.  
Since Bikard et al. had found the C-terminal fusion variant had yielded the 
highest CRISPRa effect (2.8-fold increase (dCas9-ω) compared to ~1.8-fold 
increase (ω-dCas9)), our design for dCas9-ω(Bs) and dCas9-Φ29 followed the 
same approach59. Similarly, the Ala-Ala linker region between dCas9 and ω(Ec), 
used by Bikard et al., was retained in our new dCas9-effector combinations. 
 
5.3.1.2 Fluorescence-based transcriptional regulation screen 
Bikard et al. observed CRISPRa to be functional in E. coli only when rpoZ 
had been deleted59. The WT strain had not been tested in parallel, but the 
assumption was carried through from results by Dove and Hochschild where 
transcriptional activation in E. coli, with an alternative DNA binding protein fused to 




genome editing method to delete rpoZ from the chromosome of B. subtilis 168,  
yielding BAC0110.   
GFPmut3, a variant of the jellyfish Aequorea victoria GFP (containing 
mutations S65G and S72A) with an increased fluorescence intensity and a 106 nm 
shifted excitation maxima165, was selected as the reporter for screening of CRISPRa 
candidates due to its ease of detection by fluorescence following excitation by blue 
light (470 nm) and its prior use within B. subtilis113,124. PliaG is known to be a 
constitutive promoter139. Ligation independent cloning (LIC – section 2.5.13) was 
utilised for the insertion of PliaG upstream of gfpmut3 in pGFPbglS124. The resulting 
plasmid, pBAC0091, was recombined onto the chromosome at the bglS locus of 
both the WT B. subtilis 168 and BAC0110 strains, yielding strains BAC0205 and 
BAC0206 respectively following validation of the site-specific integration by colony 
PCR. Furthermore, integrants were identified by growth on an LB agar 
supplemented with kanamycin as the resistance gene (aph(3’)-lIIa) was also 
chromosomally integrated upstream of gfpmut3. A further two background strains 
were prepared where gfpmut3 expression was under control of the stronger 
promoters Pveg and PrrnB P1, strains BAC0288 and BAC0289 respectively. The 
expression levels of gfpmut3 under the control of PliaG, Pveg and PrrnB P1 are shown in 
Figure 5.3. PliaG was taken forward for initial CRISPRa analysis as it would allow the 
easiest identification of when CRISPRa is most effective since a further increase in 






Figure 5.3 – Fluorescence signal of GFPmut3 transcriptional reporters. 
Levels of fluorescence signal with strong (Pveg – BAC0288), medium (PrrnB P1 – BAC0289) 
and weak (PliaG – BAC0205) promoters controlling the expression of gfpmut3. The negative 
control strain was unaltered B. subtilis 168. Error bars indicate the standard deviation 
between three biological replicates. 
 
To screen the selected effector proteins for CRISPRa activity by GFPmut3 
transcriptional increase, various sgRNAs were designed varying in the distance 
between the PAM site and the -35 element of the promoter: 80 bp; 97 bp; 105 bp; 
129 bp; 145 bp; 154 bp.  
Six PAM sites were selected between 80 and 154 bp upstream of the 
PliaG -35 element for targeting with the dCas9-effector protein fusions. In addition, a 
non-targeting plasmid was prepared for each dCas9-effector protein fusion to act as 
a negative control for CRISPRa.  
Of the 21 designed dCas9-effector/sgRNA plasmids, 14 were successfully 
constructed. These CRISPRa targeting and non-targeting plasmids were used to 
transform BAC0205 (WT with PliaG-gfpmut3) and BAC0206 (ΔrpoZ with 
PliaG-gfpmut3) background strains. These 28 strains (BAC0238-BAC0265) were 
subsequently analysed for GFPmut3 fluorescence (section 2.10.2) in order to 
determine if the targeted dCas9-effector fusions caused an increase in GFPmut3 
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fluorescence levels (Figure 5.4, Figure 5.5 and Figure 5.6). Also included in each 
plate, was a positive control strain where gfpmut3 was introduced onto the pHT01 
plasmid and expressed by IPTG induced Pgrac to ensure GFPmut3 could be 
detected (data not shown). 
The results indicate the dCas9-ω(Bs) fusion protein yielded an increase of 
91.3% in GFPmut3 fluorescence, relative to the non-targeting control following 
20 hours of growth, when targeting the PAM site 80 nt upstream of the -35 element 
in strain BAC0243 (Figure 5.5). The effect can be seen in the mean of the replicates 
from 8 hours into the analysis, with the effect becoming more pronounced following 
15 hours of growth. The same increase in fluorescence was not observed in the 
ΔrpoZ background strain. No detectable CRISPRa effect was observed for the 
dCas9-ω(Ec) and dCas9-Φ29 fusion proteins under the tested conditions, relative to 





Figure 5.4 – Screening of a dCas9-ω(Ec) enabled CRISPRa system based on GFPmut3 transcriptional reporters. 
Levels of fluorescence (solid symbols) and OD 600 nm (hollow symbols). gfpmut3 expression is controlled by PliaG. In either the ‘WT’ BAC0205 (left) or a 
ΔrpoZ BAC0206 (right) background strains, a plasmid is present expressing the candidate CRISPRa dCas9-effector fusion protein, dCas9-ω(Ec). Each 
plasmid expressed an sgRNA targeting PAM sites at the indicated distance from the 5´ of the -35 element of PliaG. A non-targeting (NT) sgRNA control 
strain for each background strain was included (pink). All screened sgRNA targeted PAM sites on the sense strand. Error bars indicate the standard 





Figure 5.5 – Screening of a dCas9-ω(Bs) enabled CRISPRa system based on GFPmut3 transcriptional reporters. 
Levels of fluorescence (solid symbols) and OD 600 nm (hollow symbols). gfpmut3 expression is controlled by PliaG. In either the ‘WT’ BAC0205 (left) or a 
ΔrpoZ BAC0206 (right) background strains, a plasmid is present expressing the candidate CRISPRa dCas9-effector fusion protein, dCas9-ω(Bs). Each 
plasmid expressed an sgRNA targeting PAM sites at the indicated distance from the 5´ of the -35 element of PliaG. A non-targeting (NT) sgRNA control 
strain for each background strain was included (pink). All screened sgRNA targeted PAM sites on the sense strand. Error bars indicate the standard 





Figure 5.6 - Screening of a dCas9-Φ29 enabled CRISPRa system based on GFPmut3 transcriptional reporters. 
Levels of fluorescence (solid symbols) and OD 600 nm (hollow symbols). gfpmut3 expression is controlled by PliaG. In either the ‘WT’ BAC0205 (left) or a 
ΔrpoZ BAC0206 (right) background strains, a plasmid is present expressing the candidate CRISPRa dCas9-effector fusion protein, dCas9-Φ29. Each 
plasmid expressed an sgRNA targeting PAM sites at the indicated distance from the 5´ of the -35 element of PliaG. A non-targeting (NT) sgRNA control 
strain for each background strain was included (pink). All screened sgRNA targeted PAM sites on the sense strand. Error bars indicate the standard 





These findings informed the selection of the dCas9-ω(Bs) fusion protein in 
the BAC0205 background strain for further analysis using the RoboLector 
micro-fermentation system. Furthermore, the BAC0288 and BAC0289 background 
strains (where gfpmut3 is under the control of Pveg and PrrnB P1 respectively) were 
also included in subsequent analysis to determine if CRISPRa was detectable when 
the promoter of the targeted gene is of a greater strength. Additional sgRNAs were 
designed and the subsequent plasmids were cloned to target dCas9-ω(Bs) a range 
of sites upstream or within the -35 element for each promoter (PliaG, 11 to 97 bp; 
PrrnB P1, -20 to 200 bp; Pveg, 16 to 200 bp).  
Figure 5.7, Figure 5.8 and Figure 5.9 show the RoboLector analysis (section 
2.2.3) of all the tested strains, relative to the non-targeting control strain, for the 
three transcription reporters with weak (PliaG strains BAC243-BAC0245 and 
BAC0279-BAC0286), intermediate (PrrnB P1 strains BAC0305-BAC0315) and strong 
(Pveg, strains BAC0295-BAC0304) promoters (Figure 5.3). Tuneable transcription 
activation could not be detected with the GFPmut3 fluorescence reporters. However, 
an upregulation in fluorescence, relative to the non-targeting control strain, was 
noted from 18 hours onwards when dCas9-ω(Bs) was targeted 30 nt upstream of 
the PliaG -35 element (strain BAC0284), with the highest GFPmut3 fluorescence 
detected after 24 hours of growth (Figure 5.7). Additionally, targeting dCas9-ω(Bs) 
163 nt upstream of the Pveg -35 element (strain BAC0303), an increase in relative 
fluorescence was detected from 3 hours to 4.5 hours growth (Figure 5.9). The same 
plasmid did not elicit the same response in the equivalent PrrnB P1 strain (BAC0312 
(Figure 5.8)).   
sgRNAs targeting PAM sites in close proximity to, or -20 nt downstream, of 
the -35 element were included as controls to show a decrease in gfpmut3 
expression levels by CRISPRi of up to 85.5% (Figure 5.9), thus confirming the ability 
of the fusion protein to bind the DNA as designed. RoboLector analysis indicated 
these controls act as expected with the expression of dCas9-ω(Bs) lowering 
detectable GFPmut3 fluorescence when strains utilising PrrnB P1 (Figure 5.8) or Pveg 
(Figure 5.9) promoters were used. However, no lowering of expression levels was 
observed in PliaG background strains (Figure 5.7). This was thought to be due to the 
very low expression levels observed (see Figure 5.3) making any reduction in 






Figure 5.7 – CRISPRa screen of GFPmut3 transcriptional reporters expressed by PliaG. 
Levels of GFPmut3 fluorescence in strains with plasmids expressing dcas9-ω(Bs) and 
sgRNA targeting PAM sites at the indicated distance from the 5´ of the -35 element of the 
PliaG promoter. Fluorescence levels are normalised by biomass (λ620 nm) relative to the 
non-targeting (NT) sgRNA control strain for each background promoter. sgRNAs target PAM 
sites on either sense (solid shapes) or antisense strand (hollow shapes). Error bars indicate 
the standard deviation between three biological replicates. 
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Figure 5.8 – CRISPRa screen of GFPmut3 transcriptional reporters expressed by PrrnB 
P1. 
Levels of GFPmut3 fluorescence in strains with plasmids expressing dcas9-ω(Bs) and 
sgRNA targeting PAM sites at the indicated distance from the 5´ of the -35 element of the 
PrrnB P1 promoter. Fluorescence levels are normalised by biomass (λ620 nm) relative to the 
non-targeting (NT) sgRNA control strain for each background promoter. sgRNAs target PAM 
sites on either sense (solid shapes) or antisense strand (hollow shapes). Error bars indicate 
the standard deviation between three biological replicates. 
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Figure 5.9 – CRISPRa screen of GFPmut3 transcriptional reporters expressed by Pveg. 
Levels of GFPmut3 fluorescence in strains with plasmids expressing dcas9-ω(Bs) and 
sgRNA targeting PAM sites at the indicated distance from the 5´ of the -35 element of the 
Pveg promoter. Fluorescence levels are normalised by biomass (λ620 nm) relative to the 
non-targeting (NT) sgRNA control strain for each background promoter. sgRNAs target PAM 
sites on either sense (solid shapes) or antisense strand (hollow shapes). Error bars indicate 
the standard deviation between three biological replicates. 
 
Taking the potential CRISPRa observations and CRISPRi control strains, 
Figure 5.10, Figure 5.11 and Figure 5.12 investigates the relationship between 
fluorescence and distance of the PAM or protospacer to the -35 element. The 
timepoint for each background strain yielding the highest fluorescence was analysed 
(PliaG – 24 hours; PrrnB P1 – 6.25 hours; Pveg – 4 hours). Using regression analysis, an 
R2 value for each analysis was established. This showed a closer relationship to the 
distance of the distal end of the protospacer to the level of fluorescence observed 
for both the PrrnB P1 and Pveg strain sets. However, no correlation could be observed 
for the PliaG strains given there was no significant difference in fluorescence.  
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Figure 5.10 – Correlation between PliaG controlled GFPmut3 relative fluorescence and distance from PAM site (A) or protospacer (B) to the -35 
element. 
Strains with gfpmut3 under the control of PliaG at 24 hours growth. Black dashed lines represent the non-targeting sgRNA control, with red dashed lines 
representing the corresponding standard deviation between three biological replicates. A solid black line of best fit is shown for each graph, and the 






Figure 5.11 – Correlation between PrrnB P1 controlled GFPmut3 relative fluorescence and distance from PAM site (A) or protospacer (B) to the -
35 element. 
Strains with gfpmut3 under the control of PrrnB P1 at 24 hours growth. Black dashed lines represent the non-targeting sgRNA control, with red dashed 
lines representing the corresponding standard deviation between three biological replicates. A solid black line of best fit is shown for each graph, and 





Figure 5.12 – Correlation between Pveg controlled GFPmut3 relative fluorescence and distance from PAM site (A) or protospacer (B) to the -35 
element. 
Strains with gfpmut3 under the control of Pveg at 24 hours growth. Black dashed lines represent the non-targeting sgRNA control, with red dashed lines 
representing the corresponding standard deviation between three biological replicates. A solid black line of best fit is shown for each graph, and the 




5.3.1.3 Analysis of CRISPRa effect by quantification of gfpmut3 mRNA 
confirms transcriptional interference but not activation 
To validate if the potential CRISPRa we had observed was a true reflection 
of an increase in the mRNA levels, RT qRT-PCR analysis was performed (section 
2.14). Since the strains where gfpmut3 was expressed using Pveg had given the 
greatest correlation between transcriptional changes, relative to the non-targeting 
strain, and the distances of either the PAM site, or protospacer from the -35 
promoter element (Figure 5.12), these were selected for analysis. Strain BAC0303 
was selected for CRISPRa analysis since a 43.7% increased level in GFPmut3 
reporter had been detected during exponential growth phase (Figure 5.9). As a 
control, the Pveg strain BAC0295 was analysed to show the decrease in relative 
fluorescence observed was due to dCas9-ω(Bs) inhibiting transcription. 
 
5.3.1.4 Validation of RT qRT-PCR primers 
Two primer sets were designed and validated (section 2.14.5) for gfpmut3 
(Figure 5.13), as well as the gapA (Figure 5.14) and sdhA (Figure 5.15) reference 
genes which are constitutively expressed under the experimental conditions in 
B. subtilis166,167. As adequate RT qPCR primers are described as allowing a PCR 
efficiency of 90-110%, all the tested primer sets were adequate for use. The primer 
sets for each gene yielding a PCR efficiency closest to 100% were selected for use 







Figure 5.13 – Validation of RT qRT-PCR primer pair for analysis of gfpmut3. 
Cq (quantification cycle) calibration curve with the subsequent PCR efficiency calculation (A 
and C), and melt curve results (B and D) for each primer set. Melt curves were carried out 
following RT qPCR with serial dilutions of BAC0288 gDNA, with a no DNA control reaction 







Figure 5.14 – Validation of RT qRT-PCR primer pair for analysis of gapA. 
Cq (quantification cycle) calibration curve with the subsequent PCR efficiency calculation (A 
and C), and melt curve results (B and D) for each primer set. Melt curves were carried out 
following RT qPCR with serial dilutions of BAC0288 gDNA, with a no DNA control reaction 







Figure 5.15 – Validation of RT qRT-PCR primer pair for analysis of sdhA. 
Cq (quantification cycle) calibration curve with the subsequent PCR efficiency calculation (A 
and C), and melt curve results (B and D) for each primer set. Melt curves were carried out 
following RT qPCR with serial dilutions of BAC0288 gDNA, with a no DNA control reaction 
also present (grey line). sdhA primer set 1 was selected for use in analysis of sdhA 
transcription 
 
5.3.1.5 RT qRT-PCR confirms gfpmut3 downregulation in control strain 
BAC0295 and lack of transcriptional activation in assay strain 
BAC0303  
RT qRT-PCR was used to quantify gfpmut3 transcription in strains BAC0295 
and BAC0303 (section 2.14). RT qRT-PCR results can be found in Appendix F. 
These transcription levels were compared to those of strain BAC0297 which 




genes gapA and sdhA (Figure 5.16). The results confirm the lowered fluorescence 
observed in BAC0295 was due to a lower mRNA pool caused by dCas9-ω(Bs) 
blocking efficient binding of the RNAP to the Pveg promoter. There was, however, no 
statistically significant increase in gfpmut3 levels in BAC0303. This confirmed that 
CRISPRa was not observed under the tested conditions. 
 
  
Figure 5.16 – Relative gfpmut3 expression following CRISPR-mediated transcriptional 
regulation. 
gfpmut3 transcription levels relative to gapA and sdhA transcription levels between assay 
strains BAC0295 (16 bp (targeting PAM site 16 bp upstream of the -35 region of Pveg)) or 
BAC0303 (163 bp (targeting PAM site 163 bp upstream of the -35 region of Pveg)) and the 
non-targeting control strain BAC0297 (ΔΔCq). ΔΔCq to gapA and sdhA was calculated as per 
Equation 2-5 and Equation 2-6 respectively. RT qRT-PCR results can be found in Appendix 
F. Error bars indicate the standard deviation between technical duplicates and biological 
triplicates. 
 
5.3.2 Multiplexed CRISPRi with dCas9 
The control reactions in section 5.3.1 exemplified CRISPRi for the first time 
using the plasmid system described in this study (Figure 5.8 and Figure 5.9). It was 
desirable to determine if this single plasmid system also allowed the simultaneous 
targeting of dCas9 to more than one locus (multiplexing). BAC0288 was selected as 
the test strain for this analysis as it had been shown to be an effective reporter for 




gene, encoding a starch degrading α-Amylase, was also used as a second reporter 
protein for CRISPRi. 
Multiplexed targeting requires more than one gRNA. Since the expression of 
each sgRNA requires an individual expression cassette 
(promoter-sgRNA-terminator), it was decided to simplify the design by using the 
native gRNA model from S. pyogenes43. The sgRNA was therefore divided again 
into its constitutive tracrRNA and crRNA components, with the new parental 
multiplexing CRISPRi, dcas9 expressing plasmid, pBAC0164, constructed to contain 
a tracrRNA expression cassette, controlled by PrrnB P1, and a crRNA array expression 
cassette, controlled by Pveg (Figure 5.1).  
The crRNA array was designed with three protospacers inserted targeting, in 
order of expression, amyE, gfpmut3 and a non-targeting protospacer. This was 
cloned into pBAC0164 by a three-part ligation of the pBAC0164 SapI digested 
backbone and two sets of annealed oligonucleotides with a 4 nt complimentary 
overhang to each other and 3 nt to the backbone. The joining site between the two 
inserted DNA oligonucleotides was the direct repeat region which had been split to 
avoid repeat sequences which are known to complicate DNA synthesis. This region 
can be further split (as described in section 2.17) with up to 12 complementary 
overhangs available (GC content: 25-75% and at least 2 bp difference to limit 
non-specific binding). Thus, where two protospacers are present on the annealed 
oligonucleotide, either side of a direct repeat region, and the subsequent linking 
region is present, up to 24 protospacers could be cloned within a single step.  
Strains BAC0331, expressing dcas9, tracrRNA and the crRNA array, and 
BAC0330, expressing dcas9 and tracrRNA only,  were grown and analysed 
following 4 and 20 hours of growth for extracellular α-Amylase activity (section 
2.9.2), and intracellular GFPmut3 fluorescence levels (section 2.10.2).  
The results (Figure 5.17), relative to the BAC0330 negative control strain 
without crRNA, show that CRISPRi was effective for downregulation of both target 
reporter proteins. The α-Amylase activity results following 4 hours of growth show a 
broad variation across the analysed replicates (58.7% ± 38%). This was thought to 
be due to expression of amyE occurring primarily in the stationary phase of growth 
and as such the level of α-Amylase in the extracellular environment is too low to 




activity levels observed following 20 hours of growth show an average, across the 
biological replicates, of 52.7% reduction when compared to the control strain. 
Since GPFmut3 is retained within the cytoplasm, and it is constitutively 
expressed by Pveg (Figure 5.3), efficient downregulation by CRISPRi could be seen 
during exponential growth at 4 hours, with an average of 75.1% reduction compared 
to the control strains (Figure 5.17). Following 20 hours of growth, a similar CRISPRi 
effect of 71.8% was observed. This was an increase in CRISPRi efficiency when 
compared to BAC0298 (BAC0288 with dCas9-ω(Bs) and the same targeted PAM 
site) where a knock-down efficiency of 55.4% was achieved following 20 hours of 
growth (Figure 5.9).  
 
 
Figure 5.17 – Relative α-Amylase activity and GFPmut3 fluorescence following dCas9 
mediated multiplexed CRISPRi. 
Bars represent extracellular α-Amylase activity (section 2.9.2), or GFPmut3 fluorescence 
intensity (section 2.10.2) normalised by OD600 nm for BAC0331 relative to a control strain 
(BAC0330). Activity was measured at 4 and 20 hours of growth. Error bars indicate the 
average standard deviation between three technical replicates for three biological replicates.  
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5.3.3 Engineering and characterisation of dMAD7 
The alternative CRISPR nuclease, MAD7, has been shown as functional for 
CRISPR enabled genome editing in E. coli, S. cerevisiae, mouse and human 
HEK293T cells67, zebrafish71, and B. subtilis in this study (section 3.3.2). Due to 
MAD7s status as free to use for both academic and commercial applications70, we 
decided to engineer a catalytically inactive variant of MAD7 to allow licence free 
CRISPRi. 
5.3.3.1 Identification of MAD7 catalytic residues 
A pairwise alignment of the amino acid sequences of MAD7 and AsCpf1, 
confirmed the 31% identity reported by Inscripta (Figure 5.18). Previously, it was 
reported that the catalytic residues of AsCpf1 are Asp908, Glu993 and 
Asp126368,137. Asp908 lies in a region of high similarity with MAD7, with residues 
905-916 corresponding to MAD7 residues 874-885. AsCpf1 Glu993 does not lie in a 
region of high homology, however the alignment revealed that this residue was 
conserved in MAD7 (Figure 5.18). Lastly, the residue corresponding to Asp1263 in 
AsCpf1 was found in a region of high homology with AsCpf1, with residues 
1261-1268 corresponding to MAD7 residues 1211-1218. The corresponding 
catalytic residues in MAD7 (Asp877, Glu962 and Asp1213) identified by sequence 
homology (Figure 5.18) were simultaneously modified to alanine in silico and the 





Figure 5.18 – Pairwise sequence alignment of AsCpf1 and MAD7 amino acid sequence for identification of the catalytic residues in MAD7. 
Blue bars represent residues of similarity between the AsCpf1 and MAD7. Red asterixis above the sequence represent the three catalytic residues 





5.3.3.2 Absence of nuclease activity 
To verify whether the DNA cleavage capacity of MAD7 was removed in the 
putative dMAD7, the synthesised dMAD7 gene was used to replace MAD7 within 
the amyE and gfpmut3 targeting plasmids pBAC0162 and pBAC0166, respectively. 
As a control, the well characterised dcas9 was used to replace cas9 in plasmids 
pBAC0041 and pBAC016573,135,138. Naturally competent B. subtilis 168 and 
BAC0288 were respectively transformed with the amyE and gfpmut3 targeting 
plasmids with both active and inactive nuclease variants. Transformations were 
spread on plates supplemented with chloramphenicol and IPTG to ensure nuclease 
expression. The number of CFUs obtained for each transformation (Table 5.2) 
indicates that the engineered dMAD7 does not catalyse DSB of DNA since it does 
not cause the reduced viability observed for the catalytically active nuclease.  
 
Table 5.2 – Average number of transformants obtained following three 
transformations of B. subtilis 168 and BAC0288 with Cas9, dCas9, MAD7 and dMAD7 
plasmids.  
Parental Strain Target Plasmid Nuclease 
Average CFU 
obtained 
B. subtilis 168 amyE 
pBAC0041 Cas9 0.3 
pBAC0184 dCas9 898 
pBAC0162 MAD7 1.7 
pBAC0188 dMAD7 1248 
BAC0288 gfpmut3 
pBAC0165 Cas9 0 
pBAC0195 dCas9 392 
pBAC0166 MAD7 0.7 
pBAC0190 dMAD7 343 
 
5.3.3.3 Retention of DNA binding capacity for CRISPRi 
Extracellular α-Amylase activity was quantified in strains expressing dMAD7 
targeting five PAM sites (5´-TTTN-3’) at the 5´ end of amyE, two on the template 
strand and three on the non-template strand. The results were directly compared to 








Figure 5.19 – Relative α-Amylase activity and GFPmut3 fluorescence following dCas9 
and dMAD7 mediated CRISPRi. 
A) and C) Schematic diagrams of gRNA binding sites for dMAD7 within amyE and gfpmut3 
respectively. Values represent the distance of each targeted PAM site from the start codon 
on either the template (blue) or non-template (red) DNA strand. B) Bar graph represents the 
extracellular α-Amylase activity (section 2.9.2) normalised by OD600 nm relative to the 
non-targeting gRNA control for either dMAD7 or dCas9, after 24 hours of growth. The 
horizontal axis indicates the PAM site targeted by each gRNA and its distance to the amyE 
start codon (+4: BAC0360; +51: BAC0363; +27: BAC0362; +11: BAC0361; +21: BAC0355; 
+25: BAC0353). Red and blue bars correspond to PAM sites on the non-template and 
template strands, respectively. Grey bars represent non-targeting controls (dMAD7: 
BAC0354; dCas9: BAC0352). D) Bar graph represents the fluorescence intensity (section 
2.10.2) normalised by OD600 nm relative to the non-targeting gRNA control for either dMAD7 
or dCas9, after 24 hours of growth. The horizontal axis indicates the PAM site targeted by 
each gRNA and its distance to the gfpmut3 start codon (+80: BAC0368; +78: BAC0367; +21: 
BAC0351; +9: BAC0364; +16: BAC0365; +43: BAC0366; +27: BAC0349). Red and blue 
bars correspond to PAM sites on the non-template and template strands, respectively. Grey 
bars represent the non-targeting controls (dMAD7: BAC0350; dCas9: BAC0348). Error bars 
indicate the standard deviation between three biological replicates. NS = not statistically 





The results confirm that dCas9-mediated CRISPRi is highly efficient with a 
99.4% reduction in α-Amylase activity, while dMAD7-mediated CRISPRi appears 
less efficient, ranging from 59.3% to 51.5% activity reduction depending on the 
gRNA and PAM site sequence. The gRNA targeting the PAM site TTTG +21 bases 
from the start codon did not exhibit significantly reduced levels of activity. The PAM 
sequence was the same as others where CRISPRi was successful, and the GC% of 
the protospacer (28.6%) is similar to the one targeting the PAM site +4 (33.3%).  
To further investigate the capacity of dMAD7 for CRISPRi, the gfpmut3 gene 
in strain BAC0288 was targeted. Here, six PAM sites (three on each strand) were 
targeted with the 5´-YTTN-3’ PAM sequence recommended by Inscripta (Figure 
5.19C). dMAD7 was targeted to the 5´ end of gfpmut3 and fluorescence was 
compared to strains expressing dCas9 targeting gfpmut3. Strains expressing 
non-targeting dMAD7 and dCas9 plasmids were used as negative controls for 
downregulation  (Figure 5.19D). Here, a broader effect on expression was observed 
for dMAD7 with statistically significant CRISPRi efficiencies ranging from 71.3% - 
26.8%. Once again, the gfpmut3 targeting dCas9 control exhibited highly efficient 
CRISPRi with a 95.1% reduction in expression. 
 
5.3.3.4 Multiplexing CRISPRi with dMAD7  
 To increase the efficiency of dMAD7 transcriptional downregulation, 
multiplexed targeting, where more than one gRNA is utilised at a time, was tested. 
gRNA arrays were inserted in the same manner as single gRNAs, with the final 
array designed with the dMAD7 handle direct repeat at both the 3’ and 5´ ends, as 
well as between the inserted protospacers.  
Additive downregulation of amyE was tested by targeting PAM sites at +4 
TTTG and +51 TTTA in strain BAC0377 (Figure 5.20B). Similarly, gfpmut3 was 
analysed by targeting PAM sites at +80 TTTC and +21 TTTG in strain BAC0380 
(Figure 5.20B). These were compared to the non-targeting dMAD7 control strain 
BAC0350, as well as the single gRNA, amyE or gfpmut3 targeting dMAD7 strains 
BAC0381, BAC0382, BAC0351 and BAC0368. To ensure the gRNA array was 




gRNA array to target amyE +4 TTTG and gfpmut3 +80 TTTC, was analysed for 





Figure 5.20 – Relative α-Amylase activity and GFPmut3 fluorescence following dMAD7 
mediated multiplexing CRISPRi in BAC0288 (previous page). 
A) Schematic diagrams of gRNA binding sites for dMAD7 within amyE and gfpmut3. Values 
represent the distance of each targeted PAM site from the start codon on the non-template 
DNA strand. B) Investigation for an additive multiplexed CRISPRi effect when two gRNAs 
target a single gene. C) Investigation for a multiplexed CRISPRi effect when two gRNAs 
target different genes within the same strain. Bars represent extracellular α-Amylase activity 
(section 2.9.2), or GFPmut3 fluorescence intensity (section 2.10.2), normalised by OD600 nm, 
relative to the non-targeting gRNA control strain, after 24 hours of growth. The horizontal 
axis indicates the targeted PAM site(s) distance to the amyE or gfpmut3 start codon (Strains 
used: +4: BAC0381; +51: BAC0382; +4 and +51: BAC0377; +4 and +80: BAC0378; +80: 
BAC0368; +21: BAC0351; +80 and +21: BAC0380). White bars indicate strains in which a 
single gRNA is utilised to target a single gene. Grey bars indicate strains in which the effect 
of two gRNAs on a single gene is investigated. Blue bars indicate BAC0378 in which the 
effect of single gRNAs on two different genes is investigated. Red bars indicate the negative 
control strain, BAC0350, in which a non-targeting gRNA is expressed alongside dMAD7. 
Error bars indicate the standard deviation between three biological replicates. NS – no 
significant difference; * – P < 0.05; ** – P < 0.01. Two-tailed P values were derived following 
unpaired t test with Welch’s correction. 
 
The results show when amyE and gfpmut3 were simultaneously targeted the 
downregulation of both genes was found to be similar to when only one was 
targeted for CRISPRi (Figure 5.20C). This confirms that dMAD7, within the 
B. subtilis 168 derivative, BAC0288 background, has the capacity to mature the 
crRNA array transcript into individual gRNA and there is no significant competition 
between the two gRNAs for the pool of dMAD7 to mediate CRISPRi. When two 
gRNAs are combined to target either gfpmut3 or amyE, the measured 
downregulation is not cumulative (Figure 5.20B).  
 
5.4 Discussion 
5.4.1 Cloning efficiency limitations with AarI 
During the initial screen of the three dCas9-effector fusion proteins (section 
5.3.1.2), some difficulty was encountered in the cloning 7/21 of the protospacer 
elements to complete the sgRNAs. This was thought to be caused by AarI digestion 




enzyme requires two copies of the restriction site to initial cleavage. An increased 
concentration of the oligonucleotide supplied with AarI by Thermo Fisher Scientific 
(containing an AarI restriction site) from the recommended 1x to 2.5x, and the 
dephosphorylation of the AarI digested plasmid backbone greatly improved the 
success of cloning in the subsequent round of transcriptional analysis and was 
implemented in all gRNA cloning thereafter (section 2.7.3).  
 
5.4.2 CRISPRa was found not to be functional in B. subtilis, in 
contrast to another study by Lu et al. 
In this chapter it was shown that, under the tested conditions, CRISPRa 
cannot be achieved in B. subtilis 168 when targeting dCas9-ω(Bs) upstream of 
gfpmut3. dCas9-ω(Ec) and dCas9-Φ29 fusion proteins were also tested for enabling 
a CRISPRa effect of gfpmut3, however these yielded no detectable significant 
increase in relative fluorescence. Bikard et al. had shown dCas9-ω(Ec) to act as an 
effective fusion protein for CRISPRa in E. coli were the RNAP ω subunit was 
deleted (ΔrpoZ)59. This was based on data where transcription was induced in 
E. coli ΔrpoZ when the ω subunit was fused to the λ bacteriophage repressor 
protein163. As an equivalent study has not been carried out in B. subtilis, this would 
be a prudent next step to ensure the ω subunit can in fact act as a transcriptional 
activator in this host. A major difference to the approach taken by Bikard et al. was 
that this method targets a chromosomally integrated reporter protein, as opposed to 
a plasmid-based system. Furthermore, the targeted region upstream of the synthetic 
promoter used by Bikard et al. was fully designed with regularly dispersed PAM 
sites.  
Since performing this study, Lu et al. successfully achieved CRISPRa within 
B. subtilis SCK6 and dCas9 fused with the ω or α RNAP subunits60. The primary 
differences that could be discerned from this paper with the study presented here 
are the B. subtilis strain used (SCK6 (Em, his, nprE18, aprE3, eglSΔ102, 
bglT/bglSΔEV, lacA::PxylA-comK) vs. the strains reported here of a B. subtilis 168 
(trpC2) background), as well as the distance from the transcriptional start site (TSS) 
to which the dCas9-ω/α was targeted (from 267 to 415 (Lu et al.) versus 51 to 235 
bases upstream of the TSS). A further significant difference is the linker region 
connecting the ω or α subunits to dCas9 (Gly-Ser-Ala-Ala-Ser by Lu et al. vs. 




linker size could enable greater flexibility for the subunits to better access and attract 
the RNAP. 
 
5.4.2.1 Alternative transcriptional activator subunits to fuse with dCas9 
to enable CRISPRa in B. subtilis 
Both in this study, and in that carried out by Lu et al., the ω subunit was the 
primary effector molecule studied for the enhancement of transcriptional activation. 
However, other proteins have been found to be more efficient transcriptional 
activators in E. coli. Dong et al. found that one such activator, SoxS, in a WT E. coli 
strain, yielded ~8-fold greater GFP expression compared to the ω subunit, and 
~2-fold greater when the ω subunit activator was used in a ΔrpoZ background168. 
This strategy employed the use of an extended sgRNA, in which an RNA scaffold 
protrudes from the Cas9 upon which the bacteriophage coat protein MS2 RNA 
binding domain, fused to SoxS, could bind to enable site specific RNAP recruitment. 
CRISPRa was found to be functional when the sgRNA targeted 60-90 bases 
upstream of the TSS168. 
SoxS is a member of the AraC family of transcriptional regulators168. While 
there is no close homolog within B. subtilis to E. coli SoxS, the AraC family of 
transcriptional regulators are present. Furthermore, the function of many proteins 
within this family (RmgR, YbFI, YbfP, YdeC, YdeE, YesN, YfiF, YisR and YobQ) 
have as yet not been elucidated17. As such, these could be of interest for future 
development of CRISPRa tools for utilisation on B. subtilis, based on the method 
employed by Dong et al.. Given that the recognition site of SoxS upon the 
C-terminal domain of the RNAP α subunit is highly conserved, this system was 
thought to potentially be directly transferrable into B. subtilis or other bacterial 
hosts168,169. Unfortunately, very recently, the published PhD thesis of Dong revealed 
that the developed was not directly transferable to B. subtilis, while it was functional 
within Pseudomonas putida78. While Dong hypothesised that the cause of this was 
B. subtilis being intolerant to exogenous regulatory elements, the system was only 
tested when the GFPmut1 reporter protein was controlled by the very weak 
synthetic J23101 promoter. We have shown in this study that J23101 was not 
suitable for sgRNA expression (section 3.3.1.1), as such it would be of interest to 
attempt CRISPRa using this system in combination with a medium strength 




Very recently, Liu et al. developed a technique by which, in E. coli and 
Klebsiella oxytoca, σ54 promoters could be activated170. These promoters, normally 
inactivated through interactions with a σ54 factor, become functional when a 
σ54-activator is present. The new tool developed by Liu et al. localises a σ54-activator 
to the -12 and -24 promoter elements through interactions with an sgRNA scaffold. 
However, this was only functional when an integration host factor (IHF)-dependent 
DNA loop structure is present to introduce a kink into the DNA structure, upstream 
of the target promoter. In B. subtilis, σ54, encoded by sigL, regulates the transcription 
of 23 genes for adaption to cold and the utilisation of arginine, acetoin and 
fructose17. While these promoters could be attractive targets to allow dynamic 
control in metabolic engineering, IHF is only found in Gram negative bacteria. A 
possible alternative to IHF for use in B. subtilis could be the histone-like protein 
HBsu, encoded by hbs, which is known to be involved in DNA packaging and DNA 
bending and has 39% and 37% identity to E. coli IHF α and β subunits 
respectively171. 
 
5.4.3 The potential commercial applications of the transcriptional 
downregulation tool, dMAD7 
Here, CRISPRi was achieved with dCas9, as well as multiplexing CRISPRi 
of the amyE and gfpmut3 reporter genes. This represents CRISPRi on both 
endogenous and heterologous gene targets and as such indicates a potentially 
powerful tool for the identification of genes to be targeted for metabolic engineering 
of B. subtilis strains for industrial applications. When two gRNAs are combined to 
target either gfpmut3 or amyE, the measured downregulation is not cumulative 
(Figure 5.20B). As the BAC0378 multiplexing results (Figure 5.20C) indicate no 
significant competition between the gRNAs for dMAD7, it is thought that there is a 
potential steric hindrance between the protospacer-dMAD7 complexes used to 
simultaneously target each reporter. As such, future analysis of dMAD7 enabled 
CRISPRi multiplexing should ensure sufficient distance between the PAM sites 
targeted. 
Ownership over the IP rights to Cas9 and its derivatives has been intense 
and is becoming increasingly complex. The alternative CRISPR nuclease, MAD7 
was shown in section 3.3.2 to be functional within B. subtilis for counterselection of 




chromosome. In this chapter we have identified the first example of a catalytically 
inactive variant of MAD7, dMAD7. The downregulation of amyE and gfpmut3 was 
not as stringent as the dCas9 control included within the assay. While this is a 
limited comparison between dCas9 and dMAD7 given that only a single sgRNA was 
used for dCas9, it is in keeping with other data where DNase dead Cpf1 (ddCpf1) 
nucleases were not as effective for CRISPRi in other prokaryotes74,172. 
Nevertheless, this new tool represents a significant improvement in the prospects of 
the commercial use of CRISPR for strain construction. We propose that dMAD7 can 
be used to identify genes for later deletion with MAD7 without the need for a costly 
licence, or read-through royalties which would be incurred through the use of Cas9 
or Cpf1 based tools70.  
A limitation to the dMAD7 tool developed here is its apparent lower capacity 
for downregulation of transcription in comparison to dCas9. Figure 5.19 shows 
α-Amylase to be downregulated at a lower efficiency when targeting the TTTG PAM 
21 bp downstream of the start codon. This PAM sequence, on the template strand, 
is the same as that targeted at 11 bp and 4 bp on the template and non-template 
strands respectively. Furthermore, the protospacer GC% is not dissimilar to that of 
the 4 bp  gRNA. We therefore hypothesise the cause of this lowered efficiency is 
due to secondary structure within the gRNA, as has previously been reported for 
Cas9173,174. 
Investigations into the DNA binding and release rate has shown that Cas9 
does not release its cleavage product readily, while Cpf1 nucleases release the 
PAM distal cleavage product but not the PAM proximal product175. Thus, dCas9 may 
bind DNA in a more stable manner than ddCpf1, provided the mutations introduced 
to remove the catalytic activity of Cas9 or Cpf1 nucleases do not alter their capacity 
for DNA binding and release. Singh et al. also reported that and DNA was released 
quicker when interrogated with a catalytically inactivated Cpf1175. They thus 
theorised that DNA cleavage stabilises PAM proximal DNA binding post cleavage 
and that the formation of a septum (a thin barrier formed by Y201 and K1065 in 
Francisella novicida Cpf1 (FnCpf1)176), post DNA cleavage only, within Cpf1 could 
be critical to this stabilisation175. Given that MAD7 is part of the Cpf1 family of 
nucleases, this may explain dMAD7 having a lower CRISPRi efficiency and mutation 
of the septum formation sites may yield insights into increasing the CRISPRi 




reveals that Y201 is not retained, however K1065  is (MAD7 – K1021) and thus 
would be of interest for future mutagenesis of this tool. 
Lastly, CRISPRi efficiency was analysed while targeting sites within the 
coding sequences of either the AmyE or GFPmut3 reporter proteins. Future 
experiments attempting to increase the efficiency of CRISPRi should target dMAD7 
to the promoter region of the reporter protein for increased direct competition of 
DNA binding with the RNAP. 
 
5.5 Conclusions 
In this chapter, we have attempted to exemplify CRISPRa tools for use within 
B. subtilis, as well as developing this system for use with dCas9 to allow CRISPRi of 
both individual and multiplexed targets. A novel tool for downregulation was 
developed through the engineering of the commercially free to use MAD7 CRISPR 
nuclease to create the catalytically inactive dMAD7 variant. CRISPRi was performed 
using dMAD7 with both single, and multiplexed gene targets. This represents a 
promising new tool for the commercial use of CRISPR based technologies, opening 
this field to smaller businesses without the resources to pay for costly licences or 





Chapter 6 – CRISPR-enabled deaminase base editing 
in Bacillus subtilis 
 
6.1 Introduction 
CRISPR tools have developed beyond the initial applications for genome 
editing and transcriptional regulation, as investigated in Chapter 3 and Chapter 5, to 
utilise dCas9 fused to effector proteins. One such tool was CRISPR guided DNA 
deamination, known as base editing. In such a process, nucleobase deaminases 
hydrolyse the amino group from deoxycytosine (C) or deoxyadenosine (A), resulting 
in the formation of deoxyuridine (U) or deoxyinosine (I) respectively (Figure 6.1A). 
These are subsequently altered to deoxythymidine (T) and deoxyguanosine (G) 
respectively during DNA replication, provided the deaminated base is not removed 
before DNA replication can utilise it as a template81,82. Fusing these deaminases 
with CRISPR nucleases, where the capacity to induce a DSB is removed, allows 
accurate DNA mutagenesis without the need for donor DNA to introduce the desired 
mutations. 
In bacteria, random C to U deamination events are identified and are 
corrected during the base excision repair process (Figure 6.1B). Uracil-DNA 
glycosylase (Ung) detects and removes U by hydrolysing the N-glycosidic bond to 
remove the base81. This results in the formation of an abasic (AP) site which is in 
turn recognised by AP endonucleases and AP lyases, breaking the phosphodiester 
bond at the 5´ and 3’ sides of the AP site respectively, and forcing the repair of the 
site using the G on the opposite strand as a template81. A to I deamination reactions 
on the other hand are not repaired in such a manner. As such, since I is not a DNA 
base, when the DNA containing the I is replicated, I is recognised as the chemically 
similar G within the limitations of the DNA polymerase binding pocket, and 
incorporated into the DNA strand80.  
Deaminases capable of inducing such DNA conversions were incorporated 
to CRISPR systems to allow accurate targeting within a host80,82,177. In such tools, 
the deaminase, fused to either the fully catalytically inactive dCas9, or partially 
inactivated nCas9, can act on the single stranded DNA exposed at the distal end of 




sgRNA has bound to the complementary strand. The ~5 base region of the opposite 
strand which is not bound to an sgRNA, and not buried within the DNA binding 
pocket of the d/nCas9, known as the editing window, is therefore free to be modified 
(Figure 6.2)80,82,177.  
 
 
Figure 6.1 – DNA deamination and repair. 
A) DNA deamination process in which a hydrolysis reaction initially creates an intermediate 
base, and DNA replication converts this intermediate to the final base. B) DNA mismatch 
repair process following deoxycytidine deamination by activation-induced cytidine deaminase 
(AID). dCas9 and nCas9(D10A) are added to indicate the route which deamination repair 
proceeds in the presence of these variants. Ung – uracil DNA glycosylase. 
 
C base editing (CBE) tools were quickly developed due to cytosine 
deaminases known to target ssDNA having been previously identified82. The 
activation-induced cytidine deaminase (AID) enzyme from humans (encoded by 
AICDA) was identified to be an efficient C deaminase tool within human embryonic 




lamprey homolog (PmCDA1) was later taken up by Wang et al., for CBE within the 
Gram positive Corynebacterium glutamicum. Within C. glutamicum, dCas9-AID was 
found to have an editing efficiency of 11.2%. Utilisation of nCas9(H840A)-AID, 
introducing a nick on the strand targeted for deamination, did not increase the CBE 
efficiency. In contrast however, nCas9(D10A)-AID, cleaving the non-edited strand 
was found to allow 100% CBE efficiency54. This tool was utilised to improve the 
production of glutamate from C. glutamicum by ~2.5-fold54. 
 
  
Figure 6.2 – Deaminase base editing window. 
Base editing occurs 5 nt window (red) in the PAM distal region of the DNA strand which is 
not bound by the single-guide DNA (sgRNA). Deaminases are localised to their target by 
fusing them with catalytically inactive Cas9 (dCas9) or partially inactive, nickase Cas9 
(nCas9). The site and strand specific DNA cleavage site for nCas9(D10A) is indicated. The 
5´-NGG-3’ PAM site recognised by S. pyogenes Cas9 is indicated (green). The positions 
within the protospacer region are also indicated, relative to the PAM site. 
 
A base editing (ABE) tools were not as readily available since there were no 
known DNA adenosine deaminases. E. coli TadA is an adenine deaminase capable 
of converting adenine to inosine in single stranded tRNA. Gaudelli et al. modified the 
E. coli TadA to convert DNA A to G, via I, through seven rounds of protein evolution 




tool, fused to the N-terminus of dCas9, was found to be active in both E. coli and 
human cells80. Recently, TadA enabled base editing has also been adapted for use 
within C. glutamicum, alongside an expansion of the targeting scope through the 
use of the alternative nucleases xCas9 3.7 and Cas9-NG which recognise 
NNG/GAA/GAT/CAA and NG PAM sites respectively84. These represent a 
significant expansion from the previously exemplified S. pyogenes Cas9 recognising 
NGG PAM sites43. 
In this chapter, the first example of CBE and ABE within B. subtilis are 
reported. Differences in editing capacity and efficiency is investigated between 
d/nCas9 when sea lamprey AID is fused to the C-terminal, and when TadA is fused 
to the N-terminus. dCas9-AID was found to allow CBE, with the highest efficiency 
found at and either side of the -18 nt position upstream of the targeted PAM site. 
TadA-nCas9 was found to allow highly efficient editing with 100% of analysed 
colonies having at least one target base modified.  
 
6.2 Materials and methods 
6.2.1 Strains and plasmids 
The strains and plasmids used in this chapter are outlined below in Table 
6.1. The oligonucleotides used in this chapter can be found in Appendix C. 
 
Table 6.1 – Strains and plasmids used in this chapter. 
Strain/Plasmid Description/Genotype Reference 
Strains   
B. subtilis 168 trpC2 Laboratory 
stock 
BAC0353 B. subtilis 168 with pBAC0184 This chapter. 
BAC0387 B. subtilis 168 with pBAC0223 This chapter. 
BAC0388 B. subtilis 168 with pBAC0169 This chapter. 
BAC0389 B. subtilis 168 with pBAC0170 This chapter. 




BAC0391 B. subtilis 168 with pBAC0172 This chapter. 
BAC0397 B. subtilis 168 with pBAC0192 This chapter. 
Plasmids   




TcR; p15a ori; cat; Ptrc; nCas9(D10A)-AID Laboratory 
stock 
pTFG020A pBR322 ori; bla; PCMV; tadA-dCas9 Laboratory 
stock 
pCMV-ABE7.10 pBR322 ori; bla; PCMV; tadA-nCas9(D10A) 80 
pHT01 E. coli/B. subtilis shuttle vector carrying Pgrac and lacI, 
bla, cat 
MoBiTec 
pBAC0001 pHT01 with SapI sites removed Section 
3.2.1.1 
pBAC0008 pBAC0001 with rrnB T1 T2; sgRNA Cas9 handle; 
protospacer cloning site; Pveg 
Section 
3.2.1.1 
pBAC0015 pBAC0008 with cas9 (S. pyogenes). Cas9 expression 
regulated by the Pgrac 
Section 
3.2.1.1 
pBAC0018 pBAC0008 with dcas9 (S. pyogenes). dCas9 
expression regulated by the Pgrac 
Section 
5.2.1.1 
pBAC0041 pBAC0015 with sgRNA targeting 25 bp downstream of 
the start codon within B. subtilis 168 amyE 
Section 
3.2.1.1 
pBAC0169 pBAC0041 with tadA-dcas9 replacing cas9 This chapter. 
pBAC0170 pBAC0041 with tadA-ncas9 replacing cas9 This chapter. 
pBAC0171 pBAC0041 with dcas9-AID replacing cas9 This chapter. 
pBAC0172 pBAC0041 with ncas9-AID replacing cas9 This chapter. 
pBAC0175 pBAC0015 with dcas9-AID replacing cas9 This chapter. 
pBAC0176 pBAC0015 with ncas9-AID replacing cas9 This chapter. 





pBAC0192 pBAC0175 with sgRNA targeting 40 bp downstream of 
the start codon within B. subtilis 168 nicK. 
oMAP0682/0683 
This chapter. 
pBAC0193 pBAC0176 with sgRNA targeting 40 bp downstream of 
the start codon within B. subtilis 168 nicK. 
oMAP0682/0683 
This chapter. 
pBAC0223 pBAC0018 with sgRNA targeting 40 bp downstream of 
the start codon within B. subtilis 168 nicK. 
oMAP0682/0683 
This chapter. 
pBAC0224 pBAC0041 with ncas9(D10A) replacing cas9 This chapter. 
 
6.2.1.1 Plasmid construction 
The construction of plasmid pBAC0008 using the inABLE® assembly 
technique is described in detailed in Section 3.2.1.1. The introduction of cas9 into 
pBAC0008 (yielding pBAC0015) is also described in detailed in Section 3.2.1.1. The 
introduction of dcas9 into pBAC0008 and pBAC0041 (yielding pBAC0018 and 
pBAC0184 respectively) is described in detailed in Section 5.2.1.1.  
pBAC0169/0170/0171/0172/0224 were prepared by digesting pBAC0041 
with BamHI-HF and XbaI to remove cas9 and subsequently ligating with BsaI and 
XbaI digested PCR products prepared using the following respective templates and 
PCR primers: tadA-dcas9 from pTFG020A with oMAP0638/0639; tadA-ncas9(D10A) 
from pCMV-ABE7.10 with oMAP0638/0639; dcas9-AID from pdCas9-AID with 
oMAP0640/0641; ncas9(D10A)-AID from pnCas9(D10A)-AID with oMAP0640/0641; 
ncas9(D10A) from pBAC0176 with oMAP0073/0074. The same digested 
TadA-ncas9(D10A), dcas9-AID and ncas9(D10A)-AID PCR products were ligated to 
the BamHI-HF and XbaI digested pBAC0015 backbone to yield plasmids 
pBAC0175/0176 respectively. pCMV-ABE7.10 was a gift from David Liu (Addgene 
plasmid #102919)80. pTFG020A was a gift from Changhao Bi in which 
tadA-nCas9(D10A) from pCMV-ABE7.10 had been modified to tadA-dCas9 and 
inserted into a E. coli expression vector also containing an sgRNA expression 
cassette. pdCas9-AID and pnCas9(D10A) were also gifts from Changhao Bi in 
which the relevant fusion gene was ligated with the low copy E. coli plasmid, 




Plasmids used for analysis of the base editing fusion proteins dCas9-AID or 
nCas9-AID were prepared from the pBAC0175 or pBAC0176 parental plasmids 
respectively, using phosphorylated and annealed oligonucleotide pairs as described 
in section 2.5.4.1. Control plasmids were prepared from pBAC0018 in a similar 
manner. Information on the oligonucleotides used in construction, target gene and 
PAM site for the following CRISPR plasmids used in this chapter can be found in 
Table 2.12: pBAC0192; pBAC0193, pBAC0223. 
 
6.2.1.2 Strain construction 
All strains described in Table 6.1, other than B. subtilis 168, were prepared 
by making B. subtilis 168 naturally competent (section 2.4.2) and transforming with 
the plasmid also described in Table 6.1. 
 
6.3 Results 
6.3.1 Deaminase base editing as a method for DNA modification 
without the need for a double strand break within 
Bacillus subtilis  
To exemplify deaminase base editing within B. subtilis, the fusion genes 
tadA-dcas9, tadA-ncas9, dcas9-AID and ncas9-AID (provided by Changhao Bi – 
Tianjin, China) were used to replace cas9 in pBAC0041, creating plasmids 
pBAC0169/0170/0171/0172 respectively. Plasmid pBAC0041 had previously been 
found to efficiently allow the targeting of the CRISPR-Cas9 system to amyE for 
counterselection by DNA cleavage within cells which had not undergone 
homologous recombination of the linear dDNA fragment conveying mutations to 
amyE alongside a synonymous PAM site mutation (section 3.3.1.4). pBAC0041 was 
also modified, replacing cas9 with dcas9, to allow the down regulation of amyE 
mRNA levels for a reduced level of α-Amylase activity (section 5.3.3.3). Assuming 
the deaminase base editing window (Figure 6.2) is the same in B. subtilis, it was 
hypothesised that during treatment with TadA, two A bases, -16 and -20 nt from the 
PAM site, would be available for deaminase base editing to G, while with AID 
treatment one C, -18 nt from the PAM site, would be available for conversion to T 






Figure 6.3 – Deaminase base editing window identification in pBAC0041 based 
plasmids. 
A) The proposed ‘window’ in which deaminase base editing can occur. B) The observed 
‘window’ in which deaminase base editing can occur. Deaminase proteins are fused to 
dCas9 or nCas9. 1) Activation-induced cytidine deaminase (AID) was C-terminally fused or, 
2) the modified E. coli TadA, ABE7.1080, was N-terminally fused to enable the targeted 
deamination reaction. The nCas9(D10A) strand specific cut site is indicated with the yellow 
triangle. Proposed or observed bases susceptible to deamination by TadA (red) or AID 
(brown) are indicated. Bold bases indicate where base editing was common, while non-bold 






6.3.1.1 AID enabled CBE within B. subtilis 
Upon transformation of B. subtilis 168 with pBAC0171 and pBAC0172, 
carrying dCas9-AID and nCas9-AID respectively, transformants were only obtained 
with dCas9-AID. Transformation of the control plasmids pBAC0184 and pBAC0224, 
expressing dCas9 or nCas9 respectively, and targeting the same PAM site as 
pBAC0171 also showed nCas9 to be lethal to the cell in the absence of AID while 
dCas9 yielded similarly high CFUs as dCas9-AID – a similar result to that observed 
in E. coli by Banno et al.178, but contrasting the results obtained by Wang et al. 
where nCas9-AID was used to increase base editing efficiencies in the Gram 
positive C. glutamicum54. 
Colony PCR (cPCR) and sequencing was used to analyse three 
transformants of B. subtilis with dCas9-AID targeting amyE (pBAC0171, strain 
BAC0390). A mixed signal was observed in all the sequencing chromatograms at 
the targeted base within the base editing window. This indicated the colony was 
made up of cells with a mixed genotype, and deaminase base editing of C to T with 
AID was achievable. No other C within the sequencing reactions was found to be 
edited, indicating the deaminase reaction is targeted with the CRISPR-Cas9 system 
and not random.  
To determine the proportion of cells edited within these initial colonies, two 
were streaked out to isolate individual cells from the transformant. cPCR and 
sequencing was subsequently used to analyse eight CFUs of the sub-population in 
the same manner. No homogenous non-edited (WT) colonies were observed. 55% 
of the colonies exhibited a mixed C/T genotype, while 45% were found to only have 
the signal indicating T (Figure 6.4). The lack of a statistically significant difference 
between the edited and WT colonies in the transformants indicates that AID base 
editing is likely to occur during DNA replication with one daughter cell being edited 
and the other non-edited. This hypothesis also implies the lack of editing prior to 
colony formation commencing on the agar plate as editing during the recovery 
phase would enable the full colony being of the single, edited genotype. 
To further characterise the editing window of this new B. subtilis CBE tool, 
pBAC0192 (dCas9-AID) and pBAC0193 (nCas9-AID) were constructed to target a 
region of seven consecutive C bases (Figure 6.5A) within the nicK gene, encoding a 
non-essential DNA relaxase17. Once again, no transformants were obtained with the 




cPCR and sequencing, revealing a mixed genotype at positions -17 and -19 from 
the PAM site, while position -18 appeared to be almost fully edited in both colonies, 
with only a very weak C signal observed in one of the colonies (Figure 6.5B).  
 
 
Figure 6.4 – AID enabled C to T deaminase base editing efficiency within B. subtilis 
transformants. 
Bars represent the genotype observed (%) following sequencing of the targeted region of 
eight subpopulations from original transformants targeting dCas9-AID to amyE in strain 
BAC0390. Levels of fully edited (T), mixed (C/T) and WT (C) traces are indicated.  
 
In an attempt to fully edit the additional target bases, each colony was grown 
in LB supplemented with chloramphenicol and 1 mmol L-1 IPTG to mid-log phase 
and subsequently grown for 24 hours in fresh media of the same composition. IPTG 
was included for dCas9-AID expression. Following 24 hours of growth, colonies 
were isolated by spreading on LB agar plates supplemented with chloramphenicol 
only. Eight subpopulation colonies were analysed from each culture by cPCR and 
sequencing. All chromatographs for one culture set were found to be of single 
genotype reads, while the other set exhibited one mixed genotype, at position -17 
only, and two failed sequencing reactions. Using the 8 and 5, single genotype 
chromatograms, a base editing efficiency was established for positions -19 (16.3%), 































sequencing of three colonies for each of three transformants expressing dCas9 only 
and grown in the same manner for 24 hours showed no modifications at either the 
amyE (strain BAC0353) or nicK (strain BAC0387) target sites. Thus, CBE was 
confirmed as having been caused by the AID fused to dCas9. 
 
 
Figure 6.5 – dCas9-AID deaminase base editing ‘window’ analysis. 
A) Targeting schematic of seven consecutive C bases (brown) by dCas9-AID to analyse the 
deaminase base editing window. The PAM site targeted is indicated in green. B) Sequencing 
chromatogram following analysis of two initial transformants for dCas9-AID targeting nicK in 
strain BAC0397 (C – blue; G – black; A – green; T – red). The starting wild-type (WT) DNA 
sequence and its position within the sgRNA are indicated. C) Bars represent dCas9-AID 
base editing efficiencies at each targeted base within region covered by the sgRNA. Error 
bars indicate the standard deviation between subpopulation genotypes of the initial starting 
colonies. 
 
6.3.1.2 N-terminally fused TadA enabled ABE within B. subtilis and 
masks the lethality of nCas9 
The readily available fusion constructs, TadA-dCas9 and TadA-nCas9 were 
used to replace Cas9 in pBAC0041, yielding plasmids pBAC0169 and pBAC0170 




of dCas9 or nCas9(D10A). The resulting plasmids, also expressing a sgRNA 
specific for amyE, both enabled the formation of colonies following transformation of 
B. subtilis 168.  While the C-terminal fusion of dCas9-AID had enabled the formation 
of colonies, nCas9-AID had not. Additionally, nCas9 alone had also conveyed a 
similar lethality when targeting amyE. Therefore, the fusion of TadA to the 
N-terminus of nCas9 was hypothesised to convey a masking effect to the lethality  of 
the catalytic activity for the HNH domain, retained within nCas9(D10A).  
To determine if TadA enables deaminase base editing within B. subtilis, 
three transformants were first screened by cPCR and sequencing of the amyE 
region targeted by TadA-dCas9 and TadA-nCas9 (Figure 6.3) in strains BAC0388 
and BAC0389 respectively. Only the WT sequence was identified in all 
chromatograms. Each colony was grown in LB supplemented with chloramphenicol 
and 1 mmol L-1 IPTG to mid-log phase and subsequently grown in fresh media of 
the same composition. Single colonies were isolated on LB agar supplemented with 
chloramphenicol only following 16, 24 and 48 hours of growth. Six of these colonies 
for each original transformant were screened for deaminase base editing at each 
timepoint by cPCR and sequencing.  
The results indicate that TadA is functional for deaminase base editing within 
B. subtilis 168 when fused to the N-terminus of either dCas9 or nCas9 (Figure 6.6). 
A maximum average editing rate of 33% was observed between the biological 
replicates, after 48 hours of induction, at position -15, when treated with 
TadA-dCas9. In contrast, the same position had an average editing rate of 83% 
when treated with TadA-nCas9. This, along with position -16 after 24 hours, was 
also the maximum base editing efficiency achieved at a given protospacer position 
with TadA-nCas9. A similar increase in efficiency between the two fusion proteins 
was noted at positions  -13 and -16 for all timepoints. A clear relationship was 
therefore observed between an increase in the observed base edited sites, and the 
use of TadA-nCas9 when compared to TadA-dCas9. This indicates a level of 
selection conveyed by nCas9(D10A) and thus we determined that TadA does not 
fully mask the catalytic activity of the HNH domain.  
Position -12 appears to be the inner extremity of the deaminase base editing 
window under the tested conditions with a 66% drop in efficiency at 24 hours 
between positions -13 and -12 when treated with TadA-nCas9, and no editing 




of the editing window was not identified in a similarly robust manner since no drop 
off in efficiency was observed. However, since another A was available at 
position -20 within the protospacer, and no editing was observed here in any sample 
with either fusion protein, this appears to be the minimum cut off point for the editing 
window of TadA-d/nCas9. 
 
 
Figure 6.6 – TadA-dCas9 and TadA-nCas9 base editing levels at the amyE locus. 
Base editing levels were determined by colony PCR and sequencing of isolated colonies 
following 16 (white), 24 (grey) and 48 (blue) hours of growth. Bars represent the rate (%) 
where base editing has occurred and is indicated on the sequencing chromatogram across 
the analysed colonies. Error bars indicate the standard deviation between subpopulation 





While TadA-dCas9 was found to successfully enable deaminase base 
editing, it was striking that of the 18 sequencing reactions (three biological replicates 
with analysis of six individual colonies for each) following 16, 24 and 48 hours of 
induction, only 7, 11 and 9 chromatograms respectively did not reveal any mixed 
genotypes by the presence of a mixed signal. TadA-nCas9 on the other hand 
yielded 17/18 homogenous chromatograms at each sampling point. Analysis of the 
single genotype chromatograms only for each sample point further emphasised the 
benefit of fusing TadA to nCas9 since no WT colonies were identified, whereas non-
edited colonies made up 70% of those treated with TadA-dCas9 (Figure 6.7). 
Furthermore, there appears to be a preference for two base editing events when 
treated with TadA-nCas9, with 73% showing this genotype when all 16, 24 and 48 
hour sample sets are combined. Of these, positions -16, -15 and -13 were edited in 
59%, 78% and 62% of colonies respectively. Position -12 was not edited in any case 
where only two sites were modified. As such, there appears to be a slight preference 
for the editing of position -15 by TadA-nCas9. 
 
  
Figure 6.7 – Number of TadA deaminase base editing events observed in 
chromatograms exhibiting a single genotype. 
Bars represent the total number of single genotype chromatograms obtained following 
colony PCR and sequencing of all colonies screened following 16, 24 and 48 hours of 
growth. Bars are split between chromatograms where no base editing (WT) was observed 









































1 2 30  (W T )





It was hypothesised that TadA only partially masks the catalytic activity of the 
Cas9 HNH domain when fused to the N-terminus of nCas9(D10A) following the 
clear increase in base editing efficiency in comparison to TadA-dCas9 (Figure 6.6). 
Due to nCas9-AID and nCas9 on its own being lethal to B. subtilis 168, the growth of 
BAC0388 and BAC0389 (B. subtilis 168 maintaining pBAC0168 or pBAC0170, as 
well as expressing TadA-dCas9 and TadA-nCas9 respectively) was investigated to 
determine if the presence of TadA-nCas9 conveyed a negative effect on growth 
rate. B. subtilis 168 was re-transformed with pBAC0169 and pBAC0170 and 
transformants spread on LB agar supplemented with chloramphenicol only. Three 
transformants for each strain were grown to mid-log phase in LB supplemented with 
chloramphenicol only, before the growth for each was continuously monitored by 
light backscatter, within a 50 mL shake flask culture, using the cell growth 
quantification system (Aquila Biolabs – section 2.2.5). The same medium was 
utilised with the further supplementation of 1 mmol L-1 IPTG for TadA-dCas9 and 
TadA-nCas9 expression induction.  
The results show a slower initial growth rate for the cultures in which 
TadA-nCas9 was expressed. This subsequently increases to a maximum of 
0.29 A.U./min following 6.38 hours of growth, which is comparable to the 
0.27 A.U./min growth rate at 3.13 hours when TadA-dCas9 is expressed (Figure 
6.8). We hypothesise this reduced initial growth rate to be caused by nicking of DNA 
by nCas9 at reduced efficiency, and therefore not lethal to the whole population (as 






Figure 6.8 – Growth curves of strains expressing TadA-dCas9 or TadA-nCas9. 
The growth of strains BAC0388 (blue) and BAC0389 (red) containing pBAC0169 
(TadA-dCas9) and pBAC0170 (TadA-nCas9) respectively were monitored with light 
backscatter using the Cell Growth Quantifier (Aquila Biolabs – section 2.2.5) over 15 hours 
with a measurement taken every 60 seconds. Grey error bars represent the standard 
deviation between 3 biological replicates.  
 
6.4 Discussion 
6.4.1 dCas9-AID enable CBE activity is centred around nucleotide 18 
within the protospacer 
While the targeting of amyE with dCas9-AID only had a single target 
nucleotide, it appears serendipitous that this target was at nucleotide -18 within the 
protospacer region. Analysis of an alternative site within nicK, containing 
7 consecutive target C nucleotides, indicated a significantly reduced activity at 
positions -16 and -19, with highly efficient editing observed at both positions -17 and 
-18. This is in contrast to results shown by Wang et al., where editing frequencies of 
~40-70% were observed across positions -16 to -2054. 
Notably, here we have only tested the C-terminally fused dCas9-AID for 
CBE. It would be of interest to determine if N-terminally fused AID-dCas9 allowed a 
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similar level of CBE efficiency. Furthermore, investigation of an N-terminally fused 
AID-nCas9 would be of interest to determine if it enabled a reduction in the 
efficiency of nCas9 DNA cleavage, removing the absolute lethality of nCas9 in a 
similar manner to TadA-nCas9. This could allow CBE within B. subtilis at a greater 
editing efficiency, a higher proportion of isolated colonies with a homogenous 
genotype, and the isolation of colonies where bases are modified which are not 
currently with the dCas9-AID tool developed here. 
 
6.4.2 TadA-nCas9 enriches the selection of cells which have 
undergone ABE 
We have observed that nCas9 is lethal to B. subtilis 168 when targeted to the 
chromosome both on its own and also when AID is fused to its C-terminus 
(nCas9-AID). This has recently been confirmed and exploited by Liu et al. to 
establish a multiplexed editing technique within B. subtilis 168116. Interestingly, we 
also observed that when the ABE deaminase, TadA, was fused to the N-terminus of 
nCas9, the absolute lethality of nCas9 was lost. The partial toxicity which remained 
(Figure 6.8) was harnessed to allow the selection and enrichment of cells which had 
undergone successful base editing. 
Peak growth rate for the TadA-dCas9 expressing strain, BAC0388, was 
observed at 3.13 hours (Figure 6.8), while that of BAC0389 was observed at 6.38 
hours (0.27 and 0.29 A.U./min respectively) after recovering from an initial 
comparatively poor growth rate. Given that transformants had shown no editing to 
occur prior to growth in the presence of IPTG, we propose the recovery in growth 
rate was due to the successful editing of the target sites within the BAC0389 
population. This editing in turn prevents the full hybridisation of the sgRNA and 
subsequently stops the final conformational changes within nCas9, required for the 
HNH domain to cleave its DNA strand (Figure 1.1)179. Furthermore, only two 
colonies were identified as having only a single base edited (Figure 6.7), both of 
which were identified following 16 hours of growth, further indicating an enrichment 
over time of cells containing a modified target region with ≥2 bases edited. 
It is interesting that it appears that the amyE targeting sgRNA screened here 
causes a loss in the ability for nCas9 to cleave the DNA, when ≥2 sites within the 




sites within the seed region (8 nt adjacent to the PAM site within the protospacer) 
significantly or totally inhibits the effectiveness of the sgRNA to bind the target 
locus179. Changes to the PAM-distal end on the other hand are known to reduce 
activity, with up to 5 changes being tolerated within E. coli180 before full loss of 
cleavage. It is interesting therefore that such an apparent drop in cleavage capacity 
(observed through the re-establishment of a comparable growth rate in Figure 6.8) is 
caused by a modification at 1-3 target nucleotides in B. subtilis 168, and could 
indicate the sgRNA utilised is not optimally designed. 
 
6.4.3 TadA-nCas9 enables a greater editing efficiency in B. subtilis 
than in C. glutamicum 
Wang et al. found that the editing window for TadA-nCas9(D10A) within the 
Gram-positive C. glutamicum was from positions -13 to -17 within the protospacer 
region of 14 targets84. However, the editing efficiency observed by Wang et al. only 
ranged from 2.5% to 44.2%. This tool therefore, albeit only at a single target, confers 
a greater editing capacity within B. subtilis with an editing range of 6% to 83% 
across positions -12 to -16. Wang et al. speculated that A to I editing events are 
repaired differently in prokaryotes than eukaryotes given the drop in editing 
efficiency in comparison to humans (~50%)80, and that this was the cause of lower 
editing efficiencies. The results presented here do not support this theory for 
prokaryotes in general, and may even be isolated to C. glutamicum and other close 
relatives, since B. subtilis is the Gram-positive model organism. However, more 
sgRNAs must be examined within B. subtilis and other prokaryotes to draw robust 
conclusions on this matter. 
 
6.5 Conclusion 
In this chapter we have established the first example of deaminase base 
editing within B. subtilis. Both CBE and ABE systems were exemplified with initial 
experiments to characterise the editing window for both systems carried out. TadA 
fused to the N-terminus domain of nCas9 masked the lethality observed with nCas9 




Chapter 7 – Conclusions and future work 
 
In this study we have developed a flexible toolbox enabling the use of 
CRISPR based genome editing techniques within the Gram-positive model 
organism, Bacillus subtilis. Our system consists of a single plasmid for 
IPTG-inducible expression of a nuclease, and constitutive expression of a gRNA. 
This plasmid is co-transformed alongside a dDNA which is PCR amplified or 
constructed by OE-PCR. Transcriptional regulation was achieved using a 
catalytically inactivated variant of the CRISPR nuclease, expressed from a similar 
single plasmid system, and used to transform B. subtilis in the absence of dDNA. 
Furthermore, we developed a tool, the use of which had previously not been 
exemplified in B. subtilis, for genome editing via DNA deamination in the absence of 
dDNA as a template for modifications. We have focused on the industrial 
applications of these tools, demonstrating protein engineering in situ, creating a 
library of knockouts to increase heterologous protein production, and developing 
genome editing and transcriptional interference with a commercially attractive 
CRISPR nuclease.  
We have demonstrated that the widely used CRISPR nuclease, S. pyogenes 
Cas9, and the potentially industrially significant alternative CRISPR nuclease, 
MAD7, are both efficient for B. subtilis genome editing. Cas9 was primarily used 
throughout this study and successfully enabled point mutations and DNA insertions, 
while also enabling the knock-out of genes, and knock-in of promoters, during the 
construction of strains used for analysis of transcriptional upregulation. MAD7 was 
investigated for its genome editing capacity within B. subtilis following its release by 
Inscripta. A comparable editing rate was observed in comparison to Cas9, showing 
that MAD7 could, along with the required gRNA modifications, directly replace Cas9 
in our editing system. MAD7 was subsequently used for the construction of a strain 
library intended for the production of heterologous proteins. This was constructed 
though frame-shift mutations of extracellular proteases. These strains could be 
further developed for the knock-out of additional genes such as amyE, spoIIE and 
srfAC. Such strains would have a greater applicability towards industrial 
fermentation processes as they would have less extracellular proteins interfering 
with product purification, an inability to sporulate, and a reduced liability to foam 




We have provided evidence that homologous recombination of the dDNA 
prevents nuclease activity through disruption of the PAM site, or protospacer region. 
This is true for both Cas9 and MAD7 CRISPR nucleases. In the context of the assay 
used to display this, the CRISPR nuclease was not required since the curing of 
tryptophan auxotrophy in B. subtilis was used as a selection mechanism on a 
minimal medium. This feature enabled the clarification that homology directed repair 
of the DNA DSB with the dDNA was not a significant factor in CFU formation 
following co-transformation with a plasmid targeting the trpC2 lesion. However, 
where such a selection mechanism is unavailable, the CRISPR system acts as a 
counterselection tool against cells which have not undergone homologous 
recombination of the dDNA. In the absence of the CRISPR system, transforming 
B. subtilis with only dDNA and spreading on plates without an antibiotic selection 
pressure, it can be expected that a similarly high proportion of the cells will be 
transformed. However, significant dilution of the transformation culture would be 
required to isolate individual colonies. Thereafter, screening of transformants would 
require colony PCR and sequencing of many colonies to potentially only identify a 
single successfully edited colony. Thus, following co-transformation with dDNA 
(which does not contain an antibiotic resistance gene for the selection of successful 
genomic integrants), the CRISPR system drastically reduces the number of 
transformants to be screened following counterselection with the nuclease, as well 
as antibiotic selection for the presence of the CRISPR plasmid.  
We additionally tested the capacity for AsCpf1 to enable genome editing in 
B. subtilis. AsCpf1 in combination with a non-targeting gRNA was found to be toxic 
to the cell, with very few transformants obtained. A similar non-targeting gRNA was 
used with MAD7 and Cas9 as a control for transformation efficiency determination 
and toxicity to B. subtilis. As MAD7 is within the Cpf1 family of nucleases and was 
found not to be toxic to B. subtilis without a targeting gRNA, we hypothesise that this 
toxicity was not due to the AsCpf1 nuclease being intrinsically toxic to the cell. 
Instead, we suggest the human codon optimised gene we used inhibited growth due 
to pauses in the mRNA translation causing an accumulation of misfolded or 
incomplete insoluble protein, known to be toxic to the cell. Future experiments 
should utilise either the WT sequence of AsCpf1, or an equivalent which is codon 
optimised for expression within B. subtilis.   
We used this co-transformational CRISPR approach to rapidly develop an 




(1.4 °C) and activity (46.5%) under neutral conditions. These were modified in situ, 
incorporating a salt-bridge known to aid thermotolerance in the B. clausii homolog, 
M-protease. This is an exemplification of our system for the modification of 
established production strains for any given protein of interest. dDNA libraries can 
be constructed through OE-PCR to introduce a mutation within the PAM site, 
followed by error-prone PCR to introduce random modifications within the sequence. 
Alternatively, OE-PCR products could be constructed using oligonucleotide pools 
where a specific region is targeted for a designed set of modifications, for example 
an enzyme binding pocket. Such modifications have the capacity to further increase 
the efficiency of enzymes currently being produced and make established industrial 
fermentation processes more profitable. 
The co-transformational approach utilised here worked well in B. subtilis 168, 
however its limitations began to become apparent when BAC0288 (B. subtilis 168 
ΔbglS::aph(3’)-lIIa-Pveg-gfpmut3) was utilised. An ~10-fold drop in transformation 
efficiency was observed, severely impacting on the number of transformants 
obtained. This may replicate the lower transformation efficiencies which have been 
observed within some industrial strains that have been significantly modified, and as 
such indicates a limitation with our approach. In cases where strains of B. subtilis 
with a poor transformation efficiency are utilised, it may be more appropriate to 
utilise other systems, for example that of Altenbuchner63, where the dDNA is 
contained within the editing plasmid alongside the sgRNA and Cas9 nuclease 
expression cassettes. However, for strains with efficient natural competency, our 
system represents a rapid and versatile approach for genomic modifications. 
MAD7 was successfully engineered to carry three amino acid modifications 
(D877A, E962A and D1213A). Through survival data, we interpret this variant to be 
the first catalytically inactive MAD7 variant – dMAD7. Further development and 
characterisation, through purification and in vitro assays, would be of great interest 
to directly demonstrate that this dMAD7 variant lacks the capacity to cleave DNA. 
We have shown here that multiplexing is possible with dMAD7, however we have 
not confirmed if MAD7, or our engineered dMAD7, has the capacity to mature its 
own pre-crRNA in a similar manner to other Cpf1 nucleases181. In bacterial hosts, 
dMAD7 may, like Cas9, combine with RNase III to mature the pre-crRNA. This 
process is not the same in mammalian hosts and therefore it is desirable to know if 
dMAD7 can mature its own crRNA array to allow multiplexing in higher eukaryotes. 




the modified amino acids to their WT form in an effort to obtain a DNase inactivated 
variant of MAD7 which can cleave and mature pre-crRNA. This is the case, for 
example, in AsCpf1 E993A which retains the capacity to cleave and mature its own 
pre-crRNA array, while removing its capacity for DNA cleavage74. However, the 
putative residues for pre-crRNA processing in AsCpf1 are His800, Lys809 and 
Lys860 (corresponding to His759, Arg768 and Lys830 within MAD7). The 
corresponding residues in Francisella novicida Cpf1 (FnCpf1), when altered to 
alanine, did not impact on its DNase capacity while inhibiting RNase activity181. 
Therefore, it is unlikely that the modified residues in dMAD7 would impact on RNase 
activity, if present. The elucidation of the crystal structure for MAD7, bound to its 
DNA target, or pre-crRNA transcript, will yield greater insights into other residues for 
modification, as well as inform experiments where effector proteins, such as 
deaminases, can be fused to dMAD7 thus increasing the toolbox of MAD7 and 
dMAD7 based tools.  
MAD7 and dMAD7 represent a potential game-changer within the 
commercial genome engineering community. Where previously a potentially costly 
licence or royalty fee was required, commercial enterprises without significant 
budgets now have the ability to harness the revolutionary impact of CRISPR tools. 
However, it is likely that there remains a wariness to the use of CRISPR-MAD7 for 
commercial strain construction due to the complexity and rapidly changing IP 
landscape around CRISPR tools. Commercial enterprises may still wish to proceed 
with a costly freedom-to-operate search to have full confidence that strains which 
have been modified with MAD7 will not incur read-through royalty fees from other 
CRISPR patents. This is likely to remain unclear until a final legal decision is 
reached on the ownership of the initial CRISPR patents submitted and contest by 
the University of California and the Broad Institute. Furthermore, companies may not 
wish to use CRISPR-MAD7 genome editing before the MAD7 patent held by 
Inscripta, or their claim it is free-to-use for commercial research and strain 
construction, is unsuccessfully challenged by the eventual owner of the original 
CRISPR patents. That being said, the CRISPR IP battle is primarily focused on the 
use of CRISPR-Cas9 tools within eukaryotic hosts. As such, the use of CRISPR 
tools within bacteria, and the use of Cpf1 based tools, of which MAD7 is a distant 
relative, could be considered as a less complex research approach upon which to 




The development of CRISPRa within bacterial hosts has remained rare since 
its first exemplification within E. coli by Bikard et al. where dCas9 was fused to the ω 
subunit of RNAP59. Alternative CRISPRa tools have since been established for use 
within E. coli and are based around the SoxS transcriptional regulator168. However 
these have since been shown not to be functional within B. subtilis78. Alternatively, 
σ54 promoters have been successfully targeted in E. coli with a integration host 
factor (IHF) dependent system170. This may be transferrable to B. subtilis, however it 
is likely that an alternative to the DNA bending IHF would be required, such as the 
histone-like protein HBsu, as IHF is only found in Gram-negative bacteria. To date, 
the only example of CRISPRa in B. subtilis was exemplified by Lu et al. where 
dCas9 was fused to the ω or α subunits of RNAP to increase the expression of the 
extracellular chaperone, PrsA, while simultaneously down regulating (CRISPRi) the 
extracellular proteases Vpr, Bpr and NprB60. In this study, the ω subunit of RNAP 
was also fused to dCas9, but did not allow the exemplification of CRISPRa under 
the tested conditions. It is possible that our analysis did not have a sufficiently 
flexible linking region between the ω subunit and dCas9 (Ala-Ala) to enable 
interactions between the fusion protein and RNAP in comparison to that used by 
Lu et al. (Gly-Ser-Ala-Ala-Ser). It would be of interest to determine if the linker and 
effector protein, exemplified by Lu et al., could be fused with the dMAD7 developed 
here for transcriptional upregulation within B. subtilis.  
Our system has also enabled the expansion of the B. subtilis CRISPR 
toolbox through the development of genome editing tools which do not rely on a 
DNA DSB. C base editors (CBE) and A base editors (ABE) were shown to function 
well in B. subtilis. Furthermore, the N-terminal fusion of the ABE protein TadA to 
nCas9 enabled greater selection and isolation of successfully edited cells. Such 
deaminase base editing could prove a useful tool for extensive multiplexed editing of 
B. subtilis for the introduction of stop codons to disrupt gene expression with CBEs, 
or the editing of, for example, an enzyme binding pocket with CBE or ABE systems. 
Very recently, an alternative CRISPR based method was developed in S. cerevisiae 
and human cells which may be worthy of further investigation within bacterial hosts. 
This prime editing approach utilised nCas9 fused to a reverse transcriptase, 
alongside an extended sgRNA containing a targeted insertion182. However, as this 
tool requires the use of nCas9, which we have observed to be lethal to B. subtilis in 
the absence of the TadA effector protein, it may not be applicable within this host in 




linker may enable repair of the nicked strand and allow prime editing within 
B. subtilis, if the reverse transcriptase alone does not mask the activity of nCas9 in a 
similar manner to TadA.  
In conclusion, this study has advanced the CRISPR toolbox available for use 
within B. subtilis. The utilisation of MAD7 will enable commercial enterprises to 
develop novel strains in a more rapid manner than previously, while dMAD7 can aid 
in the identification of genes to be deleted, or their expression lowered. 
Academically, there are many avenues of research open where further CRISPR 
tools can be developed and investigated, as outlined above, for use of these tools 
within B. subtilis or other organisms. We hope the tools developed here are taken up 
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Appendix B  
Growth Media used in this study. 
 
LB 
Tryptone 10 g/L 
Sodium chloride 10 g/L 
Yeast Extract 5 g/L 
pH 7.2-7.5 
 
 LB agar 
Tryptone 10 g/L 
Sodium Chloride 10 g/L 
Yeast Extract 5 g/L 
Agar 15 g/L 
pH 7.2-7.5 
 
No salt LB 
Tryptone 10 g/L 









Ammonium chloride 1.34 g/L 
Ammonium nitrate 0.1 g/L 
Potassium dihydrogen phosphate 1.36 g/L 
Sodium sulphate 0.11 g/L 
L-glutamic acid 3.68 g/L 
L-asparagine 1.39 g/L 
L-alanine 1.2 g/L 
Casein hydrolysate 10 g/L 
Ferric chloride hexahydrate 0.001 g/L 
Magnesium sulphate heptahydrate 0.99 g/L 
Calcium chloride 0.02 g/L 
Manganese(II) sulphate tetrahydrate 0.022 g/L 
L-tryptophan 0.02 g/L 














Sodium hydrogen phosphate 
heptahydrate 
12.8 g/L 
Potassium dihydrogen phosphate 3 g/L 
Sodium chloride 0.5 g/L 
Ammonium chloride 1 g/L 
Magnesium sulphate heptahydrate 0.25 g/L 
Glucose 4 g/L 
Calcium chloride dihydrate 0.015 g/L 
Agar 15 g/L 
pH 7.4 
 
Starvation medium 1 (SM1) 
Ammonium sulphate 2 g/L 
Dipotassium hydrogen phosphate 12 g/L 
Potassium dihydrogen phosphate 6 g/L 
Sodium citrate dehydrate 1 g/L 
Magnesium sulphate heptahydrate 2 g/L 
Yeast extract 2 g/L 
Casamino acids 0.25 g/L 
L-tryptophan 0.1 g/L 






Starvation medium 2 (SM2) 
Ammonium sulphate 2 g/L 
Dipotassium hydrogen phosphate 12 g/L 
Potassium dihydrogen phosphate 6 g/L 
Sodium citrate dehydrate 1 g/L 
Magnesium sulphate heptahydrate 8 g/L 
Yeast extract 1 g/L 
Casamino acids 0.125 g/L 
L-tryptophan 0.1 g/L 
Glucose 5 g/L 
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Appendix D  
DNA alignment report comparing MAD7 as provided by Inscripta Inc., 
Bacillus subtilis codon optimised MAD7 and dMAD7 sequences. B. subtilis codon 












Appendix E  
Copy of “CRISPR-Cas9 In Situ engineering of subtilisin E in Bacillus subtilis” 
by Marcus A. Price, Rita Cruz, Scott Baxter, Franck Escalettes and Susan J. 
Rosser. Published on 7th January 2019 in PLoS ONE. 
RESEARCH ARTICLE
CRISPR-Cas9 In Situ engineering of subtilisin E
in Bacillus subtilis
Marcus A. PriceID
1,2*, Rita Cruz2, Scott Baxter2, Franck Escalettes2☯, Susan J. Rosser1☯*
1 Department of Quantitative Biology, Biochemistry and Biotechnology, University of Edinburgh, Edinburgh,
United Kingdom, 2 Ingenza Ltd., Roslin Innovation Centre, Roslin, United Kingdom
☯ These authors contributed equally to this work.
* M.A.Price-4@sms.ed.ac.uk (MAP); Susan.Rosser@ed.ac.uk (SJR)
Abstract
CRISPR-Cas systems have become widely used across all fields of biology as a genome
engineering tool. With its recent demonstration in the Gram positive industrial workhorse
Bacillus subtilis, this tool has become an attractive option for rapid, markerless strain engi-
neering of industrial production hosts. Previously described strategies for CRISPR-Cas9
genome editing in B. subtilis have involved chromosomal integrations of Cas9 and single
guide RNA expression cassettes, or construction of large plasmids for simultaneous trans-
formation of both single guide RNA and donor DNA. Here we use a flexible, co-transforma-
tion approach where the single guide RNA is inserted in a plasmid for Cas9 co-expression,
and the donor DNA is supplied as a linear PCR product observing an editing efficiency of
76%. This allowed multiple, rapid rounds of in situ editing of the subtilisin E gene to incorpo-
rate a salt bridge triad present in the Bacillus clausii thermotolerant homolog, M-protease. A
novel subtilisin E variant was obtained with increased thermotolerance and activity.
Introduction
The clustered regularly interspaced short palindromic repeats (CRISPR)-associated (Cas) sys-
tems of adaptive immunity in bacteria have become widely used across all fields of biology as a
genome editing tool since demonstration of its use as a RNA-guided DNA endonuclease in
2012 [1]. The technique, based on the type II CRISPR-Cas9 system from Streptococcus pyo-
genes, makes use of the host DNA double-strand break (DSB) repair machinery to introduce
mutations within the DNA sequence. DSBs can be repaired by the error-prone non-homolo-
gous end joining (NHEJ) or homology directed DNA repair (HDR) mechanisms of the cell.
NHEJ can introduce random mutations during repair, while HDR allows the introduction of
selected modifications in the presence of an engineered template with chromosome homology
regions flanking the desired mutations. Uptake of CRISPR-Cas9 genome editing in the Gram
positive model organism Bacillus subtilis was however relatively slow, perhaps, in part, due to
the high number of well-established genomic modification tools already available. However,
recently several publications were released in quick succession showing the development of
the CRISPR-Cas9 system in this host [2–6]. These initially showed use of the catalytically active
Cas9 for large scale genomic deletions, small and large DNA insertions, gene silencing by
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introduction of a stop codon and engineering of increased resistance to bacteriophage SPP1
[2–6]. Additionally, the catalytically inactivated ‘dead’ Cas9 (dCas9) was used to allow pheno-
typic analysis of all essential genes in B. subtilis. This was performed by dCas9 binding at the
target region within the gene and not inducing a DSB, subsequently reducing the level of tran-
scription from that gene and any other genes downstream in the same operon. [7].
Two methodologies have been exemplified in B. subtilis using the catalytically active Cas9.
First, Westbrook et al. (2016) demonstrated a system where a single plasmid simultaneously deliv-
ers an integration cassette for expression of the chromosome targeting crRNA and the donor
DNA (dDNA) for DSB repair, in a strain where the cas9 gene and tracrRNA, which associates
Cas9 to the crRNA, was previously integrated in the chromosome [3]. Others have used an alter-
native system where cas9 and sgRNA (single guide RNA where tracrRNA and crRNA are com-
bined as a single fragment) expression cassettes, as well as dDNA, are delivered in a single
temperature sensitive plasmid [2,5,6]. With the first method, the crRNA expression cassette must
be removed with a subsequent transformation step to restore the integration site before next
rounds of editing are possible. The second strategy, although more amenable to multiple rounds
of editing, involves a 2-step construction of a large shuttle vector to introduce the sgRNA and
dDNA [2]. Here, we present a simple and straightforward method which allows rapid in situ edits
of the genome, using a plasmid which can target any loci within B. subtilis in a single cloning step,
and without previous genome modifications. During the editing process, this plasmid transcribes
the sgRNA under the control of the strong constitutive promoter, Pveg, and utilises the basal
expression level of the Pgrac promoter to regulate cas9 expression. The dDNA in the form of a lin-
ear PCR product is co-transformed with the plasmid, providing the template for DSB repair.
The use of CRISPR-Cas9 mediated genome editing using this approach was first exempli-
fied by knock-out of the α-amylase encoding gene, amyE. Subsequently our system was shown
to be compatible for engineering of industrial production hosts by in situ modification of the
aprE gene. This encodes for the industrially relevant enzyme subtilisin E, used globally within
the detergent industry. As the wild type enzyme can be broken down by detergent formula-
tions and heat, subtilisin variants with improved thermostability and pH tolerance have long
been of interest. Subtilisin E has been widely used as a target for protein engineering experi-
ments [8]. A salt-bridge triad (Arg19-Glu271-Arg275), identified in the subtilisin E homolog
from Bacillus clausii (M-protease), was found to be a contributor for the characteristic thermo-
tolerance of this enzyme [9]. Here, we use CRISPR-Cas9 mediated genome editing to replace
the respective residues in subtilisin E (Gln125-Gln377-Gln381), and evaluate the effect of the
salt bridge on the thermostability and activity of the new variant. This work illustrates the use
of a simple CRISPR-Cas9 system for B. subtilis rapid, in situ protein engineering, which is at
the core of industrial biotechnology to provide new, suitable and competitive biocatalysts.
Materials and methods
Strains and media
The strains and plasmids used in this study are listed in Table 1. All oligonucleotides used in this
study are listed in S1 Table. Escherichia coli Top10 strains were used to construct recombinant
plasmids. Bacterial cells were cultured in Lysogeny broth (LB) or LB agar (VWR) media at 37˚C.
Unless otherwise stated, the following antibiotics were added to the media when required: ampi-
cillin (200 μg/mL), chloramphenicol (10 μg/mL), or spectinomycin (100 μg/mL).
Plasmid construction
Unless otherwise stated, plasmid construction was performed as described in Sambrook and
Russell [12]. DNA oligonucleotides were purchased from Sigma-Aldrich. The reagents for
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PCR, restriction digest, Gibson assembly, DNA phosphorylation and ligation were purchased
from New England Biolabs (NEB). DNA purification was performed using the kits from NEB.
DNA sequences were confirmed by Source Bioscience.
pBAC0001 was constructed by Gibson assembly to remove the SapI sites present in pHT01
(MoBiTec) [13]. PCR products for Gibson assembly were prepared from pHT01 using oligo-
nucleotides oMAP0002/0003/0004/0005.
pBAC0008 plasmid was constructed using the inABLE plasmid assembly method [14].
Individual 5’ truncated parts were prepared by PCR followed by restriction digest at 5’ and 3’
regions with SapI. These parts were ligated to phosphorylated and annealed oligonucleotides
at each terminus, containing 3 nt and 16 nt single strands at the 5’ and 3’ ends, respectively.
The part- oligonucleotides fusions were annealed at the homologous 16 nt overhangs for 1
hour at 37˚C, and used to transform electrocompetent E. coli.
Table 1. Strains and plasmids used in this study.
Strain/ Plasmid Genotype Reference
Strains
B. subtilis
168 trpC2 Laboratory stock
BAC0094 B. subtilis 168 with aprE Q125R variant. This work
BAC0095 B. subtilis 168 with aprE Q377E and Q381R variant. This work
BAC0097 BAC0095 with aprE Q125R, Q377E and Q381R variant This work
BAC0114 B. subtilis 168 ΔaprE::aad9 This work
BAC0119 BAC0114, pBAC0059. This work
BAC0120 BAC0114, pBAC0060. This work
BAC0121 BAC0114, pBAC0068. This work
BAC0122 BAC0114, pBAC0069. This work
E. coli
Top10 F- mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 ΔlacX74 recA1 araD139 Δ(araleu) 7697 galU galK rpsL (StrR) endA1 nupG Invitrogen
Plasmids
pHT01 E. coli/B. subtilis shuttle vector carrying Pgrac and lacI, bla, cat. MoBiTec
pdCas9-bacteria tetR; dCas9 (S. pyogenes); rrnB T1; p15a ori; cat [10]
pING0001 Pbad; rrnB T1; rrnB T2; bla; pBR327 ori; araC Ingenza Ltd.
pING0002 Pbad; aphAI; pMB1 ori; araC Ingenza Ltd.
pDR111 bla; 5’ amyE; aad9; Pspac;lacI; 3’ amyE [11]
pBAC0001 pHT01 with SapI sites removed. This work
pBAC0008 pBAC0001 with rrnB T1 T2; sgRNA Cas9 handle; protospacer cloning site; Pveg This work
pBAC0013 pdCas9-bacteria with catalytically active cas9. This work
pBAC0015 pBAC0008 with cas9 (S. pyogenes) from pBAC0013. Cas9 expression regulated by the Pgrac promoter. This work
pBAC0027 pBAC0015 with amyE-1 sgRNA DNA. This work
pBAC0035 pBAC0015 with non-targeting sgRNA DNA. This work
pBAC0041 pBAC0015 with amyE-2 sgRNA DNA. This work
pBAC0047 pBAC0015 with amyE-3 sgRNA DNA. This work
pBAC0054 pBAC0015 with aprE-1 sgRNA DNA. This work
pBAC0055 pBAC0015 with aprE-2 sgRNA DNA. This work
pBAC0059 pHT01 with aprE (native) from B. subtilis 168 with ATG start codon. This work
pBAC0060 pHT01 with aprE (Q125R, Q377E and Q381R variant) from BAC0097 with ATG start codon. This work
pBAC0068 pHT01 with aprE (Q125R variant) from BAC0094 with ATG start codon. This work
pBAC0069 pHT01 with aprE (Q377E and Q381R variant) from BAC0095 with ATG start codon. This work
https://doi.org/10.1371/journal.pone.0210121.t001
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pBAC0008 consisted of four parts: 1. the E. coli/B. subtilis shuttle vector backbone from
pBAC0001; 2. the LacI repressor and isopropyl β-D-1-thiogalactopyranoside (IPTG) inducible
Pgrac promoter from pBAC0001, including a multiple cloning site; 3. the bidirectional strong
rrnB T1 and T2 terminators; 4. the sgRNA expression module consisting of a kanamycin resis-
tance gene flanked by AarI sites expressed under the control of the Pveg promoter, and the
’Cas9 handle’ section of the sgRNA (5’ truncated parts were prepared by PCR from the indi-
cated template and oligonucleotides: 1. pBAC0001 with oMAP0010/0011; 2. pBAC0001 with
oMAP0018/0019; 3. pING0001 with oMAP0024/0025; 4. pING0002 with oMAP0030/0031.
Parts were ligated at 5’ and 3’ respectively with annealed oligonucleotides: 1. oMAP0008/0009
and oMAP0014/0015; 2. oMAP0016/0017 and oMAP0020/0021; 3. oMAP0022/0023 and
oMAP0048/0049; 4. oMAP0050/0051 and oMAP0052/0053.)
pBAC0013 was constructed by converting the catalytically inactive dcas9 gene from
pdCas9-bacteria to active cas9. This was done by introducing mutations A10D, A840H and
removing a BamHI site by PCR (oligonucleotides oMAP0062/0063/0064/0065/0066/0067) and
a subsequent 3-part Gibson Assembly (pdCas9-bacteria was a gift from Stanley Qi (Addgene
plasmid # 44249) [10].
Subsequently the catalytically active cas9 gene was amplified with oligonucleotides
oMAP0073/0074, introducing a BsaI site and XbaI recognition sites at the 5’ and 3’ end of the
gene, respectively. The amplified cas9 was digested with BsaI and XbaI, pBAC0008 was
digested with BamHI and XbaI and both fragments were ligated with T4 DNA ligase, yielding
pBAC0015.
To construct the subtilisin E overexpression plasmids pBAC0059, pBAC0060, pBAC0068
and pBAC0069, each subtilisin E variant and the wild type (WT) gene was amplified from
chromosomal DNA derived from the relevant strain (Table 1) with oligonucleotides
oMAP0186/0203, oMAP0200/0203, oMAP0186/0203, and oMAP0200/0203 respectively, each
set containing 5’-BamHI and 3’-XmaI recognition sites. Oligonucleotides oMAP0203 also
replaced the native GTG start codon with an ATG codon. The genes were cloned into pHT01
using the BamHI and XmaI recognition sites in the multiple cloning site of the plasmid.
CRISPR-Cas9-Mediated gene editing in B. subtilis
Analysis of editing efficiency. For CRISPR-Cas9 mediated editing efficiency analysis,
plasmids targeting the α-amylase amyE in B. subtilis were constructed. Plasmid pBAC0015
was digested with AarI (Thermo Fisher Scientific) to remove the kanamycin resistance gene
and ligated to two annealed and phosphorylated DNA oligonucleotides of 24 nucleotides. The
annealed oligonucleotides consisted of the 20 nucleotide protospacer region for targeting of
the Cas9 protein and 4 nucleotides to generate a single stranded overhang for compatibility
with the AarI digested vector. DNA phosphorylation was performed using T4 Polynucleotide
Kinase according to the manufacturer’s instructions. The protospacer regions were identified
using the online tool CRISPR-ERA: a comprehensive designer tool for CRISPR genome edit-
ing, (gene) repression, and activation, and selected based on the proximity to the desired mod-
ification [15]. The oligonucleotide pairs oMAP0089/0091, oMAP0125/0127 and oMAP0140/
0142 yielded plasmids pBAC0027, pBAC0041 and pBAC0047 respectively. As a positive con-
trol for transformation efficiency, a sgRNA designed not to target the B. subtilis 168 chromo-
some was inserted into pBAC0015 with the oligonucleotide pair oMAP0145/0147, yielding
pBAC0035. dDNA to introduce stop codons and repair the sgRNA-targeted Cas9 DSB were
constructed by overlap extension PCR (OE-PCR) of two DNA fragments as described by Bryk-
sin and Matsumura [16]. The desired edits were introduced in the homology overlap of the
two DNA fragments. These included the silent mutation of the 5’-NGG-3’ protospacer
CRISPR-Cas9 enabled protein engineering in Bacillus subtilis
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adjacent motif (PAM) site to prevent continuous cutting by the RNA-guided Cas9 endonucle-
ase. OE-PCR products from oligonucleotides sets oMAP0121/0122/0123/0124, oMAP0121/
0122/0128/0129 and oMAP0121/0122/0143/0144 were used alongside pBAC0027, pBAC0041
and pBAC0047 respectively. Genome editing was carried out in triplicate by co-transforming
naturally competent B. subtilis 168 with 200 ng CRISPR-Cas9/sgRNA plasmid DNA and 1 μg
dDNA [17]. Transformants were spread on LB agar plates supplemented with 1% soluble
potato starch (VWR) and chloramphenicol (5 μg/mL). IPTG was not added for cas9 expression
induction to limit cellular burden and it was found that basal expression under the Pgrac pro-
moter was sufficient for cas9 expression. Effective knock-out of amyE by stop codon introduc-
tion was determined by staining transformation plates with iodine [18].
Editing of aprE. Using the approach described above, CRISPR-Cas9 mediated editing of the
aprE gene in B. subtilis 168 was carried out. The oligonucleotide pairs oMAP0150/0151 and
oMAP0156/0157 were ligated with pBAC0015 prepared as above, yielding plasmids pBAC0054
and pBAC0055 respectively. dDNA OE-PCR products from oligonucleotides sets oMAP0152/
0153/0154/0155 and oMAP0158/0159/0160/0161 were used alongside pBAC0054 and pBAC0055
respectively. Editing was confirmed by PCR of the aprE gene with oligonucleotides oMAP0152/
0161, followed by sequencing using oligonucleotides oMAP0158 and oMAP0155 for candidates
edited with pMAP0054 and pMAP0055 respectively. The CRISPR-Cas9/sgRNA plasmid was
removed from the edited strain by promoting plasmid loss in LB supplemented with 1 mM IPTG
overnight. Here the presence of IPTG encourages curing by introducing the pressure of protein
expression without the presence of chloramphenicol to retain the plasmid within the cell. Plasmid
loss was confirmed by counter plating on LB agar plates with and without chloramphenicol before
a subsequent round of editing. Following the second round of editing, these mutations and those
introduced previously were confirmed to be present by sequencing (as above).
Protein purification
The three subtilisin E variants and WT protein were overexpressed in the aprE knock-out
strain BAC0114. BAC0114 was constructed by transformation of B. subtilis 168 with OE-PCR
product containing a spectinomycin resistance cassette flanked by homology arms upstream
and downstream of aprE (oligonucleotides oMAP0217/0218/0219/0220/0221/0222). Confir-
mation of aprE deletion was obtained by purification of the genomic DNA for BAC0114 and
PCR of ΔaprE::aad9 locus with oligonucleotides oMAP0670 (hybridising to aad9) and
oMAP0671 (hybridising to the genome, upstream of the homology arm region). Additionally,
PCR with oligonucleotide pair oMAP0217/0220 (hybridising to the extremities of the homol-
ogy arm region) revealed the expected increase in product size for ΔaprE::aad9 relative to the
WT PCR product. This strain was then transformed with plasmids pBAC0059/0060/0068/
0069, resulting in strains BAC0119/0120/0121/0122 respectively. These strains were grown for
24 hours at 37˚C with agitation (250 rpm) in 20 mL LB supplemented with chloramphenicol.
The supernatant was clarified and dialysed overnight into 100 mM Tris-HCl with 150 mM
sodium chloride at pH 8. The dialysed supernatant was concentrated to 5 mL with Amicon
Ultra-15 (10 kDa membrane (Merck)), filtered through a 0.2 μm filter (Sartorius). This was
loaded onto a HiPrep Sephacryl S-200 HR, 120 mL 16/60 size exclusion column (GE Health-
care), eluted in the same buffer composition used for dialysis and fractions found to contain
subtilisin E were pooled. Protein concentration was determined by absorbance at 280 nm.
Thermal shift assay
The fluorescence-based thermal shift assay was used to determine the melting temperature
(Tm) of the subtilisin E variants and WT [19]. The assay reaction was prepared in a total
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volume of 20 μL (18 μL purified subtilisin E variant in purification buffer, 1 μL 100 mM cal-
cium acetate and 1 μL 1:50 SYPRO Orange (Sigma-Aldrich)). The assay was performed with
six technical replicates for each variant. The reaction was analysed using the Pikoreal 96
(Thermo Scientific) which recorded changes in fluorescence with increasing temperature
(40˚C—80˚C in increments of 0.2˚C, held for 6 seconds at each point).
Subtilisin E activity assay
Subtilisin E variants and WT activity was determined by casein degradation as described by
Cupp-Enyard [20].
Residual enzyme activity tests
Residual enzyme activity was analysed by incubation of the purified enzymes at 55˚C for 10,
20, 40, and 60 minutes prior to the activity assay.
Results
Analysis of CRISPR-Cas9 mediated gene editing efficiency
To analyse CRISPR-Cas9 mediated gene editing efficiency using our co-transformation sys-
tem, the amyE gene encoding an α-amylase was selected for knock-out using a starch degrada-
tion assay. The three tested amyE targeting plasmids (pBAC0027/0041/0047) yielded on
average an editing efficiency of 63.9%, 89.2% and 74.4% when co-transformed with dDNA
(Fig 1).
Rapid in situ modification of aprE with CRISPR-Cas9
The crystal structures for B. subtilis subtilisin E (PDB ID 1SCJ) and its B. clausii homolog, M-
protease (PDB ID 1WSD), were overlaid using Swiss-Pdb viewer (Fig 2) [21–23]. The residues
corresponding to the salt-bridge triad (R19-E271-R275) that have previously been shown to
contribute towards M-protease thermotolerance were identified in the subtilisin E structure
(Q125-Q377-Q381) [9].
A CRISPR-Cas9 mediated chromosome editing strategy was designed to introduce the
mutations Q125R, Q377E and Q381R. pBAC0015 was altered to include the oligonucleotide
pairs oMAP0150/oMAP0151 or oMAP0156/oMAP0157, yielding plasmids pBAC0054 (target-
ing Q125R locus) and pBAC0055 (targeting Q377E and Q381R locus) respectively. Due to
their proximity, Q377E and Q381R modifications were combined into a single CRISPR-Cas9
mediated editing step with a single dDNA. Q125R was modified in a separate editing step. The
desired edits, included the modification of the PAM site to prevent continuous cutting by the
RNA-guided Cas9 endonuclease, were introduced in the homology overlap of the two DNA
fragments prepared using PCR. These were subsequently combined using OE-PCR and co-
transformed alongside the respective plasmid (Fig 2). OE-PCR products from oligonucleotides
sets oMAP0152/0153/0154/0155 and oMAP0158/0159/0160/0161 were used alongside
pBAC0054 and pBAC0055 respectively. Following an efficient curing process yielding strains
BAC0094 (Q125R) and BAC0095 (Q377E and Q381R) respectively, a second round of editing
using the second set of editing plasmid and dDNA yielded the final strain (BAC0097) contain-
ing all three modified residues. All screened colonies were found to contain the desired muta-
tions following sequencing.
This system represents a rapid technique for in situ protein modifications within B. subtilis
168. Once the Cas9-sgRNA expression plasmid is prepared, the same region on the
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chromosome can be targeted with alternative, rapidly prepared, linear dDNA templates con-
veying novel modifications of interest.
Thermotolerance of subtilisin E variants
The thermotolerance of purified subtilisin E variants and WT (purification described in mate-
rials and methods section) was analysed by the thermal shift assay (Fig 3). Variants Q377E
+Q381R and Q125+Q377E+Q381R showed increased thermotolerance when compared to the
WT and Q125R proteins, confirming the importance of residues E377 and R381 for protein
stability at higher temperatures. In contrast, the Q125R variant showed no increase in thermo-
tolerance, most likely as there is no mutated residue with which it can form salt bridge.
The average Tm for each variant was established by performing a melt curve analysis of the
thermal shift assay data (Fig 3). An increase in Tm of up to 1.4˚C was established and verified
as statistically significant by use of an unpaired t test with Welch’s correction (Fig 4). The
greatest increase in Tm of 1.4˚C was found in the Q377E + Q381R variant (54.8˚C, P value =<
0.0001), while the full salt bridge triad variant showed an increase of 1.2˚C (54.6˚C, P value =
< 0.0001). The Q125R variant showed no significant difference in Tm when compared to the
WT (53.4˚C and 53.5˚C respectively).
Activity retention of subtilisin E variants
To ensure the introduced mutations had not negatively affected catalytic efficiency of the
enzyme, the activity for each variant and the WT was established under neutral conditions
(pH 7.5, 37˚C) by measuring the degradation of casein using Folin’s reagent (Fig 5) [20]. Both
the Q125R and Q125+Q377E+Q381R variants were 60% less active when compared to the
WT, suggesting that the Q125R residue is important for catalytic activity. The Q377E+Q381R
variant showed an increase in protease activity of 46.5% (P value =< 0.0001).
Fig 1. Number of transformants and editing efficiencies obtained following CRISPR-Cas9 genome editing of
amyE. White bars represent the number of CFU obtained following transformation of three amyE targeting plasmids
(pBAC0027/0041/0047) with or without editing template (dDNA) to introduce stop codons and repair the sgRNA-
targeted Cas9 DSB. A plasmid containing a non-targeting sgRNA (pBAC0035) was transformed to monitor
transformation efficiency. The blue bars represent the editing efficiency of the obtained CFU determined by observing
the presence or absence of a halo following iodine staining of the starch-containing transformation plates. Error bars
indicate the standard deviation between three transformations.
https://doi.org/10.1371/journal.pone.0210121.g001
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Residual enzyme activity was measured following incubation of the enzyme variants at
55˚C (Fig 6). Variant Q377E + Q381R was found to be the best at retaining its enzymatic activ-
ity when incubated for over 20 minutes. An improvement of 12.1% and 15.1% in activity rela-
tive to the WT following incubation for 40 and 60 minutes respectively was noted. The Q125
+ Q377E + Q381R variant showed a 34.9% decreased in activity relative to the WT following
20 minutes incubation. Similarly, the Q125R variant showed a decreased in activity of 54.1% at
20 minutes incubation.
Discussion
We have developed a B. subtilis specific, rapid, in situ protein engineering technique based on
the ground breaking CRISPR-Cas9 technology. The rapid engineering of established and
Fig 2. Design and CRISPR-Cas9 editing process of aprE. A) B. subtilis 168 subtilisin E crystal structure (green) and overlay with B. clausii M protease crystal structure
(cyan), with the associated salt bridge (dashed yellow line). B) Design of the sgRNA and dDNA OE-PCR product for CRISPR-Cas9 genome editing. The two rounds of
editing are described in blue and red, the PAM recognition sequences for each sgRNA was also targeted for disruption in each dDNA. C) Description of editing process
where the second round of editing occurs following a blunt DSB by sgRNA guided Cas9.
https://doi.org/10.1371/journal.pone.0210121.g002
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novel industrially relevant proteins yielding markerless, and potentially non-GMO compliant
strains, is an attractive proposition for industrial biotechnology. This is due to the lowering in
Fig 3. Thermal shift assay of the thermostability of each subtilisin E variant and WT. Increase in fluorescence was
detected as hydrophobic regions of the protein were exposed as the protein denatured. The protein melting
temperature of each variant and WT was calculated with a melt curve analysis, determining the peak rate of protein
unfolding per temperature increase. Error bars indicate the standard deviation between six replicates.
https://doi.org/10.1371/journal.pone.0210121.g003
Fig 4. Average Tm between Subtilisin variants and WT replicates. The Tm of each subtilisin E variant and WT was
calculated as the temperature at which the peak rate of protein unfolding was observed for each of six replicated. Error
bars indicate the standard deviation. ���� = p value summary (p =< 0.0001) following unpaired t test with Welch’s
correction.
https://doi.org/10.1371/journal.pone.0210121.g004
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costs and time associated with product development and governmental regulatory compliance,
while increasing the time a product is in production.
Initial exemplification of our system on the α-amylase encoding gene, amyE, showed an
average editing efficiency of 76% across the three targeted PAM sites selected. While our co-
transformation-based approach to genome editing may result in lower transformation efficien-
cies due to the requirement that both plasmid and dDNA molecules enter the cell, the rate of
editing efficiency observed enables a high degree of confidence that most colonies obtained
Fig 5. Protease activity assay. Protease activity at pH 7.5, 37˚C for 10 minutes. Normalised for protein concentration
determined by absorbance at 280 nm. Absorbance units (AU) determined at 660 nm. ���� = p value summary (p =<
0.0001) following unpaired t test with Welch’s correction. Error bars indicate standard deviation between triplicates.
https://doi.org/10.1371/journal.pone.0210121.g005
Fig 6. Residual protease activity assay. Residual protease activity under neutral conditions following incubation at
55˚C for various lengths of time, determined by a casein degradation enzymatic assay. Error bars indicate standard
deviation between technical triplicates.
https://doi.org/10.1371/journal.pone.0210121.g006
CRISPR-Cas9 enabled protein engineering in Bacillus subtilis
PLOS ONE | https://doi.org/10.1371/journal.pone.0210121 January 7, 2019 10 / 13
have been edited as designed. This system, where one round of plasmid construction is
required and transformed alongside an easily prepared PCR product, represents an alternative
to the B. subtilis CRISPR-Cas9 genome editing strategies published to date. These involve pre-
vious chromosome integration of the cas9 gene and subsequent eviction of cas9/tracrRNA and
crRNA expression cassettes after editing, or a two-step plasmid construction to introduce the
sgRNA expression cassette and dDNA [2,3,5,6].
In under a week we carried out two rounds of in situ CRISPR-Cas9 editing of the subtilisin
E gene, aprE. A salt bridge triad was introduced and the Q337E + Q381R variant showed an
increase of 46.5% in subtilisin E activity, as well as a 1.4˚C increase in thermostability. To the
best of our knowledge these modifications have not been combined before in B. subtilis subtili-
sin E.
Interestingly, the Q125R + Q377E + Q381R variant did not retain its activity levels to the
same level as the Q377E + Q381R variant. Indeed, in both variants where the Q125R mutation
is introduced a drastic drop in enzyme activity retention was observed (Figs 5 and 6), indicat-
ing a vital catalytic activity role for residue Q125 within B. subtilis subtilisin E. A similar study
of salt bridges in subtilisin E was performed by Erwin et al., where mutations Q125E + Q377E
formed a salt bridge based on X-ray crystal structure, but resulted in a 1.2˚C drop in thermoto-
lerance [24].
In summary, this method for genomic modifications by CRISPR-Cas9 allows rapid, in situ
protein engineering of industrially relevant strains. Furthermore, discovery and optimisation
of new molecular biology tools such as the work presented here, increases the speed and effi-
ciency at which novel biocatalysts can be developed for sustainable bioprocesses.
Supporting information
S1 Fig. Thermal shift assay of the thermostability of each subtilisin E variant and WT.
Fluorescence increase observed as a result of protein unfolding and hydrophobic residue expo-
sure during the thermal shift assay.
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S1 File. Thermo denaturation assay and melt curve analysis data.
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Appendix F  
RT qRT-PCR results. 
Table F.1 – Mean and standard deviation (SD) of the ΔCq expression of gfpmut3 in 
BAC0295 (dCas9-ω(Bs) targeted 16 bp upstream of the -35 promoter element for 
gfpmut3) and BAC0297 (dCas9-ω(Bs) non-targeting control). The Cq values were 
averaged from two technical replicates for each of three biological replicates. The ΔCq 
values correspond to the difference between the Cq of the gene of interest and the 
control gene – either gapA or sdhA. 
  ΔCq Expression 
 Control gene Mean SD 
BAC0295, 
gfpmut3 
gapA 1.612 0.275 
sdhA -1.012 0.554 
BAC0297, 
gfpmut3 
gapA -3.163 0.238 
sdhA -6.553 0.675 
 
Table F.2 – Mean and standard deviation (SD) of the ΔCq expression of gfpmut3 in 
BAC0303 (dCas9-ω(Bs) targeted 163 bp upstream of the -35 promoter element for 
gfpmut3) and BAC0297 (dCas9-ω(Bs) non-targeting control). The Cq values were 
averaged from two technical replicates for each of three biological replicates. The ΔCq 
values correspond to the difference between the Cq of the gene of interest and the 
control gene – either gapA or sdhA. 
  ΔCq Expression 
 Control gene Mean SD 
BAC0303, 
gfpmut3 
gapA -3.982 0.245 
sdhA -5.357 0.191 
BAC0297, 
gfpmut3 
gapA -3.737 0.344 
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Abstract
The CRISPR‐Cas9 system has become increasingly popular for genome engineering
across all fields of biological research, including in the Gram‐positive model organism
Bacillus subtilis. A major drawback for the commercial use of Cas9 is the IP landscape
requiring a license for its use, as well as reach‐through royalties on the final product.
Recently an alternative CRISPR nuclease, free to use for industrial R&D, MAD7 was
released by Inscripta (CO). Here we report the first use of MAD7 for gene editing in
B. subtilis, in which editing rates of 93% and 100% were established. Additionally, we
engineer the first reported catalytically inactive MAD7 (dMAD7) variant (D877A,
E962A, and D1213A) and demonstrate its utility for CRISPR interference (CRISPRi)
at up to 71.3% reduction of expression at single and multiplexed target sites within
B. subtilis. We also confirm the CRISPR‐based editing mode of action in B. subtilis
providing evidence that the nuclease‐mediated DNA double‐strand break acts as a
counterselection mechanism after homologous recombination of the donor DNA.
K E YWORD S
Bacillus subtilis, Cas9, CRISPR, homologous recombination, MAD7
1 | INTRODUCTION
In recent years, precise genome editing with clustered regularly inter-
spaced short palindromic repeats (CRISPR)‐associated (Cas) systems have
become widely used in many fields of biology (Jinek et al., 2012), enabling
significant advances in genome editing tools for industrially relevant mi-
croorganisms, such as Bacillus subtilis (Altenbuchner, 2016; Burby &
Simmons, 2017; Price, Cruz, Baxter, Escalettes, & Rosser, 2019; West-
brook, Moo‐Young, & Chou, 2016b). Since the adaptation of the type II
CRISPR‐Cas9 system from Streptococcus pyogenes in 2012 for genomic
engineering, along with subsequent iterations—including but not limited
to CRISPR interference (CRISPRi) and CRISPR activation systems—it has
become the most broadly utilized CRISPR based system in prokaryotes
and eukaryotes (Altenbuchner, 2016; Burby & Simmons, 2017; Dicarlo
et al., 2013; Jakočiūnas, Jensen, & Keasling, 2015; Jakutyte‐Giraitiene &
Gasiunas, 2016; Jinek et al., 2012; Lu et al., 2019; Peng et al., 2017;
Peters et al., 2016; Price et al., 2019; Westbrook et al., 2016b; K. Zhang,
Duan, & Wu, 2016; Zhu et al., 2017). Cas9 induces a blunt DNA double‐
strand break (DSB) when in complex with either a two‐component
crRNA–tracrRNA or where these are combined into a single guide RNA
complex (Jinek et al., 2012). Previous literature describes that once the
DSB is introduced, it can be repaired by nonhomologous end‐joining
(NHEJ), or by homology directed repair (HDR) when a donor template
DNA (dDNA) is supplied (Adli, 2018; Altenbuchner, 2016; Burby &
Simmons, 2017; Jinek et al., 2012; Westbrook, Moo‐Young, &
Chou, 2016a). The inefficiency or total lack of an NHEJ system within
most bacteria limits the choice for repair of the cut to HDR in most of
these hosts (Shuman & Glickman, 2007).
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CRISPRi in bacteria functions through the targeting of a cataly-
tically inactive (D10A and H840A) Cas9 variant, dCas9 to the pro-
moter or within the 5′ region of a gene of interest. This sterically
hinders transcription by the RNA polymerase, thus lowering the
successful expression of the target gene (Qi et al., 2013). CRISPRi has
been exemplified within the Gram‐positive model organism Bacillus
subtilis (Westbrook et al., 2016b), perhaps most notably by Peters
et al. (2006) for the functional analysis of all essential genes.
An alternative CRISPR nuclease family, Cpf1 (also known as Cas12a),
has similarly been used for genome editing since the first report in 2015
(Zetsche et al., 2015). Cpf1 nucleases exhibit different characteristics to
Cas9 nucleases, such as a staggered DSB, a T‐rich PAM and the native
use of only 1 guide RNA molecule to form a complex with Cpf1 and
target the DNA. These characteristics enable Cpf1 nucleases to be used
in target organisms or regions within an organism's genome were a lower
GC content makes the use of Cas9 less feasible.
While the commercial application of Cas9 nucleases, and in-
creasingly also Cpf1 nucleases, have been widely pursued, a sig-
nificant drawback for the use of these nucleases is the requirement
of a research license and potentially subsequent royalty fees for the
commercial exploitation of any developed product.
Recently, Inscripta (CO) released the alternative CRISPR nucle-
ase MAD7 which is free for all commercial or academic research with
no reach‐through royalties or costs provided the final engineered
strain does not contain the MAD7 nuclease (Inscripta, 2019b). As
such, its use for commercial genome editing is of great interest. In-
scripta report that MAD7 was developed from Eubacterium rectale
and has proven its functionality in E. coli, S. cerevisiae and in the
human HEK293T cell line. Recently, MAD7 (also known as ErCas12a)
was shown to be compatible with genome editing in Zebrafish
(Wierson et al., 2019). MAD7 has 31% identity with Acidaminococcus
sp. BV3L6 Cpf1 (AsCpf1), to which it also shares a T‐rich PAM site
(5′‐YTTN‐3′), and a protospacer (the region of the gRNA which as-
sociates the nuclease to the DNA target) length of 21 nucleotides
(Inscripta, 2019a). A catalytically inactive variant of MAD7 has the
potential to be combined with inactive dCas9 and/or ddCpf1 based
tools to enable the construction of increasingly sophisticated syn-
thetic biology genetic circuits.
Several CRISPR genome modification systems have been re-
ported for use in the Gram‐positive model organism Bacillus subtilis
based around the efficient homologous recombination (HR) machin-
ery, all of which utilize the Cas9 nuclease (Altenbuchner, 2016; Burby
& Simmons, 2017; Price et al., 2019; Westbrook et al., 2016b;
K. Zhang et al., 2016), or recently also the partially inactivate nCas9
(D10A) (Liu et al., 2019). Here we demonstrate that CRISPR‐Cas9
genome editing in B. subtilis 168 is driven primarily by HR by curing B.
subtilis 168 tryptophan auxotrophy. Subsequently, we show editing
with MAD7 is also driven primarily by HR. We used the reporter
proteins, AmyE and GFPmut3, to analyze the editing efficiency of this
CRISPR‐MAD7 system and engineered MAD7 to generate the first
reported catalytically inactive, “dead,” MAD7 (dMAD7) for single
target and multiplexed transcriptional downregulation by dMAD7‐
mediated CRISPRi.
2 | MATERIALS AND METHODS
2.1 | Strains and media
The strains and plasmids used in this study are listed in Table S1.
All oligonucleotides used in this study are listed in Table S2.
Escherichia coli Top10 cells were used to construct recombinant
plasmids. Bacterial cells were cultured in Lysogeny broth (LB)
broth or LB agar (VWR) media at 37°C with agitation (250 rpm)
where appropriate. B. subtilis 168 tryptophan auxotrophy or pro-
totrophy were selected for by growth on M9 agar supplemented
with or without 20 µg/mL tryptophan (Harwood & Cutting, 1990).
When required, the following antibiotics were supplied to the
media: ampicillin (200 µg/mL), chloramphenicol (10 µg/mL), and
kanamycin (E. coli: 100 µg/mL; B. subtilis: 10 µg/mL).
2.2 | Plasmid and strain construction
Unless otherwise stated, plasmid construction was performed as
described in Sambrook and Russell (2001). DNA oligonucleotides
were purchased from Merck or Integrated DNA Technologies. The
reagents for polymerase chain reaction (PCR), restriction digest,
DNA phosphorylation, and ligation were purchased from New
England Biolabs (NEB). DNA purification was performed using the
Monarch® Nucleic Acid Purification Kits from NEB. DNA sequences
were confirmed by Source Bioscience.
2.2.1 | CRISPR plasmid construction
pBAC0155 was constructed using the inABLE plasmid assembly
method (Che, Knight, Canton, Kelly, & Shetty, 2015; Price et al., 2019).
Individual 5′ truncated parts were prepared by PCR followed by re-
striction digest at 5′ and 3′ regions with SapI. Where parts <120 base
pair (bp) were used, complementary oligonucleotides were phos-
phorylated and annealed leaving three nucleotides (nts) single strands
at both the 5′ and 3′ ends to remove the need for SapI digestion. The
parts were ligated to phosphorylated and annealed oligonucleotides at
each terminus, containing 3 nt and 16 nt single strands at the 5′ and
3′ ends, respectively. The part‐ oligonucleotides fusions were annealed
at the homologous 16 nt overhangs for 1 hr at 37°C, and used to
transform electrocompetent E. coli.
pBAC0155 consisted of four parts: 1. the E. coli/B. subtilis shuttle
vector backbone from pBAC0001; 2. the LacI repressor and isopropyl
β‐D‐1‐thiogalactopyranoside (IPTG) inducible Pgrac promoter from
pBAC0001, including a multiple cloning site; 3. the bidirectional strong
rrnB T1 and T2 terminators; 4. the MAD7 gRNA expression module
consisting of the Pveg promoter, the “MAD7 handle” section of the
gRNA and spacer DNA flanked by SapI sites for cloning of the pro-
tospacer DNA. Three 5′ truncated parts were prepared by PCR from
the indicated template and oligonucleotides: 1. pBAC0001 with
oMAP0010/0011; 2. pBAC0001 with oMAP0018/0019; 3. pING0001
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with oMAP0024/0025. The short part 4 was prepared as described
from oMAP0492/0493. Parts were ligated at 5′ and 3′ respectively
with annealed oligonucleotides: 1. oMAP0008/0009 and oMAP0014/
0015; 2. oMAP0016/0017 and oMAP0020/0021; 3. oMAP0022/0023
and oMAP0486/0487; 4. oMAP0488/0489 and oMAP0498/0499.
pBAC0158 was constructed by digesting pBAC0155 and pMK‐RQ‐
MAD7 (MAD7, codon‐optimized for B. subtilis and flanked by BamHI and
XbaI recognition sites, synthesized by Thermo Fisher Scientific) with
BamHI and XbaI restriction enzymes, and ligating the pBAC0155 back-
bone with the MAD7 gene using T4 DNA ligase.
pBAC0184, pBAC0194, and pBAC0195 were constructed by PCR
amplifying dCas9 from pdCas9‐bacteria with oligonucleotides
oMAP0073/0074, introducing a BsaI site and XbaI recognition sites at
the 5′ and 3′ end of the gene, respectively. The amplified dcas9 was
digested with BsaI and XbaI. pBAC0041, pBAC0035, and pBAC0165
were digested with BamHI and XbaI to remove the cas9 gene. The
dcas9 gene fragment was subsequently ligated with the pBAC0041/
0035/0165 backbones using T4 DNA ligase. pdCas9‐bacteria was a
gift from Stanley Qi (plasmid #44249; Addgene; Qi et al., 2013).
pBAC0187, pBAC0188, pBAC0189, and pBAC0190 were con-
structed by digesting pBAC0158, pBAC0162, pBAC0163, and
pBAC0166, respectively, as well as pMK‐RQ‐dMAD7 (dMAD7 [MAD7
gene with D877A [codon GCT to GAT], E962A [codon GCA to GAA],
D1213A [codon GCT to GAT] modifications] flanked by BamHI and XbaI
recognition sites, synthesised by Thermo Fisher Scientific), with BamHI
and XbaI. The dMAD7 gene fragment was subsequently ligated with the
pBAC0158/0162/0163/0166 backbones using T4 DNA ligase.
The protospacer insertion into pBAC0015, for the completion of
Cas9‐mediated genome editing plasmids, was carried out as pre-
viously described (Price et al., 2019). The construction of CRISPR
plasmids for MAD7 or dMAD7 was carried out in a similar fashion,
however SapI, instead of AarI, was used to cleave the pBAC0158 and
pBAC0187 backbones to yield 3 nt single‐stranded DNA overhangs
compatible with the gRNA protospacer constructed by annealing of
an oligonucleotide pair. All protospacer regions were identified using
the online tool, CHOPCHOP (Labun, Montague, Gagnon, Thyme, &
Valen, 2016; Montague, Cruz, Gagnon, Church, & Valen, 2014).
The following plasmids for Cas9‐mediated editing were pre-
pared with the pBAC0015 backbone using the indicated oligo-
nucleotide pairs: pBAC0129 (oMAP0386/0387); pBAC0165
(oMAP0573/0574); pBAC0185 (oMAP0694/0695). The following
plasmids for MAD7‐mediated editing were prepared from the
pBAC00158 backbone using the indicated oligonucleotide pairs:
pBAC0162 (oMAP0549/0550); pBAC0163 (oMAP0553/0554);
pBAC0166 (oMAP0571/0572); pBAC0218 (oMAP0799/0800).
The following plasmids where prepared from the pBAC0187
backbone using the indicated oligonucleotide pairs: pBAC0207
(oMAP0759/0760); pBAC0208 (oMAP0761/0762); pBAC0209
(oMAP0763/0764); pBAC0210 (oMAP0765/0766); pBAC0211
(oMAP0767/0768); pBAC0212 (oMAP0769/0770); pBAC0213
(oMAP0771/0772); pBAC0214 (oMAP0775/0776); pBAC0215
(oMAP0777/0778); pBAC0219 (oMAP0793/0794); pBAC0220
(oMAP0797/0798); and pBAC0222 (oMAP0795/0796).
Schematic representations of plasmids pBAC0015, pBAC0155,
pBAC0158, and pBAC0187 can be found in the supplementary
information.
2.2.2 | dDNA preparation
dDNA, encoding a programmed target site edit together with a sy-
nonymous PAM mutation to eliminate Cas9 or MAD7 cleavage at the
edited site after HR or HDR was constructed by overlap extension
PCR (OE‐PCR) as described previously (Bryksin & Matsumura, 2010;
Price et al., 2019).
2.2.3 | Strain construction
BAC0111 was constructed by transforming naturally competent B.
subtilis 168 with the integration plasmid pGFPbglS (Anagnostopoulos
& Spizizen, 1961; Bennallack, Burt, Heder, Robison, & Griffitts, 2014;
Bisicchia, Botella, & Devine, 2010). Transformants were selected on
LB agar plates supplemented with kanamycin (Figure S1).
A total of 1 µg of an OE‐PCR product generated using the oligonu-
cleotides set oMAP0388/0393/0394/0395 and the genomic DNA
(gDNA) of strain BAC0111 as template was co‐transformed alongside
200ng of the editing plasmid pBAC0129 for the modification of
BAC0111 to insert Pveg upstream of gfpmut3. The editing plasmid was
removed from the edited strain by overnight growth in LB supplemented
with 1mmol/L IPTG and subsequent confirmation by counter plating on
LB agar plates with and without chloramphenicol, yielding strain
BAC0288 (Figure S1; Price et al., 2019). The insertion of Pveg was verified
by sequencing and by fluorescence emission analysis using Safe Imager
2.0 Blue Light Transilluminator and Amber Filter System (excitation:
470 nm, emission: 530 nm; Thermo Fisher Scientific) to detect GFPmut3.
BAC0348‐0355 and BAC0360‐0368 were constructed by
transforming naturally competent cells of the relevant parental strain
with the appropriate plasmid (Table S1; Anagnostopoulos &
Spizizen, 1961; Bennallack et al., 2014). Transformants were selected
on LB agar plates supplemented with chloramphenicol.
2.3 | CRISPR‐Cas9/MAD7‐Mediated gene editing in
B. subtilis
A single OE‐PCR product was used to allow a direct comparison between
Cas9 and MAD7 editing efficiencies at the amyE locus. The OE‐PCR
product generated using the oligonucleotide set oMAP0121/0551/0552/
0122 was co‐transformed alongside the editing plasmids pBAC0041 and
pBAC0162.
dDNA for gfpmut3 editing was generated by PCR using oligos
oMAP0575/0578 and the synthesized plasmid pMK‐RQ‐gfpmut3‐
dDNA as a template.
Genome editing was carried out in triplicate by co‐transforming
naturally competent B. subtilis with 200ng editing plasmid DNA and 1µg
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dDNA (Anagnostopoulos & Spizizen, 1961; Bennallack et al., 2014; Price
et al., 2019). When targeting gfpmut3, transformants were spread on LB
agar plates supplemented with chloramphenicol and IPTG (1mmol/L).
Effective knock‐out of gfpmut3 by stop codon introduction was de-
termined by analysis of fluorescence emission using Safe Imager 2.0 Blue
Light Transilluminator and Amber Filter System (excitation: 470 nm,
emission: 530 nm; Thermo Fisher Scientific). Genotypes were confirmed
by colony PCR with oligonucleotides hybridizing to the chromosome
(oMAP0393/0814) outside of the dDNA homology arm region and se-
quenced with primer oMAP0815 to ensure accurate coverage of the
targeted region. When targeting amyE, transformants were spread on LB
agar plates supplemented with chloramphenicol, IPTG (1mmol/L) and 1%
soluble potato starch (VWR). Effective knock‐out of amyE by stop codon
introduction was determined by staining transformation plates with io-
dine (Price et al., 2019; Zhang, Yan, Cui, Hong, & Li, 2006). Genotypes
were confirmed by colony PCR with oligonucleotides hybridizing to the
chromosome (oMAP0811/0812) outside of the dDNA homology arm
region and sequenced with primer oMAP0813 to ensure accurate cov-
erage of the targeted region.
2.4 | Restoring B. subtilis tryptophan prototrophy
The CRISPR‐Cas9 genome editing mechanism in B. subtilis was in-
vestigated by restoring tryptophan prototrophy when transforming an
OE‐PCR product (oligonucleotides set oMAP0236/0696/0697/0239 and
gDNA of B. subtilis 168 as template) containing the mutation needed to
remove the trpC2 lesion, in the presence and absence of editing plasmid
pBAC0185, or Nontargeting plasmid pBAC0035 (Altenbuchner, 2016).
Transformations were carried out in triplicate in naturally competent B.
subtilis as previously described, and tryptophan prototroph cells were
selected in M9 minimal medium (Anagnostopoulos & Spizizen, 1961;
Bennallack et al., 2014; Price et al., 2019). Before spreading transfor-
mants on M9 agar plates, the cells were washed three times with
10mmol/L phosphate‐buffered saline to ensure there was no carryover
of tryptophan from the transformation process.
The CRISPR‐MAD7 genome editing mechanism in B. subtilis was
investigated in the same manner. OE‐PCR product (oligonucleotides
set oMAP0236/0801/0802/0239 and gDNA of B. subtilis 168 as
template) containing the mutation needed to remove the trpC2 lesion
was transformed in the presence and absence of editing plasmid
pBAC0218, or nontargeting plasmid pBAC0163. IPTG was included
in all transformation plates to limit the background of nonselected
colony forming units (CFUs).
Transformation results between different batches of competent
cells were normalized by the transformation efficiency obtained
when transforming only the nontargeting plasmid for the nuclease
being analyzed and selecting on LB agar supplemented with chlor-
amphenicol (Cas9), or LB agar supplemented with chloramphenicol
and IPTG (MAD7).
Unpaired t tests with Welch's correction were performed to de-
termine two‐tailed p values and identify statistically significant or non-
significant differences between the number of colonies obtained.
2.5 | Quantitative analysis of α‐amylase activity
Relative extracellular α‐amylase activity was quantified in the culture
supernatant of strains BAC0352‐0355 and BAC0360‐0363 using a
starch degradation assay. For each strain, an overnight culture was
used to inoculate a pre‐culture supplemented with chloramphenicol
and 1mmol/L IPTG. Once in exponential growth phase, the pre‐
culture was back diluted in triplicate into fresh and prewarmed
medium also supplemented with chloramphenicol and 1mmol/L IPTG
and grown for 24 hr. Supernatant samples were clarified by cen-
trifugation and 25 µL were mixed in triplicate with 100 µL assay so-
lution (50mmol/L Tris‐HCl, pH 6.8, 25mmol/L CaCl2, 0.05% [wt/vol]
soluble potato starch) and incubated for 30min at 37°C. 50 µL stop
solution (1mol/L HCl, 0.01% [wt/vol] I2, 0.1% [wt/vol] KI) was added
and absorbance at 620 nm measured. Unpaired t tests with Welch's
correction were performed to determine two‐tailed p values and
identify statistically significant or nonsignificant differences.
2.6 | Quantitative analysis of GFPmut3 expression
detection
Relative fluorescence was quantified in the cultures of strains
BAC0348‐0351 and BAC0364‐0368. For each strain, an overnight
culture was used to inoculate a pre‐culture supplemented with
chloramphenicol and 1mmol/L IPTG. Once in exponential growth
phase, the pre‐culture was back diluted into fresh and prewarmed
medium also supplemented with chloramphenicol and 1mmol/L IPTG
and grown for 24 hr. The culture fluorescence was measured in
samples of 100 µL using the FLUOstar Omega Microplate Reader
(BMG LABTECH) in 96‐well flat‐bottom plates (excitation: 485 nm;
emission: 520 nm; gain: 1,000; Greiner). Unpaired t tests with
Welch's correction were performed to determine two‐tailed p values
and identify statistically significant or nonsignificant differences.
3 | RESULTS
3.1 | Comparison of CRISPR‐Cas9 and
CRISPR‐MAD7 enabled genome editing efficiencies
To compare the gene‐editing efficiencies between Cas9 and MAD7 in
B. subtilis, chromosomally expressed amyE and gfpmut3 genes were
selected due to ease of analysis of successfully edited colonies by
starch degradation or fluorescence respectively. For both nucleases,
a single dDNA with 1 kbp homology arms, either side of the site
targeted for modification, was designed to introduce a stop codon at
the 5′ of the gene and remove the PAM sites selected based on their
proximity (Figure 1a,b).
Cas9 and MAD7 yielded amyE knock‐out efficiencies of 98% and
93% respectively when the editing plasmids were co‐transformed
with dDNA to B. subtilis 168 (Figure 1c). When knocking out gfpmut3,
editing efficiencies of 75% and 100% were observed for Cas9 and
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MAD7 respectively despite the lower transformation efficiency of
BAC0288 (Figure 1c). In the absence of dDNA, the DSB catalyzed by
either nuclease drastically reduces cell viability and no successfully
edited colonies were identified. Following phenotypic analysis, the
genotypes of a selected population of the transformants were con-
firmed by colony PCR and sequencing for both amyE and gfpmut3
(Table S3).
Nontargeting plasmids, containing a gRNA with a random DNA
sequence which does not target anywhere in the genome of B. subtilis
168 were transformed with and without dDNA for both amyE and
gfpmut3 to determine the basal level of editing in the absence of the
DSB induced by a CRISPR nuclease (Figure 1c). A basal level of editing
of 2 in 1,117 CFUs and 1 in 534 CFUs was phenotypically detected
when the dDNA for gfpmut3 editing was co‐transformed with the Cas9
or MAD7 nontargeting plasmids, respectively. In the case of amyE, no
edited colonies were detected with the same strategy. This highlights
the importance of having both the nuclease and targeting gRNA pre-
sent to ensure high editing efficiency is obtained due to the counter-
selection of unedited colonies. The higher number of colonies analyzed
following transformation of the nontargeting plasmids was due to the
absence of the selective pressure, against colony formation, in non‐
edited cells when a targeting gRNA is present.
F IGURE 1 CRISPR‐Cas9 or CRISPR‐MAD7‐mediated editing of amyE and gfpmut3. (a) Non‐edited (WT) and edited sequences with their
corresponding amino acid sequences (*=stop codon). The targeted PAM sites are indicated for both Cas9 and MAD7. The modified base pairs are
highlighted in bold and the introduced stop codons are marked with red boxes. (b) Co‐transformational editing approach were the CRISPR plasmid
expressing the gRNA and nuclease is transformed alongside a linear editing template (dDNA) containing the editing region. (c) Editing efficiency
following co‐transformation of B. subtilis 168 (amyE) or BAC0288 (gfpmut3). Bars represent the average editing efficiency obtained following
transformation of the targeting or nontargeting (NT) gRNA expression plasmids for each nuclease with or without dDNA (amyE targeting: Cas9:
pBAC0041; MAD7: pBAC0162. gfpmut3: Cas9: pBAC0165; MAD7: pBAC0166. NT: Cas9: pBAC0035; MAD7: pBAC0163). Editing efficiency (%)
was determined by observing either starch degradation or fluorescence in the transformation plates. The circled number above each bar indicates
the total number of colonies phenotypically screened. Error bars indicate the standard deviation between three independent transformation
events. dRNA, donor template DNA; gRNA, guide RNA; WT, wild‐type [Color figure can be viewed at wileyonlinelibrary.com]
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3.2 | Homologous recombination versus DNA
double‐strand break repair as the driving mechanism
for CRISPR genome editing in B. subtilis 168
To elucidate the mechanism with which CRISPR‐mediated editing takes
place in B. subtilis 168, we made use of this strain's tryptophan auxo-
trophy to compare the efficiency in restoring prototrophy when a linear
dDNA is transformed on its own, or in the presence of either a Cas9 or
MAD7 nontargeting or trpC2‐targeting plasmid. The linear dDNA, har-
boring 1 kbp homology regions either side of the site targeted for
modification, was designed to simultaneously introduce an additional
isoleucine residue adjacent to I110 residue of TrpC2, returning the
strain to a prototrophic state, and a synonymous mutation to eliminate
the PAM recognition site and prevent continuous cutting by the trpC2‐
targeting plasmid (Figure 2a,b; Altenbuchner, 2016). By selecting
transformants in M9 minimal medium supplemented with or without
either chloramphenicol (plasmid selection) or tryptophan, we could
clarify whether HR drives genome editing, preventing a DSB, or if the
DSB induces DNA repair by HR. As the procedure to induce natural
competence utilizes tryptophan within the growth medium throughout,
there is no selection for prototrophic cells before the spreading of the
transformants on the agar plates.
In the absence of tryptophan, there is not a significant difference in
CFU obtained when transforming the linear dDNA to restore tryptophan
prototrophy on its own or in the presence of either the trpC2 targeting or
nontargeting plasmids (Figure 2). Furthermore, when cells with restored
F IGURE 2 Restoration of B. subtilis prototrophy using CRISPR‐Cas9 and CRISPR‐MAD7 for genome editing. (a and b) show the non‐edited (WT) and
edited sequences for Cas9 and MAD7 editing respectively as well as their corresponding amino acid sequences. The modified base pairs are highlighted
in bold and the inserted isoleucine (Ile) codon, adjacent to I110, is marked with red boxes. (c) Co‐transformational editing approach were the CRISPR
plasmid expressing the gRNA and nuclease is transformed alongside a linear editing template (dDNA) containing the editing region. (d and e) Graphs
show the number of transformants following transformations with the indicated combinations of dDNA and targeting (pBAC0185 for Cas9 and
pBAC0218 for MAD7) or nontargeting plasmid (pBAC0035 for Cas9 and pBAC0163 for MAD7) to restore B. subtilis 168 prototrophy, with Cas9 and
MAD7, respectively. Bars represent the average number of colony‐forming unit (CFU) normalized by the transformation efficiency of pBAC0035 (Cas9)
selected on LB agar supplemented with chloramphenicol or pBAC0163 (MAD7) selected on LB agar supplemented with chloramphenicol and IPTG.
Error bars indicate the standard deviation between three independent transformation events. Cm, chloramphenicol; dRNA, donor template DNA; IPTG,
isopropyl β‐D‐1‐thiogalactopyranoside; LB, Lysogeny broth; Trp, tryptophan; WT, wild‐type [Color figure can be viewed at wileyonlinelibrary.com]
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prototrophy were also selected in the presence of chloramphenicol, there
was no significant difference between the co‐transformation of dDNA
with either the trpC2‐targeting or nontargeting CRISPR‐Cas9 plasmids
(Figure 2). Both these results indicate that HR is the main driving force
for CRISPR‐Cas9 editing in the presence of dDNA. When M9 was sup-
plemented with tryptophan, the absence of selective pressure for re-
stored prototrophy results in a significantly lower number of CFU when
co‐transforming the dDNA and the trpC2‐targeting plasmid compared
with the co‐transformation of dDNA with the nontargeting plasmid
(Figure 2). In this case, the lethal cut induced by the nuclease counter-
selects the transformants in which HR of dDNA has not occurred. As
such, while the high efficiency of HR is the main driving force for genome
editing, the nuclease induced DSB is essential to obtain high editing ef-
ficiency in B. subtilis 168.
3.3 | Engineering of MAD7 to construct and
characterize the catalytically inactive dMAD7
3.3.1 | Identification of MAD7 catalytic residues
A pairwise alignment of the amino acid sequences of MAD7 and
AsCpf1, confirmed the 31% identity (Figure S2). Previously, it was
reported that the catalytic residues of AsCpf1 are Asp908, Glu993,
and Asp1263 (Yamano et al., 2016; Zetsche et al., 2015). Asp908 lies
in a region of high similarity with MAD7, with residues 905‐916
corresponding to MAD7 residues 874‐885. AsCpf1 Glu993 does not
lie in a region of high homology, however, the alignment revealed
that this residue was conserved in MAD7. Finally, the residue cor-
responding to Asp1263 in AsCpf1 was found in a region on high
homology with AsCpf1, with residues 1261–1268 corresponding to
MAD7 residues 1211–1218. The corresponding catalytic residues in
MAD7 (Asp877, Glu962, and Asp1213) identified by sequence
homology (Figure S2) were simultaneously modified to alanine in
silico and the corresponding gene dMAD7 was synthesized.
3.3.2 | dMAD7 lacks the ability to induce a lethal
DNA double‐strand break
To verify whether the DNA cleavage capacity of MAD7 was removed in
the putative dMAD7, the synthesized dMAD7 gene was used to replace
MAD7 within the amyE and gfpmut3 targeting plasmids pBAC0162 and
pBAC0166, respectively. As a control, the well‐characterized dcas9 was
used to replace cas9 in plasmids pBAC0041 and pBAC0165 (Peters
et al., 2016; Qi et al., 2013; Westbrook et al., 2016b). Naturally compe-
tent B. subtilis 168 and BAC0288 were respectively transformed with the
amyE and gfpmut3 targeting plasmids with both active and inactive
nuclease variants. Triplicate transformations were spread on plates sup-
plemented with chloramphenicol and IPTG to ensure nuclease expres-
sion. The average number of CFUs obtained for each set of
transformations (Table 1) indicates that the engineered dMAD7 does
not catalyze DSB of DNA since it does not cause the reduced viability
observed for the catalytically active nuclease.
3.3.3 | dMAD7 retains DNA binding capacity to
enable CRISPRi
Extracellular α‐amylase activity was quantified in strains ex-
pressing dMAD7 targeting five PAM sites (5′‐TTTN‐3′) at the 5′
end of amyE, two on the template strand and three on the non‐
template strand. The results were directly compared with strains
expressing dCas9 targeting amyE +25 bases downstream of the
start codon. Strains expressing nontargeting dMAD7 and dCas9
plasmids were used as the negative controls for downregulation
(Figure 3a,b).
The results confirm that dCas9‐mediated CRISPRi is highly effi-
cient with a 99.4% reduction in α‐amylase activity, while dMAD7‐
mediated CRISPRi appears less efficient, ranging from 59.3% to
51.5% activity reduction depending on the gRNA and PAM site
sequence. The gRNA targeting the PAM site TTTG +21 bases from
the start codon did not exhibit significantly reduced levels of activity.
As this PAM sequence was the same as others where CRISPRi was
successful, and the GC % of the protospacer (28.6%) is similar to the
one targeting the PAM site +4 (33.3%), we hypothesize the cause of
this lowered efficiency is due to secondary structure within the
gRNA, as has previously been reported for Cas9 (Thyme, Akhmetova,
Montague, Valen, & Schier, 2016; Xu, Lian, Jia, Li, & Huang, 2017).
To further investigate the capacity of dMAD7 for CRISPRi, the
gfpmut3 gene in strain BAC0288 was targeted. Here, six PAM sites
(three on each strand) where targeted with the 5′‐YTTN‐3′ PAM
sequence recommended by Inscripta (Figure 3c). dMAD7 was
targeted to the 5′ end of gfpmut3 and fluorescence was compared
with strains expressing dCas9 targeting gfpmut3 +27 bases down-
stream of the start codon. Strains expressing nontargeting dMAD7
and dCas9 plasmids were used as negative controls for
TABLE 1 Average number of transformants (CFU) obtained
following triplicate transformation reactions of naturally competent
B. subtilis 168 and BAC0288 with 200 ng of Cas9, dCas9, MAD7, and
dMAD7 plasmids
Parental
strain Target Plasmid Nuclease
Average CFU
obtained








Abbreviation: CFU, colony‐forming unit.
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downregulation (Figure 3d). Here, a broader effect on expression was
observed for dMAD7 with statistically significant CRISPRi effi-
ciencies ranging from 71.3% to 26.8%. Once again, the gfpmut3 tar-
geting dCas9 control exhibited highly efficient CRISPRi with a 95.1%
reduction in expression. This difference in efficiency may indicate
that further modifications to dMAD7 could be made to increase its
ability to bind DNA efficiently.
3.3.4 | Multiplexed CRISPRi of amyE and gfpmut3
with dMAD7
To increase the efficiency of dMAD7 transcriptional downregulation,
multiplexed targeting, where more than one gRNA is utilized at a
time, was tested. gRNA arrays were inserted in the same manner as
single gRNAs, with the final array designed with the dMAD7 handle
direct repeat at both the 3′ and 5′ ends, as well as between the
inserted protospacers.
Additive downregulation of amyE was tested by targeting PAM sites
at +4 TTTG and +51 TTTA in strain BAC0377 (Figure 4b). Similarly,
gfpmut3 was analyzed by targeting PAM sites at +80 TTTC and +21
TTTG in strain BAC0380 (Figure 4b). These were compared with the
nontargeting dMAD7 control strain BAC0350, as well as the single gRNA,
amyE or gfpmut3 targeting dMAD7 strains BAC0381, BAC0382,
BAC0351, and BAC0368. To ensure the gRNA array was matured from a
single transcript into single gRNA units, strain BAC0378, carrying a gRNA
array to target amyE +4 TTTG and gfpmut3 +80 TTTC was analyzed for
transcriptional interference of both targets (Figure 4c).
The results show when amyE and gfpmut3 were simultaneously
targeted the downregulation of both genes was found to be similar to
when only one was targeted for CRISPRi (Figure 4c). As such, the
gRNA array was correctly matured to single gRNAs and there is no
significant competition between the two gRNAs for dMAD7‐
mediated CRISPRi.
When two gRNAs are combined to target either gfpmut3 or
amyE, the measured downregulation is not cumulative. As the
BAC0378 multiplexing results indicate no significant competition
between the gRNAs for dMAD7, it is thought that there is a potential
steric hindrance between the protospacer‐dMAD7 complexes used
to simultaneously target each reporter.
F IGURE 3 Relative α‐amylase activity and GFPmut3 fluorescence following dCas9 and dMAD7‐mediated CRISPRi. (a and c) Schematic
diagrams of gRNA binding sites for dMAD7 within amyE and gfpmut3 respectively. Values represent the distance of each targeted PAM site
from the start codon on either the template (blue) or non‐template (red) DNA strand. (b) Bar graph represents the extracellular α‐amylase
activity normalized by OD600 nm relative to the nontargeting gRNA control for either dMAD7 or dCas9, after 24 hr of growth. The horizontal
axis indicates the PAM site targeted by each gRNA for both dMAD7 and dCas9 and its distance to the amyE start codon (+4: BAC0360; +51:
BAC0363; +27: BAC0362; +11: BAC0361; +21: BAC0355; +25: BAC0353). Red and blue bars correspond to PAM sites on the non‐template
and template strands, respectively. Gray bars represent nontargeting controls (dMAD7: BAC0354; dCas9: BAC0352). (d) Bar graph represents
the fluorescence intensity normalized by OD600 nm relative to the nontargeting gRNA control for either dMAD7 or dCas9, after 24 hr of growth.
The horizontal axis indicates the PAM site targeted by each gRNA for both dMAD7 and dCas9 and its distance to the gfpmut3 start codon (+80:
BAC0368; +78: BAC0367; +21: BAC0351; +9: BAC0364; +16: BAC0365; +43: BAC0366; +27: BAC0349). Red and blue bars correspond to
PAM sites on the non‐template and template strands, respectively. Gray bars represent the nontargeting controls (dMAD7: BAC0350; dCas9:
BAC0348). Error bars indicate the standard deviation between three biological replicates. Two‐tailed p values following unpaired t test with
Welch's correction. gRNA, guide RNA; NS, not significant [Color figure can be viewed at wileyonlinelibrary.com]
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F IGURE 4 Relative α‐amylase activity and GFPmut3 fluorescence following dMAD7‐mediated multiplexing CRISPRi in BAC0288.
(a) Schematic diagrams of gRNA binding sites for dMAD7 within amyE and gfpmut3. Values represent the distance of each targeted PAM site
from the start codon on the non‐template DNA strand. (b) Investigation for an additive multiplexed CRISPRi effect when two gRNAs target a
single gene. (c) Investigation for a multiplexed CRISPRi effect when two gRNAs target different genes within the same strain. Bars represent
extracellular α‐amylase activity, or GFPmut3 fluorescence intensity, normalized by OD600 nm, relative to the nontargeting gRNA control strain,
after 24 hr of growth. The horizontal axis indicates the targeted PAM site(s) distance to the amyE or gfpmut3 start codon (Strains used: +4:
BAC0381; +51: BAC0382;+4 and +51: BAC0377; +4 and +80: BAC0378; +80: BAC0368; +21: BAC0351; +80 and +21: BAC0380). White bars
indicate strains in which a single gRNA is utilized to target a single gene. Gray bars indicate strains in which the effect of two gRNAs on a single
gene is investigated. Blue bars indicate BAC0378 in which the effect of single gRNAs on two different genes is investigated. Red bars indicate
the negative control strain, BAC0350, in which a nontargeting gRNA is expressed alongside dMAD7. Error bars indicate the standard deviation
between three biological replicates. *p < .05; **p < .01. Two‐tailed p values were derived following unpaired t test with Welch's correction. gRNA,
guide RNA; NS, not significant [Color figure can be viewed at wileyonlinelibrary.com]
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4 | DISCUSSION
We have exemplified the first reported use of the CRISPR‐associated
nuclease MAD7 free for all commercial or academic research in the
Gram‐positive model organism, B. subtilis. The MAD7‐mediated gen-
ome editing efficiency determined by targeting amyE (93%) and
gfpmut3 (100%) was comparable to the commonly used Cas9 nuclease.
This indicates that MAD7 is a viable alternative to Cas9 for strain
development of the industrial workhorse B. subtilis. These results also
indicate that the killing efficiency of MAD7 (amyE: 99.84%; trpC2:
99.62%) in B. subtilis, determined by the total number of CFUs fol-
lowing transformation with targeting versus nontargeting plasmids
only, was similar to that of Cas9 (amyE: 99.98%; trpC2: 99.89%). It is
hypothesized that, due to the strong selection for survival, these “es-
caper” colonies may harbor mutations deactivating the killing capacity
of the CRISPR systems. Such mutations may occur within the editing
plasmid, or on the chromosome at the PAM site or the first 10–12 nt
of the gRNA protospacer (known as the seed region) within which any
mutations cause a severely deleterious effect on cleavage efficiency
(Jiang, Bikard, Cox, Zhang, & Marraffini, 2013; Jinek et al., 2012).
We have provided evidence that, in B. subtilis 168, CRISPR‐
Cas9 and CRISPR‐MAD7 genome editing efficiency is driven
primarily by HR of dDNA preventing the lethal Cas9 or MAD7‐
induced DNA DSB, rather than HDR following the DSB.
Mougiakos et al. reported the endogenous HR machinery within
Bacillus smithii incorporating plasmid‐borne dDNA while Cas9
was inactive at ≥42°C. Counterselection of the cells which had
not undergone HR was then performed at 37°C where the Cas9
was once again functional. Here we have shown HR as the driving
mechanism under temperatures where the nuclease is active and
growth is optimal (Mougiakos et al., 2017). The presence of the
CRISPR‐Cas9 or CRISPR‐MAD7 system was not required to de-
tect successful HR due to prototrophic selection on M9 minimal
medium. However, where such a selection is not possible, the
CRISPR‐Cas9 or CRISPR‐MAD7 systems act as a powerful
counterselection for unedited cells. Additionally, the editing
efficiency reported here with pBAC0041 and dDNA (Figure 1) in
the presence of IPTG for Cas9 expression induction (91%) is si-
milar to that previously reported in the absence of IPTG (89.2%;
Price et al., 2019). Thus, editing rates are decoupled from Cas9
expression levels with leaky Pgrac promoter activity being suffi-
cient to induce the lethal DSB. Moreover, as the natural compe-
tency master regulator ComK activates transcription of the
primary component of HR, recA, and DNA uptake is single‐
stranded, yielding a substrate with which RecA can bind, HR can
readily proceed at the target site before the DSB taking place
(Cheo, Bayles, & Yasbin, 1993; Dubnau, 1999).
Furthermore, a catalytically inactive variant of MAD7 was en-
gineered retaining its ability to bind DNA in the presence of a DNA‐
targeting gRNA. Our data highlights the importance of testing multiple
gRNA sequences when optimizing the MAD7‐mediated downregulation
of a target gene. The level of downregulation is likely influenced by a
combination of factors, such as PAM site sequence, gRNA binding
efficiency, GC % of the protospacer, and gRNA secondary structure
(Labun et al., 2016; Thyme et al., 2016; Wilson, O'Brien, & Bauer, 2018;
Zetsche et al., 2015). Interestingly, the significance of gRNA selection
does not seem to be as great when preforming MAD7‐mediated editing
compared to CRISPRi. The amyE +21 targeting PAM site resulted in 98%
editing efficiency while only showing a 7.9% decrease of α‐amylase ac-
tivity when preforming CRISPRi with dMAD7. This is likely because the
nuclease DSB is a single event whereas CRISPRi requires a stable and
continuous interaction between the nuclease and targeted coding se-
quence for efficient transcriptional downregulation. Multiplexed targeting
of dMAD7 to an endogenous and heterologous gene target was ex-
emplified, with no detectable competition between gRNAs on the pool of
expressed dMAD7 when compared to strains with only a single gRNA. It
is feasible that technologies developed were effector proteins are fused
to dCas9 for pathway optimization or in vivo mutagenesis could be
adapted for use with dMAD7 further expanding its potential (Bikard
et al., 2013; Wang et al., 2018; Yang et al., 2018).
An attractive feature of MAD7 is its freedom to use for industrial
R&D and commercial strain construction (provided the final strain
does not retain the MAD7 nuclease (Inscripta, 2019b)). This has the
capacity to disrupt the slow commercial uptake of genome editing
technologies allowing the use of MAD7 in sectors that were put off by
licensing and royalty fees associated with for instance Cas9 and Cpf1
CRISPR nucleases, such as large‐scale fermentation biotechnology.
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